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ABSTRACT

GENES DIFFERENTIALLY EXPRESSED AT 1 DAY, 6 WEEKS, AND 6
MONTHS OF AGE IN AORTAS OF SPONTANEOUSLY ATHEROSCLEROTIC
WHITE CARNEAU PIGEONS

By
Suzanne Lee Pearlman
University of New Hampshire, May, 2011

Genetics is reported to be the primary causative factor for individuals diagnosed
with atherosclerosis, in the absence of known risk factors. The development of
atherosclerosis in White Carneau (WC) pigeons is of genetic origin, making it an
excellent model to study genetic factors.
Representational Difference Analysis (RDA) was used to determine genes
differentially upregulated between three ages, at the celiac bifurcation of the aorta in WC
pigeons. Genes responsible for spontaneous initiation of atherosclerosis were
hypothesized as being differentially expressed at 1 day, while those differentially
expressed at 6 weeks and 6 months were related to progression.
Multiple candidate genes were upregulated at 1 day, although they were not
definitively assigned to initiation. Genes upregulated at 6 weeks reflected increases in
protein synthesis, loss of cellular integrity, and changes in muscle contraction. By 6
months, increases in lipid metabolism and changes in energy metabolism from oxidative
phosphorylation to glycolysis were apparent.

xi

INTRODUCTION

Atherosclerotic heart disease continues to be the number one cause of morbidity
and mortality in the United States and other developed countries (1, 2). Atherosclerosis is a
chronic multifactorial disease that results from both environmental and genetic factors, as
well as their interactions (3-5). Diet, lack of exercise, high blood cholesterol levels,
smoking, gender, and high blood pressure are known risk factors that contribute to
approximately half of the cases in the United States (1, 2, 6). Upon clinical diagnosis of
the disease, treatments modifying these factors are successful in only about 50 % of the
cases (1). There is a dichotomy here because many people who have some or all of these
known risk factors never develop atherosclerosis (1), while others who do develop
atherosclerosis never exhibit any of these known risk factors. Heritability studies reveal an
increased familial relationship for death from coronary heart disease. Interestingly,
monozygotic twins have an even greater risk than dizygotic twins, suggesting a strong
genetic component (7).
Heredity is therefore becoming more widely accepted as the underlying factor,
particularly in those individuals who do not respond to prevention or treatment strategies,
which focus on risk factor modification (1-3, 8, 9). Unfortunately, current research has not
been successful in identifying the underlying human genetic factors that contribute to the
development of atherosclerotic lesions. In addition, research conducted on humans is
difficult due to ethical issues. This emphasizes the need for using animal models,
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particularly those that exhibit atherosclerotic development similar to that observed in
human cases.
White Carneau (WC) pigeons have been used for many years to study
atherosclerosis and are an appropriate model for multiple reasons (8, 10-12). In the WC
pigeon, lesions occur at branch points along the aorta, and progress into full blown plaques
which pose a striking resemblance to those found in humans (8, 10-14). Also, the
development of atherosclerosis in WC pigeons occurs spontaneously (non-induced) in the
absence of any known risk factors (8, 10, 12) making it easier to identify underlying
genetic components. In contrast, the Show Racer (SR) pigeon is resistant to the disease,
providing an experimental control to compare differences in genetic expression (8).
Research also shows that atherosclerosis in the WC pigeon is inherited as a single-gene,
autosomal recessive trait (15) potentially facilitating efforts to identify the gene responsible
for the disease in pigeons. Once the gene contributing to atherosclerosis in the WC pigeon
is identified, it can then be compared with the human genome to assist in understanding the
mechanisms responsible for atherosclerosis in humans.
While the precise mechanisms of initiation and progression of atherosclerosis are
not clear in humans, biochemical changes in the aorta of WC pigeons occur by 6 weeks of
age while morphological changes are observed by 6 months of age (2, 16, 17). These
predictable changes provide specific time-frames in which to search for genetic changes in
the WC pigeon to better understand stages of lesion development. Comparing the
differential expression between these ages in the WC pigeon will help to distinguish genes
responsible for initiation and progression of atherosclerosis.
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Representational Difference Analysis (RDA) was developed to identify
differentially expressed genes between two similar populations (18). This method couples
Subtractive Hybridization (SH) with Polymerase Chain Reaction (PCR), to exponentially
amplify only those genes that are differentially expressed between two similar populations.
Compared to other methods, isolation of genes using RDA is both cost effective and
efficient in a small laboratory setting, when the genome under investigation (pigeon) has
not yet been characterized (18, 19). RDA has the potential to capture unknown genes even
when expressed in low copy number. Once these genes are sequenced, they can be
identified by comparing them with known sequences of other species due to genetic
homology (18). This work described herein utilized RDA to identify genes differentially
upregulated in the WC pigeon at ages known to reflect biochemical and morphological
changes associated with atherosclerosis.

3

CHAPTERI

REVIEW of LITERATURE

Human Atherosclerosis
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in the
United States with atherosclerosis being the primary cause of this pathology (20-23). It is
estimated that one in three adults has CVD, which on average translates into one death
every 37 seconds from that cause (24). Atherosclerosis is considered a chronic
multifactorial disease (25) caused by individual environmental and genetic factors, as well
as synergistic environmental and genetic interactions (3-5). Chronic multifactorial diseases
collectively account for the greatest burden on health care services in the U.S. (26).
Multiple risk factors associated with the clinical expression of atherosclerosis
include age, gender, hypertension, hypercholesterolemia, diabetes, obesity, smoking, lack
of physical activity, and stress (22, 27, 28). These risk factors alone, however, cannot
always account for the development of atherosclerosis (20). Many individuals who develop
atherosclerosis do so in the absence of any of these known risk factors. In fact,
approximately 50% of men and women who die suddenly from this disease have no
obvious risk factors or prior symptoms (24). For example, many individuals who have
what are considered healthy cholesterol levels, still suffer heart attacks (29).
Adding to the complexity, often people who have some or all of these known risk
factors never develop clinical atherosclerosis (1, 30). Once diagnosis of the disease is
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made, however, treatments used to modify these factors are only successful in
approximately 50% or less of the cases (1, 30).
In spite of the fact that millions of dollars have already been spent to study
atherosclerosis, little is known about the early mechanism(s) of this disease (31). One
explanation is that the ability to distinguish between lesion initiation and progression
continues to elude current research. Another issue is that atherosclerosis in humans
develops very slowly, and at different rates depending on the individual, making it difficult
to map out a consistent pattern. In addition, humans develop a thickened intima before
clinical "atherosclerosis" presents itself, and there has been much disagreement whether
this thickened intima is actually the precursor or earliest stage of the disease. There are
further questions of whether or not the accumulation of extracellular proteoglycans and
lipid precede the infiltration of macrophage cells (31). Given that atherosclerosis is a
chronic disease exhibiting many multifactorial contributions there is a surprising shortage
of information dealing with the earliest stages of atherogenesis (28).
Post-mortem studies are helpful in that they provide evidence of the sub-clinical
stages of atherosclerosis, revealing visible lesions, that often do not manifest clinically until
the third or fourth decade of life (20, 29). These visible manifestations are considered the
earliest stage of atherosclerosis and present as foam cells or fatty streaks due to the
collection of lipid droplets within the cytoplasm of cells (22).
Autopsies conducted from 1987 - 1994 on victims who died from accidents
revealed that atherosclerosis begins in youth (32). Strong et al., found that intimal lesions
were present in all aortas, and in more than half of the right coronary arteries of 15 - 19
year olds with increasing prevalence and extent through 30 - 34 years of age. They also
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found that all the age groups contained fatty streaks in their aortas while fibrous plaques
appeared in coronary arteries of only a few individuals under the age of 20 (32). The
researchers concluded that while fatty streaks are usually innocuous, if they persist, and in
the presence of specific conditions, they can progress to the clinical disease state (32).
Additional human autopsies reveal that some regions in the vessel wall have a propensity
for early atherosclerotic lesions while others are resistant (11). These same autopsies also
reveal a very distinct pattern in the distribution of early atherosclerotic lesions, which is in
agreement with Caro's low sheer stress theory (11).
Stary's work supports the research conducted on these autopsies and states, while
advanced lesions may result in clinical symptoms, the early lesions that pave the way are
silent (33). Given these findings, it is essential to understand the earliest molecular and
cellular mechanisms responsible for atherosclerotic development in order to establish
approaches that will delay onset as well as progression of the disease before it produces
adverse clinical outcomes (34).
Additional histological studies of coronary arteries from human autopsies of various
ages, from infants to adults, demonstrate regions that are susceptible to atherosclerosis are
abundant in smooth muscle cells (SMCs), while regions that are resistant to its
development contain very few SMCs (33-35). Some animal experiments also demonstrate
that SMCs are integral components that increase during the initial stage of lesion formation
(33). Studies also show that intimal SMCs express lower levels of proteins associated with
contractile function, and have an increased capacity for producing extracellular matrix,
proteases and cytokines, compared with medial SMCs (34, 36, 37). In addition, intimal
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SMCs, also known as synthetic SMCs have a higher proliferative index, and can synthesize
up to 46 times more collagen than medial (contractile) SMCs (34, 36-38).
Until recently, it has not been clear whether extracellular lipid and proteoglycan
accumulation, occurs before macrophage infiltration in the human disease (31). It is
suggested that SMCs play a key role in initiation and early progression of atherosclerosis,
since alterations of their extracellular matrix can cause SMCs to proliferate and increase
their lipid content (31,33). This lipid accumulation by SMCs then contributes to foam cell
formation in a pattern that is analogous to the pattern observed with macrophages, which is
believed to then accelerate the formation of lesions (34, 39).
It is now widely agreed that the SMCs of human atherosclerotic lesions originate
from the medial layer and that most of these intimal SMCs contain lipid droplets (33). One
of the challenges with determining which cell type is ultimately responsible for lesion
development and progression is that many of the functions that are attributable to SMCs
during early lesion development are known to occur in other cell types such as
macrophages (34).
The current paradigm as laid out by the American Heart Association (AHA) (Table
1) proposes an orderly, linear pattern of lesion development where an initial lesion or fatty
streak progresses into an advanced lesion (40).
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Table 1: Current AHA Classification
Current AHA Classification
Other Terms for the Same Lesions Often Based on
Terms for Atherosclerotic Lesions According
Appearance to the Unaided Eye
to Histological Classification
Fatty dot or streak
Early lesion
Type I lesion
Initial lesion
Fatty dot or streak
Early lesion
Type Ila lesion
Progression-prone type II
lesion
Progression-resistant type II Fatty dot or streak
Early lesion
Type lib lesion
lesion
Intermediate lesion (preType III lesion
atheroma)
Type IV lesion
Atheroma
Atheromatous plaque, fibrolipid Advanced lesions,
plaque, fibrousplaque, plaque
raised lesions
Type Va lesion
Fibroatheroma (type V
Atheromatous plaque, fibrolipid Advanced lesions,
lesion)
plaque, fibrousplaque, plaque
raised lesions
Type Vb lesion
Calcific lesion (type VII
Calcified plaque
Advanced lesions,
lesion)
raised lesions
Type Vc lesion
Fibrotic lesion (type VIII)
Fibrous plaque
Advanced lesions,
raised lesions
Type VI lesion
Lesion with surface defect
Complicated lesion,
Advanced lesions,
and/or
complicated plaque
raised lesions
hematoma/hemorrhage
and/or thrombotic deposit

(40)

Studies used to formulate this paradigm were conducted on animals. One of the
problems with this is that lesions in induced animal models differ from lesions found in
humans (31, 32, 40). To complicate matters further, lesions from human autopsy studies
demonstrated a wide array of morphological variations that are not entirely consistent with
the current AHA paradigm (40). Work by Virmani et al., found that there is insufficient
direct experimental evidence from humans and animal models to clearly explain lesion
formation and progression as laid out by the AHA (40). Nakashima also found that the
morphological features of early atherosclerosis differ between humans and animal models
(31). For example, the site of lipid deposition differs between animals and humans (41).
He found that the narrow subendothelial space was the site of lipid deposition in animal
models unlike in humans where the earliest lipid deposits occurred in the deep layer of the
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thickened intima (31). As a result, Virmani et al., devised a more thorough classification
(Table 2) that is consistent with the AHA paradigm, yet which more accurately classifies
the morphological variations that exist in such models of atherosclerotic research (40).

Table #2: Virmani's Modified AHA Characterization
Modified AHA Classification Based on Morphological Description
Nonatherosclerotic intimal lesions
Intimal thickening
The normal accumulation of smooth muscle cells
(prone)
(SMCs) in the intima in the absence of lipid or
macrophage foam cells
Intimal xanthoma, or
Luminal accumulation of foam cells without a necrotic
"fatty streak"
core or fibrous cap. Based on animal and human data,
(resistant)
such lesions usually regress.
Progressive atherosclerotic lesions
Pathological intimal
SMCs in a proteoglycan-rich matrix with areas of
thickening
extracellular lipid accumulation without necrosis
Erosion
Luminal thrombosis; plaque same as above

Fibrous cap atheroma
Erosion

Thin Fibrous cap
atheroma
Plaque rupture
Calcified nodule
Fibrocalcific plaque

Well-formed necrotic core with an overlying fibrous
cap
Luminal thrombosis; plaque same as above; no
communication of thrombus with necrotic core
A thin fibrous cap infiltrated by macrophages and
lymphocytes with rare SMCs and an underlying
necrotic core
Fibroatheroma with cap disruption; luminal thrombus
communicates with the underlying necrotic core
Eruptive nodular calcification with underlying
fibrocalcific plaque
Collagen-rich plaque with significant stenosis usually
contains large areas of calcification with few
inflammatory cells; a necrotic core may be present

Thrombus absent

Thrombus absent

Thrombus absent
Thrombus mostly
mural and infrequently
occlusive
Thrombus absent
Thrombus mostly
mural and infrequently
occlusive
Thrombus absent; may
contain intraplaque
hemorrhage/fibrin
Thrombus usually
occlusive
Thrombus usually
nonocclusive
Thrombus absent

(40)

Virmani reorganized the AHA classification of type I and II lesions as nonatherosclerotic, intimal xanthomas that do not develop into progressive atherosclerotic
lesions in animal models (40). He also found that intimal xanthomas are consistently
prevalent in all populations especially when exposed to a Western diet (40). According to
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human, as well as animal studies, intimal xanthomas usually regress. On the other hand,
intimal thickenings include SMCs that are clonal in nature which can readily progress to
"pathological" intimal thickenings that include a proteoglycan rich matrix along with some
areas of extracellular lipid accumulation (40). Intimal lesions are characterized by the
infiltration of mononuclear cells in the absence of foam cells thus outlining the earliest
stage of atherosclerotic lesion development (28). Doran et al., found that SMCs are the
first cells present at sites destined to develop into atherosclerotic lesions (34). Recent
studies reveal that intimal thickenings are in fact the precursors for advanced
atherosclerotic lesions and that intimal proteoglycans are actively involved in the disease
process of atherosclerosis in humans (31, 41, 42).
While human and animal models contribute to the understanding and
characterization of the morphological features that present in early atherosclerosis, they
raise many more questions regarding the underlying pathology of the disease. Challenging
these classifications, however, will provide a valuable framework from which to develop a
more complete understanding of the processes involved in this complex multifactorial
disease (22).
Research thus far, emphasizes the need to look deeper to explore the genetic
factors that contribute to susceptibility to atherosclerosis in some individuals while others
maintain resistance (21). Collectively, clinical genetic studies have established that genetic
factors do play a major role in susceptibility to atherosclerosis (5), but because of the
phenotypic complexity of atherosclerosis in humans it has been increasingly difficult to
characterize genetic mechanisms responsible for the disease (15). While examining
heritability of atherosclerosis in both family and twin studies, inheritance was a reliable
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factor for determining atherosclerotic risk, in most cases exceeding 50% of those evaluated
(43). This was further demonstrated in a study by Marenberg et al., which found the
concordance rate among monozygotic twins to be twice as high
(8.1:3.8 <$\ 15:2.6 $, with a 95% confidence interval) as that of dizygotic twins (7).
Given this understanding, atherosclerosis does not behave like a single gene
Mendelian disease (5). In general, atherosclerosis in humans is believed to be a complex
polygenic disorder that results from a combination of numerous genes and environmental
factors (5). In addition, atherosclerosis is also a heterogeneous disease in that different
individuals express various manifestations of the disease with respect to genetic and
environmental contributions (5, 30, 43). As a result, understanding the various contributing
factors of the disease may determine the therapy or therapies best suited to treat it (43).
Understanding Mendelian diseases and known Mendelian forms of atherosclerosis could
also provide an understanding into the pathogenesis of common non-Mendelian forms of
atherosclerosis (5).
Familial Hypercholesterolemia (FH) and Tangier disease are primary examples of
how studying Mendelian disorders have contributed to the effective treatment and
understanding of monogenic diseases (43) that ultimately lead to atherosclerotic
complications (5). The study of FH has also contributed to the determination of the
molecular pathways that regulate cholesterol metabolism, thus leading to drug treatment for
many individuals affected by this major risk factor, associated with atherosclerosis (43, 44).
It is thus becoming increasingly clear that understanding the role of inheritance is crucial to
be able to reduce mortality from this disease. In order to effectively identify genetic factors
responsible for atherosclerosis, it will be necessary to incorporate complementary
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approaches such as the use of animal models that facilitate functional genetic experiments
(43). When it comes to candidate genes, Mendelian diseases provide a logical basis for the
study of atherosclerosis (43). Many candidate genes have already been identified, but
because of the multiple factors implicated in human atherosclerosis, it is difficult to directly
examine the role of these genes (43, 44). Consequently, there has been limited success in
providing reliable explanations for disease susceptibility (3). Because atherosclerosis
involves the interactions between arterial cells, blood elements, and genetic factors acting
at the level of the arterial wall, each of these may likely influence the genetic regulation of
susceptibility to the disease process (43, 45). In addition, the heterogeneity of human
populations, as well as the growing likelihood that many genes are involved in the disease
process, makes it increasingly challenging to identify genes involved in atherosclerosis (3).
For these reasons, animal models can be particularly useful to identify genes, that may be
involved in human atherosclerosis (43).

Pigeon Models
When selecting an animal model it is essential to choose one that best approximates
the pathophysiology of the disease in humans (4). It is also important, whenever possible,
to choose a model that is low in cost, provides ease of housing, is manageable in size,
breeds relatively quickly and easily, and has a well-defined genetic background (4).
Specifically, when selecting a model, one needs to look for a model that develops
atherosclerotic lesions in a pattern similar to that in humans as described in previous
autopsies, and histology reports.
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There is no one model that meets all these criteria when designing an experiment;
therefore, one must select the best model given the available options when testing a
particular hypothesis (4). A systematic examination of the sequence of events using a
model with minimal environmental influences is therefore essential to determine the
genetic contributions, which phenotypically resembles the disease in humans (21, 26).
Studies already reveal that the genetic scaffolding of humans is shared with many
other organisms (46). The completion of the Human Genome Project is an asset in that it
provides a foundation for determining functional parts of genomes in order to improve the
health of individuals (47). Once the gene or genes responsible for atherosclerosis in an
animal model are identified, they can then be matched against the human genome to
enhance the understanding of the multifactorial process involved in human atherosclerosis
(26). The comparative analyses of genome sequences are of great value because common
functions between two organisms are often conserved, and thus encoded within the DNA
(47).
The pigeon {Columba livia) originated from Europe, Asia and North Africa, giving
rise to hundreds of varieties (48). The use of the pigeon as a model is exceptional because,
both resistant breeds as well as susceptible breeds, which spontaneously develop
atherosclerosis, exist (49). Clarkson as well as others have described the development of
spontaneous atherosclerotic lesions in the White Carneau (WC) pigeon as nearly identical
with those in humans, both grossly, microscopically, (8, 13, 14, 50, 51) and biochemically
(52).
Kjaernes reported that the results of atherosclerotic research in animal models often
contradicts the effects found in humans, while the events in WC pigeons regarding lesion
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properties and location are quite similar to those in humans (11). Kjaernes observed that the
spontaneous lesions found in WC pigeons, develop primarily at sites of low sheer stress
such as the celiac bifurcation of the aorta, which supports Caro's low sheer stress
hypothesis (at sites of turbulent flow) (11). This same pattern was also observed in human
autopsies (11, 49). It was therefore suggested that the pigeon may be the best model to
study the development of atherosclerosis in humans (4, 11).
The care and feeding of pigeons is such that they can be maintained in a wide
variety of seasonal climates as long as water is kept from freezing and that they are
permitted limited exercise in the form of a flypen (48). In general, a 12-hour light and
dark cycle is recommended, although a 14-hour light cycle will enhance breeding (48).
Pigeons achieve sexual maturity by 6-7 months and achieve peak breeding between 3-6
years (48).
Some of the advantages of using the pigeon as a model to study heart disease
include; susceptibility to atherosclerosis, lesions that are similar to those in humans, based
on location, histology, and progression, low cost, easy handling, sufficient size, and
relatively long lifespan (4). Some disadvantages of using pigeons are that they are difficult
to sex; they mate for life and often live well into their twenties. If separated from their
partner, it can take up to a year before pigeons will select a new mate and reproduce at a
maximum rate of two eggs every 6 weeks, from spring to early fall (15). Pigeons are
nonmammalian (although both sexes produce a crop milk secretion to feed their young)
(53); they are at risk of developing a herpes virus associated with atherosclerosis (50, 54);
and they undergo many changes in lipoprotein metabolism during egg-laying and through
the first few days after hatching (4).
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In addition, all pigeons, unlike humans, lack apo-E, apo-B-48, and chylomicron
formation (52). Because both breeds share the same commonalities of cholesterol transport
explained later in this report, the lack of apo-E and apo-B48 cannot explain susceptibility in
the WC and resistance in the SR, and therefore removes Apo-E and Apo-B-48 as risk
factors for the development of atherosclerosis (13, 50).
The pigeon has been the most widely used avian species in atherosclerotic research
(8, 52). The primary site of plaque development in WC pigeons is at the celiac bifurcation
(branch point) of the aorta (1, 52). As time progresses, lesions develop at other sites in the
aorta and in the coronary arteries (50). Clarkson et al., first reported that WC pigeons
develop spontaneous atherosclerosis while other breeds such as the Show Racer (SR)
pigeons maintain resistance (49). The SR pigeons originated from racing homers about
185 years ago and have remained a closed breeding colony for more than 45 years (52).
Clarkson et al., suggested that atherosclerosis in the WC pigeon is the result of a genetic
factor, independent of other risk factors (8, 13, 55).
Morphological analysis of aortas in WC pigeons revealed that lesions are present in
all WC pigeons with no difference between genders (8). The lesions appear as raised
yellow plaques that project into the lumen and are mostly found at branch points (sites of
bifurcation). Although some lesions do develop along the straight segments of the aorta, a
few plaques practically occlude the lumen of the aorta (8). Most of the spontaneous lesions
are primarily fibrous (8). The predictability of these spontaneous lesions at the celiac
bifurcation of the aorta make the WC pigeon a good model system for the study of
metabolic parameters associated with the disease (10).
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Paired muscular intimal thickenings are present at the celiac bifurcation of 10-day
embryos and very young birds, with cushions of SMCs protruding into the lumen (10). In
squabs, ridge-like thickenings were observed prior to the presentation of lipid along the
lateral edges of the celiac orifice (10). By 4-6 months, the earliest lipid accumulation can
be seen on the surface of these intimal cushions (10). According to Santerre, aggregates of
SMCs appear to be a prerequisite for lipid accumulation and appear to dominate
metabolism in the healthy state, as well as in all lesions and at all stages of the spontaneous
diseased state (10). Vacuoles appear to develop from the dilated granular endoplasmic
reticulum in modified SMCs of very young WC pigeons (14). The appearance of
thickened basement membrane envelopes on modified SMCs, disorganization of elastic
laminae, and excess collagen in WC pigeons are strikingly similar to those features seen in
the early lesions found in humans (14).
Lesions that develop in WC pigeons increase in size with age, and progress through
various stages of plaque development (49). The activation of cells involved in the disease
process, relies not only on local effects, cytokines, and growth factors, but also on intrinsic
genetic properties (49). Advanced lesions contain intra- and extracellular lipids,
cholesterol clefts, fibrous tissue, SMCs, and what appears to be macrophage foam cells
(52). Only after atherosclerotic lesions appear is there an increase in the influx of LDL at
specific sites of arterial lesions (50). As lesions progress, ulcerations, hemorrhage, mineral
deposition, and even bone formations are common (52). Complications of thrombosis and
complete occlusion in the WC pigeon develop only during the later stages of the disease
(8). A unique feature in WC pigeons, in contrast to other animal models is that myocardial
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infarctions occur in older pigeons displaying the most severe stage of atherosclerosis (50).

Richards (as well as Santerre) studied the spontaneous development of lesions in
WC pigeons from 1 month to 3 years of age (and 1 month to 6 years respectively) to
document their location and stages in development (10, 12). Richards observed that in
hatchlings, lesions progressed as age increased, though the final distribution pattern was
apparent by 5 months of age (56). In other words, no new lesions developed after this age
(12).
Comparing and contrasting susceptible and resistant breeds are useful to examine
the biochemical functions involved in atherosclerosis (49). When comparing lipid content
in the celiac bifurcation at 1 day, 6 weeks, 12 weeks and 6 months, Hajjar et al., found that
total lipid content in the WC pigeon was significantly greater by 6 weeks of age and 6
months of age when compared to the SR pigeon (57). A dramatic increase in non-esterified
fatty acids (NEFA) was also observed by 6 weeks of age in the WC when compared to the
SR and remained significantly greater as age increased. Also apparent was a marked
increase in cholesterol at celiac sites by 6months in the WC pigeon as compared to the SR
(57).
In another study, Hajjar et al., found that by 6 months of age there was a dramatic
decrease in the P/O ratios of ATP synthesis and oxygen consumption in the celiac cushions
of the WC as compared to the SR (17). They suggested that the reduced ability of the WC
to produce ATP was of a genetic origin (17). Work conducted by Curwen et al., on
quantitative electrophoretic profiles of glycosaminoglycans (GAG) in WC and SR at 1 day,
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6 weeks, 6 months and 3 years of age revealed that the WC contained more total
glycosaminoglycans than the SR at all ages in the celiac bifurcation (16). After
6 months, changes were noted in specific GAGs between WC and SR, suggesting GAGs
play a role in the pathogenesis of atherosclerosis (16).
While examining aortic tissue of both WC and SR Hajjar et al., did not notice any
ultrastructural differences between the two breeds until 6 months of age (57). It was at that
point that they consistently found more debris-like material in the celiac cushions of the
WC when compared to the SR pigeon (57). Some of this extracellular membranous
material appeared to be uniformly round while other vesicles were more heterogeneous in
shape, but both appeared to originate from SMCs (57).
Both SR and WC pigeons, unlike humans, maintain typical cholesterol levels of
approximately 300 mg/dl. Approximately, two thirds of their cholesterol is transported in
the form of HDL as part of their normal cholesterol pathway in contrast to humans, which
are LDL carriers (45, 52, 58). Since most animals do not develop spontaneous arterial
lesions, they have been historically placed on high-cholesterol diets for months at a time
prior to examination of their arteries (11). Upon feeding a 0.5% cholesterol diet, both SR
and WC pigeons develop marked hypercholesterolemia of approximately 1,000 to 2,000
mg/dl (52). The marked increase in cholesterol concentrations interestingly causes the
primary carriers of cholesterol to shift from HDL to B-VLDL and LDL.
Apo-B becomes the predominant apolipoprotein in this induced state, and acyl-CoAcholesterol acyl transferase (ACAT) activity increases to facilitate transport, which is
similar to humans and other animals (50).
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Examination of WC pigeons to determine whether blood pressure (BP) plays a
major role in the progression of atherosclerosis, showed no significant effect of season or
age on BP between 6-12 months when early atherosclerosis begins; nor was there a major
difference in BP between SR and WC (59). Wagner did find, however, that after 6 months
on an atherosclerosis-inducing diet, BP increased as a result of atherosclerosis (59) making
it therefore a secondary effect.
While examining the lumen of the aorta, Wagner found that the WC pigeon has a
larger lumen compared to the SR pigeon although there were no differences between wall
thicknesses. He also found that the WC wall contained greater amounts of elastin but little
difference in collagen (49). These differences were not found to occur in response to
plaque development but were the result of intrinsic properties within the aorta attributable
to each specific breed of pigeon (49).
In addition, when spontaneously atherosclerotic WC pigeons are fed an
atherogenic diet, lesion development is accelerated (1, 52). These induced lesions contain
lipid engorged macrophage cells, that form fatty streaks, which differ from those that
develop spontaneously (1, 50, 60). This diet-induced state not only exacerbates, but alters
the progression of the spontaneous disease (1, 52, 61, 62), no longer making it a valid
model to study the underlying early mechanisms of the disease (60). In addition, upon
examination of the induced disease, locations of these lesions are typically found at sites of
high physical stress, which correlates with Fry's high shear stress hypothesis, unlike lesions
found in non-induced states (11, 49). Once the atherogenic diet is replaced by a typical
non-inducing pigeon chow diet, cholesterol concentrations in both SR and WC pigeons
return to normal levels within a few weeks (52). In the presence of an atherogenic diet,
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resistance to atherosclerosis is maintained in the SR pigeons unlike the WC pigeons. This
difference appears to be genetically controlled (55), and the absence of lesions in the SR
pigeons suggests that genetic factors are responsible for resistance to atherosclerosis (8,
15).
Breeding experiments present the most convincing evidence regarding genetic
influence on the development of specific atherogenic lesions (55). After crossbreeding Fl
WC and SR to produce F2 progeny, Goodman and Nash suggested that genetic factors play
a major role in atherosclerosis (9). They also reported that genetic factors for initiation
were largely independent of those responsible for lesion progression (9). Smith et al.,
reported that a limitation of Goodman and Nash's study was that the pigeons were placed
on a high cholesterol diet which altered and accelerated the spontaneous disease
progression, and that the progeny were never backcrossed to determine the inheritance
pattern (15).
In 2001, after completing a 15-year study Smith, Smith and Taylor reported the
mechanism of inheritance for susceptibility to spontaneous atherosclerosis in WC pigeons
(15). They demonstrated this inheritance pattern through crossbreeding inbred strains of
susceptible WC and resistant SR pigeons to produce Fl and F2 progeny and finally
backcrossing the Fl progeny with parental WC and SR pigeons (15). Upon examination of
lesions visible at the celiac bifurcation of the various progeny, they determined that
atherosclerosis was inherited as a Mendelian single-gene, autosomal recessive pattern (15).
Smith et al thus concluded that the WC pigeon is an effective model to study genetic
factors that lead to the development of lesions at the level of the arterial wall (15). They
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therefore determined that the genetic patterns of spontaneous lesion development in the
WC pigeon makes it a simplest case scenario due to the absence of risk factors (15).
To better understand genetic factors responsible for both susceptibility and
resistance, Anderson compared differential gene expression between WC and SR pigeons
(63). Her work on SMCs (from the celiac bifurcation) in-vitro (representing a compressed
time- frame of approximately 2-3 years in-vivo) showed that genetic differences do in fact
exist between both breeds. Anderson found for example, ribosomal biogenesis was clearly
upregulated in the SR (63). While 7 genes were unique to the WC (27copies) only 1 gene
(1 copy) was unique to the SR. Five genes were differentially upregulated in both the WC
and the SR, yet the number of copies in the SR greatly exceeded those in the WC (81:10).
The primary contributor of this regulation was Ribosomal Protein L3 (RPL3) that was
differentially upregulated 69 times in the SR (63). Given the number of genes that were
differentially upregulated between both breeds, the regulation in the SR was more than
twice that of the WC.
Anderson also reported a marked difference in energy metabolism between both
breeds. While the genes Cyctochrome C oxidase subunit I (COI), NADH dehydrogenase
subunit 4 (ND4), NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10 (NDUFAIO),
and ATP synthase subunit 4B (ATP4B) representing oxidative phosphorylation were
upregulated in the SR, Enolase 1 (ENOl), Glucose 6 phosphate Isomerase (GPI), and
Lactate Dehydrogenase (LDHA) which participate in glycolysis, were upregulated in the
WC pigeon (63). Additional metabolic differences reported by Anderson revealed that
genes expressed by the SR were indicative of a healthy smooth muscle contractile
phenotype (63) while the susceptible WC pigeons expressed genes that represented a
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synthetic phenotype (or loss in smooth muscle regulation). Anderson also found that the
genes expressed by the resistant breed indicated that they were much better at organizing
and maintaining the extracellular matrix while genes expressed in the susceptible WC
indicated a lack of structural integrity of the matrix (63). Anderson concluded the
differences in genetic expression patterns between both breeds helped to explain factors
responsible for both susceptibility and resistance however, she was unable to discern the
chronological sequence of events for initiation and progression of atherosclerosis (63).
Based on the available research, it is reasonable to suggest that the WC pigeon is one of the
best models to study the genetic effects at the level of the arterial wall that are associated
with human atherosclerosis (4).

Identification of Differentially Expressed Genes
Expression patterns of genes are continuously changing during the growth and
differentiation of tissues (19). The expression of a given gene in a cell at any one point in
time defines the characteristics of the cell and impacts the downstream effects which can
ultimately invoke a disease state (19). Given that atherosclerosis is a disease that develops
slowly over time presenting various characteristics, it is important to choose a method or
methods that will capture genetic material and effectively identify genes of interest,
particularly those that are different between known ages of development.
Research conducted on WC pigeons shows that in the aorta chemical changes occur
by 6 weeks of age while morphological changes are observed by 6 months of age (2, 16,
57, 64). Given these results, it is necessary to utilize a method that examines differences in
genetic expression between these known ages of development.
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Many methods are available to target differential expression between two similar
systems. Some of the methods include Serial Analysis of Gene Expression (SAGE),
Differential Display (DD), Subtractive Hybridization (SH), Microarray and
Representational Difference Analysis (RDA). One of the main advantages of all of these
methods except for Microarray is that they do not require prior knowledge of the sequences
to be analyzed (65). Although Microarray can only analyze known genes it does allow for
large numbers of genes to be compared in a single assay (66, 67). An advantage of both
SAGE and DD is that both methods only require small amounts of total RNA as their
starting material (19, 65, 68). A disadvantage is that primers are attached to the 3' end of
transcripts in both SAGE and DD which may hinder their identification and
characterization following Polymerase Chain Reaction (PCR) (69).
Although DD is versatile, easy to monitor and offers ready access to sequence
information (19, 70), a major disadvantage is the number of false positives when
determining actual differences between transcripts (68-70). This is because determination
of differential expression relies totally on "visual" examination of the bands from agarose
gels (69). One study found that 19 out of 20 amplified bands that were analyzed were false
positives (70). While SAGE amplifies thousands of sequence tags, because they are small,
they offer little sequence information for novel genes (69). In addition the large numbers
of transcripts that are generated make it cumbersome and rather time consuming to detect
genes that are differentially expressed (69).
The method of SH involves the removal of genes that are shared between two
similar populations. Genes that do not hybridize with one another are therefore
differentially expressed and remain single stranded (ss). Subsequent steps therefore require
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additional methods such as the preparation of libraries to store the ss DNA which can be a
cumbersome and costly process (19).
Representational Difference Analysis is a positive enrichment technique that
couples both SH and PCR to amplify only those genes that differ in their expression
between two populations (69, 71, 72). The method of combining two populations includes
the primer ligated target population known as the "testers" and the non-primer attached
"drivers" which are greatly in excess of testers (69, 71, 72). Following the hybridization
reaction, three types of populations result; driver:driver (non-amplified), testendriver
populations that experience linear amplification, and finally the differentially expressed
target populations known as, tester:tester that are exponentially amplified, diluting nondifferentiated genes beyond detection (69, 71, 72). Tyson and Shanahan successfully used
this technique to compare differences between cDNA populations from human
atherosclerotic plaques and normal segments of the aorta (69).
One of the benefits associated with RDA include, its ability to detect transcripts of
low copy number due to the combination of hybridization kinetics and exponential
enrichment (71). This is especially important given that in a mammalian cell, 15,000 genes
on average are expressed at any one time and of that approximately 83% of transcripts are
present in only one copy per cell (71, 73). Also, only a small amount (100-250ug) of total
RNA is needed (69) as the starting material. Unlike other methods, RDA produces longer
expressed sequence tags (ESTs) (256bp on average) that are more likely to originate from
their parent cDNAs (72) ultimately optimizing the number of positive outcomes. Another
advantage of RDA is its ability to detect novel transcripts (72). In addition, RDA is cost
effective, sensitive, relatively quick and yields a minimum number of false positives (<
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5%), along with the fact that once the method is complete only differentially expressed
genes remain (72).
In light of the many advantages of RDA, some limitations remain. For example,
differences between genes expressed at the moment that total RNA is extracted represent
only a snapshot in time and therefore does not capture all the possible genes expressed in a
cell. Because the method selects for expressed differences, it is possible that many of these
genes have not yet been annotated, and results in genes being classified as "unknowns"
(72). Low yield can result from poor techniques so it is essential to maintain meticulous
care in planning as well as execution of techniques throughout the experiment to optimize
recovery of material (71). In addition, any cDNA fragments that are less than 100-150 base
pair in length are removed, which may potentially remove key genes of interest (72). An
additional limitation can occur when an EST of interest lacks two sticky ends on the 5'
prime ends of the double stranded cDNA. In this event, the tag is amplified linearly at best,
and therefore washed out. The current use of a four-cutter enzyme in place of the
previously used six-cutter optimizes the number of manageable sizes of cDNA that can be
used with this technique. The subsequent use of an additional four-cutter can further
optimize the recovery of genes of interest (72). Anderson's work included optimization of
the RDA method that was provided by Pastorian et al., therefore reducing many of the
limitations experienced with the method (63). When compared to other methods, RDA
presents fewer limitations, making this an excellent method of choice.
Work conducted by Anderson utilizing the optimized RDA method in WC and SR
pigeon aortic cell cultures identified 165 genes that were differentially upregulated in
SMCs (63). Seventy-four genes were differentially upregulated in the WC while 63 genes
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were uniquely upregulated in the SR pigeon. While Anderson was able to identify many of
the genes, because of the compressed developmental time-frame associated with her invitro system, she was unable to determine their chronological sequence of expression
associated with susceptibility or resistance. Anderson's findings emphasize the need to
conduct future in-vivo experiments that compare selected ages, in order to reveal the
chronological sequence of differential gene expression. Once the metabolic roles of the
differentially expressed genes are understood, the sequence of events in the disease process
can perhaps be elucidated.
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Research Objective
To distinguish between genes that are responsible for initiation of spontaneous
atherosclerosis in the pigeon model and those responsible for progression by identifying
genes that are differentially expressed at the celiac bifurcation of the aorta between 1 day, 6
weeks, and 6 months of age in White Carneau (WC) pigeons.
Genes that are differentially expressed early (1 day) will be considered to be involved in
initiation of the disease while those that are differentially expressed later (6 weeks and
months) will be considered to be involved in the progression of the disease.

Hypothesis
Genes responsible for initiation and progression of atherosclerosis in the WC pigeon will
be differentially expressed at 1 day, 6 weeks and 6 months of age.
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Experimental Design
1. Representational Difference Analysis (RDA) will be conducted to compare genes
differentially expressed in-vivo at the celiac bifurcation of the aorta in atherosclerosis
susceptible WC pigeons.

2. Vertical comparisons between three age groups (outlined in Figure 1) will be performed
using RDA in order to examine differently expressed genes:
comparison 1 (C-l):l day versus 6 weeks, comparison 2 (C-2): 1 day versus 6 months, and
finally comparison 3 (C-3): 6 weeks and 6 months.

Figure 1: RDA Experiment of WC Pigeon Comparisons Between the Ages

6 months
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CHAPTER II

METHODS AND MATERIALS

Pigeon Colonies
The WC pigeons were obtained from University of New Hampshire (UNH)
colonies that were housed in fly coops at ambient temperature and allowed free access to
water, Purina Pigeon Chow Checkers, and Kaytee Red Grit. The origin of the WC
population began from four pairs of birds that were purchased in 1915. They were then
mated with a few outsiders and a few more additions to complete the entire inbred WC
population by 1916 at the Palmetto PigeonTlant in Sumter, South Carolina (8). The UNH
colony was established in 1962 from WC pigeons obtained from the Palmetto Pigeon Plant
and have remained inbred since that time (63). The WC pigeons that are housed in the
UNH colonies are maintained under the guidelines of the UNH Animal Care and Use
Committee (Approval # 050601).

Whole Tissue Extraction Followed by cDNA Synthesis from Total RNA
Previous to this current research project RNA was extracted from aortic tissue at the
celiac bifurcation of WC pigeons at 1 day (experiment #137), 6 weeks (experiment #190a2), and 6 months of age (experiment #162) by Anderson in this lab. Surgical collection of
the celiac bifurcation of six WC pigeons at 1 day of age was conducted on two separate
occasions and stored in KNAlater® Solution (Applied Biosystems), (a tissue collection
RNA isolation stabilization solution), according to the standard protocol provided with this
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product (74). Once 62mg of whole tissue was collected, the tissue was frozen in liquid
nitrogen and ground by mortar and pestle, which was then combined with 1ml of Quantum
Prep® Master Blaster (BioRad) an RNA extraction reagent, according to the standard
protocol provided with the product (75). Master Blaster separates RNA from DNA and
cellular debris resulting in the collection of total RNA (experiment #137).
At 6 weeks of age, the celiac bifurcation of two female and one male WC pigeons
was surgically removed using the same protocol as described for the WC pigeons at 1 day
of age except, KNAlater® was not used. The reason for this was simply due to the fact
that tissue at 6 weeks of age is larger, making tissue collection easier. This allowed for the
celiac bifurcation of the birds to be collected on the same day and was followed
immediately by RNA extraction using TRIzol® (Invitrogen) instead of Master Blaster,
according to the standard protocol provided with Trizol® (76). The result was the
successful collection of total RNA (experiment #190a-2). At 6 months of age, the celiac
bifurcation was surgically removed from 3 males and 2 females according to the same
procedures outlined at 6 weeks of age resulting in sufficient amounts of total RNA
(experiment #162).
Complementary DNA synthesized from total RNA of 2 similar populations, is the
starting material for RDA (69, 71). Once 1 ug of total RNA was prepared at each age as
previously laid out the process of synthesizing cDNA ensued (63). The BD SMART ™
PCR cDNA Synthesis Kit (BD Biosciences Clontech Division #K1052-1), which includes
special oligo dT primers, was used to synthesize single stranded (ss) DNA from mature
mRNA with Poly-A tails by reverse transcriptase. This was followed by second strand
synthesis of DNA to yield full length double stranded (ds) cDNA. An advantage of the
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SMART

program is that as little as 50ng of total RNA are needed to select for mRNA in

order to produce and amplify cDNA in sufficient amounts for RDA (63). Finally, the ds
cDNA was placed in a -80° C freezer for storage awaiting the following RDA experiments.

Quantitative Analysis. Matching and Size Distribution of cDNA
Eighteen samples of cDNA (6 samples from each age 1 day, 6 weeks, and 6
months) were transferred from the -80° C freezer to the -20° C freezer for short-term use.
Standard aliquots of 2ul from each sample of cDNA in a total volume of 70ul Tris-EDTA
(TE) buffer (pH 8.0) were quantitated using spectrophotometry at 260nm (A260) to
determine yield. Next, 0.7ug of cDNA from each sample was run on a 1.2% surface
tension gel with lOul ethidium bromide (O.Olmg/ml) at 85 volts for 30 minutes. A
photograph of the cDNA samples under UV light using the MultiDoc-It Digital Imaging
System (UVP Model M-20) revealed a poor pattern of fluorescing as most of the lanes
appeared blank. Each of the cDNA samples should appear at this stage as a smear ( as
opposed to distinct banding patterns) that range between 300 and 7000 base pairs (bp) with
the greatest intensity between 2000 to 3000 base pairs to be considered for RDA (63, 72).
It was then decided to rerun the samples using a slightly thinner gel and to increase the
ethidium bromide to 15ul to ensure fluorescing of any cDNA smears that are present. In
addition, the volume was set at lul therefore increasing the amount of the cDNA in each
sample from 0.7ug to at least l.Oug. These changes resulted in quality smears in 88% of
the cDNA samples. Precise matching of cDNA smears according to bp size distributions is
essential to ensure that differentially expressed products are reflective of two similar
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comparisons (72). The three selected ages were visually matched, and stored at -20° C to
await RDA.
Representational Difference Analysis (RDA)
As described previously in the Literature Review, RDA is a multistep enrichment
technique that couples SH with PCR to discriminately select and amplify only transcripts
that are differentially expressed between two populations of cDNA. The RDA protocol,
provided by Pastorian et al., (72) was systematically modified in this laboratory by
Anderson (63) to minimize sample losses during multiple chemical and physical
manipulations.

A. Amplicon Preparation of cDNA by Restriction Digest
Five micrograms from previously matched 1 day and 6 week WC pigeon cDNA
samples (comparison one), were each combined with 4.44ul DpnII enzyme (lOU/ul; New
England BioLabs R05431), lOul 10X DpnII buffer and 18.2 Mohm water (in a total volume
of lOOul), and digested in the MasterCyler Gradient Thermal Cycler (TC) (77) (Eppendorf
#5331; 115V), for 18 hours at 37° C. DpnII is a four-cutter enzyme that recognizes and
cuts at the 5 prime end of the GATC site of double stranded cDNA leaving "sticky" ends
that allow for ligation of primers and amplification during subsequent steps. In addition,
DpnII cuts the cDNA into amplicons that are on average 256bp, (ranging in length from
200 to lOOObp) making them manageable in length which ensures amplification by PCR
(69, 72).
Following digestion, both samples were transferred to Phase Lock Gel tubes (PLG)
(Eppendorf # 955154151) and extracted first with lOOul of phenol-chloroform-isoamyl
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alcohol (PCI) and centrifuged (Eppendorf Model #5415D) at 14,000xg for 5 minutes
followed by the addition of lOOul of chloroform and repeated centrifugation. The
advantage of the PLGs is that they separate proteins and organics from the aqueous cDNA
phase and optimize recovery of cDNA.
The recovered lOOul aqueous cDNA was run through Micro-spin S-300 HR Spin
columns from Sephacryl® and centrifuged at 735xg for two minutes to remove small
pieces of cDNA less than 100-150bp in length and any remaining restriction reagents. The
samples were incubated overnight at -20° C in a mixture of lul glycogen (20 mg/ml), 0.1
volume (lOul) 3M sodium acetate (pH 5.3) and 2.5 volumes (250ul) of 100% molecular
grade ethanol to precipitate the cDNA out of solution further purifying the pellets.
The following day both tubes were centrifuged at 16,000xg for 18 minutes to pellet
the cDNA. Each pellet was washed with lOOul of 70% ethanol for an additional 2 minutes
to precipitate the glycogen and salt, purifying the cDNA. The supernatant was carefully,
vacuumed off from the cDNA using a lOul pipette tip to help prevent loss of the pellet.
The rim of the tubes were wicked dry with a paper towel and laid on their side to air dry.
Drying each cDNA pellet as much as possible facilitates the resuspension of cDNA in 20ul
of IX TE buffer. Resuspended cDNA was stored at -20° C for no more than 2 days or was
used immediately in the ligation of primers.

B. Preparation of Primers for Ligation to Drivers
The 12 and 24 primer sets presented in Table 3 purchased from Genosys (a
subdivision of Sigma), were recommended by Pastorian (72) and successfully used by
Anderson (63). The non-complementary interchangeable primer sets allow for ligation of
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primers to targeted cDNA populations, which prevent the unintentional amplification of
cDNA populations from previous rounds of RDA. This results in specific amplification of
true difference products.

Table 3: 12 / 24 RDA Primer Sets
Primer Set

A

12mer (5'-3')

24mer (5'-3')

Driver GATCAATAACTA

TGACGGACCGGTTGCGTAGTTATT

B Tester Round 1

GATCTTATGGCT

AGACAGTGCCGGATGTAGCCATAA

C Tester Round 2

GATCCTATTGAC

ATCTCAGGGGACCTGAGGCAATAG

D Tester Round 3

GATCCAGATGTA

ATACGTGCAGGCTGGTTACATCTG

E Tester Round 4

GATCTTATACTA

TAACCTCGGCCCTCGGTAGTATAA

F Tester Round 5

GATCTACGTACT

TCACATCGCCCCCTATAGTACGTA

(63)

To prevent the hydrolysis of lyophilized primers from frequent thawing and
refreezing throughout RDA, each of the (12mers and 24mers) primers were dissolved in
specified amounts of IX TE buffer according to the molecular weight (MW) provided by
Genosys. The absorbance (A260) of each of the primers was determined and calculated
with the manufactures MW, along with the dilution factor to determine the actual
molecular weight of each primer dissolved in IX TE buffer. Two different sets of aliquots
were then prepared in single use tubes, one set for the A primers and another set for primer
sets B-F and are as follows. Primer set A included: 12/24Amers (4.5ug and 9.0ug) and
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24Amers (25ug). Each of the primer sets B-F included aliquots of 12/24 primers (4.5ug
and 9.0ug), 24 primers (4.5ug) and 24 primers (18ug) that were stored at -20° C, ready for
use. Primer sets A 12/24mers were used to prepare drivers for each of the three
comparisons. Primer sets B through D 12/24mers were used to prepare testers for each of
the 3 rounds in each of the three comparisons to prevent unintentional amplification from
previous rounds throughout the RDA experiments. Primer sets E and F were not used
during the following steps however, were prepared in the event that additional rounds were
conducted, or as alternate primers during the preparation of drivers or testers.

C. Ligation of Primers to Drivers
Thel2/24mer primer set A mix (4.5 ug/9.0ug) was removed from the -20° C
freezer, thawed, pulse spun, and kept on ice. An aliquot of 9ul of 10X ligation buffer (New
England Biolabs) was thawed (kept on ice) and added directly to the 12/24mer mix
followed by enough Mohm water to bring the total volume of this core mix up to 45ul.
Both cDNA samples were removed from the -20° C freezer and thawed, and the total
contents (20ul) were transferred to thin-walled 0.5ml PCR tubes. Twenty microliters of the
core mix was then added to the PCR tubes containing the cDNA to bring the total volume
to 40ul. The PCR tubes were placed in the preheated TC at 55 ° C, preset to the "Slow
Cool" program, designed and optimized by Anderson (63). The program runs for
approximately 40 minutes and holds at 8° C until samples are removed. During this step,
the 12mers form temporary bridges with the 3 prime blunt ends of ds cDNA while the
GATC site on the 12mer anneals with the CTAG overhang on the 5'end of cDNA forming
hydrogen bonds. This allows the 24mers to temporarily anneal with nucleotides of the
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12mer and hold them in place in preparation for ligation of the 24mers to the GATC sticky
ends of the cDNA in the next phase.
A core mix containing 1 lul 10X ligation buffer, 90ul Mohm water, and 9ul T4
DNA ligase enzyme (New England Biolabs # M0202S) was made. Fifty microliters of this
mixture was transferred directly into the PCR tubes that contained the cDNA mixture, and
was incubated at 15° C overnight. During this step, the 24mer is ligated to the CTAG 5'
sticky end of the cDNA forming a covalent bond that was previously restricted by DpnII.
Following the ligation step, the cDNA products were incubated at 65° C for 10 minutes to
deactivate the ligase. Since the 12mers are not phosphorylated they easily dissociate from
the 3' end of the cDNA when incubated at 65° C (18).
The cDNA samples were run through S-300 spin columns as previously described
to remove ligase, buffer, 12mers, and any tags less than 100-150bp in length. The
recovered volume of the eluate primer-ligated cDNA products was increased by lOul of
Mohm water and the lOOul total volume was placed on ice.

D. PCR Amplification of Drivers
A core mix of 250ul 10X PCR buffer, 400ul 25mM MgCl2, 62.5ul lOmM dNTPs
and 1487.5ul Mohm water was prepared. Of that, 240ul was transferred into another tube
and placed on ice to use with Taq DNA Polymerase (5U/ul Promega Corporation Ml865).
To the remaining core mix, 15ul of the same 24mer set-A (25ug) used to ligate primers
onto drivers was added with 85ul of Mohm water to bring the total volume to 2060ul. The
core mix was divided equally between the two ligated cDNA populations and then 180ul
was transferred to 6 new PCR tubes for each population. The 12 PCR tubes were placed in
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the preheated TC at 72° C, and incubated for 1-2 minutes to fully extend the cDNAs, and to
create primer-binding sites on the 3' ends. Thirteen microliters of Taq polymerase was
added to the 240ul of core mix sitting on ice, and 20ul was added to each of the 12 PCR
tubes incubating in the TC. The PCR driver program was run for an additional 5 minutes at
72° C to fully extend the double stranded 24mer cDNA amplicons followed by 25 cycles
that alternated between denaturing at 95° C for 45 seconds, followed by 4 minutes at 72° C
to amplify the cDNA. A final incubation at 72° C for an additional 10 minutes ensured
extension of the cDNA drivers. The populations were pooled, extracted with PCI and
chloroform, precipitated, washed, vacuumed as previously described, and then resuspended
in lOOul of TE buffer.

E. Removal of Driver PCR Primers by DpnII
After the completion of amplified drivers, a restriction digest comprised of 90ul of
cDNA driver, 10.5ul of 10X DpnII buffer and 4.5ul DpnII enzyme was incubated overnight
at 37° C to remove the primers, regenerating the 5' sticky ends. Both cDNA populations
were phase extracted with PCI and chloroform, purified with S-300 spin columns, followed
by an overnight precipitation, ethanol wash, vacuuming, and finally resuspended in 50ul of
IX TE buffer.
The yield of amplified restricted drivers was determined by measuring absorbance
at A260 using an aliquot of 1.5ul of cDNA in a total volume of 70ul TE buffer. Aliquots
(0.5ug) of restricted cDNA drivers and unrestricted drivers were run on a 2.0% agarose gel
at 75V for 60 minutes, stained with 5ul ethidium bromide (O.Olmg/ml), and photographed
under UV light. Size distributions of the driver amplicons should appear as a smear as
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opposed to distinct bands, ranging between 150-lOOObp (72). While bands are not usually
visible until follow up rounds, which reflects the removal of cDNA lengths common
between both populations, visual analysis revealed that distinct bands were present in all of
the driver populations. The banding patterns ranged mostly between 250-750 bp with the
brightest intensity around 500 bp (well within the recommendations), therefore verifying
successful amplification and restriction of drivers and an abundance of differentially
expressed transcripts. Visual comparison between primer-ligated cDNA and restricted
cDNA revealed successful restriction digest by DpnII. Drivers were frozen at -20° C until
the following step.

F. Preparation of Testers
Each of the driver products were used to create the tester population of round one.
The ligation procedure is primarily the same as that performed for drivers except, that a
new interchangeable set of primers was used in each successive round of RDA to prevent
the unintentional amplification of transcripts from previous rounds. One microgram of
driver, along with a new set of B 12/24mers, was used to perform ligation in a total volume
of 60ul using the "Slow Cool" program. Following overnight enzymatic ligation at 15° C,
the TC was heated to 65° C for 10 minutes to deactivate the ligase. The newly ligated
cDNA products served as the testers in the subsequent steps of subtractive hybridization.
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G. Subtractive Hybridization of Species Common to both cDNA Populations
In each round of SH, the amount of driver used remained constant (5.0ug). The
amount of tester on the other hand was reduced in each consecutive round (1:10, 1:100 and
1:5000) to ensure that only differentially upregulated products between the comparisons
will result (72). Thirty microliters (0.5ug) from the newly ligated tester populations was
transferred into new tubes. Five micrograms from each driver was then added to the tester
populations. The total volume in each tube was adjusted to lOOul by adding IX TE buffer
resulting in two reciprocal SH reactions. Both tester:driver populations (C-1, lDay:6weeks
and 6weeks:lDay) were then extracted with PCI and chloroform, precipitated for a
minimum of 4 hours or overnight at -20° C, washed, vacuumed, and resuspended in 4ul of
hybridization buffer which helps to facilitate the hybridization reaction of like proteins
(72).
One microliter of 5M sodium chloride (NaCl) was added to two new PCR tubes,
and then placed in the TC. Both of the resuspended (4ul) testendriver populations were
placed in the TC at 95° C, with the PCR tubes containing NaCl for one minute, to denature
the double stranded cDNA of the tester and driver populations and heat the NaCl. The
contents (4ul) of the tester:driver populations were quickly transferred into the tubes
containing NaCl (facilitates hybridization reaction), followed by the addition of 20ul of
mineral oil to prevent dehydration and loss of material. Both of the PCR tubes were
returned to the TC and incubated at 95°C for an additional 3 minutes, to ensure that all the
cDNA species were denatured. The TC was reset to 67° C and hybridization was allowed
to proceed for 24 hours followed by the addition of 45ul of Mohm water to each of the
completed hybridization reactions. Both tubes were placed in the -20° C freezer for
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storage, or an aliquot of lOul from each SH population was transferred into 2 new PCR
tubes to be used for amplification.

H. PCR Amplification of Round One Subtractive Hybridization Products
Amplification of the SH products results in three possible outcomes. The first
experiences no amplification because hybridized driver:driver populations lack primers on
both of their 5'ends. The second products, testerrdriver ideally have primers ligated to the
5' end of the tester and therefore experience linear amplification at best. Finally the target
population, tester:tester contains primers on both the 5' ends of hybridized cDNA which
are amplified exponentially. Although drivers are much in excess of testers, the absence of
primers and the exponential amplification of targeted testers cause the drivers to become
diluted beyond detection due to such low copy number.
A dilution step added during the extension step of the 7th cycle of PCR at 72° C
effectively replaced the use of mung bean nuclease (72) ensuring that any linearly
amplified single stranded cDNA populations were reduced below the point of detection.
This was carried out by the addition of 4 new PCR tubes for each tester:driver population
which contained 180ul of core mix and included the same B 24mers that were used during
the ligation step along with the addition of 20ul Taq mix. Finally, aliquots of lOul were
transferred from the tester:driver populations already in the TC to each of the newly added
PCR tubes for a total volume of 210ul. The TC was resumed for an additional 20 cycles to
ensure that only exponentially amplifiable differentially upregulated products would be
present. Following PCR, the products were pooled, extracted with PCI and chloroform,
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precipitated, washed, vacuumed, and resuspended in TE buffer to yield lOOul, that were
labeled as Round One Difference Products (DPI).

I. Removal of PCR Primers by DpnII
Eighty-seven microliters of amplified DPI was transferred into new tubes. Ten
microliters of 10X DpnII buffer and 3ul DpnII enzyme were added for a total volume of
lOOul in each tube. The tubes were incubated overnight at 37° C to restrict the 24Bmers
from the tester populations and regenerate 5' sticky ends. The next day the round one,
difference products were extracted, purified, precipitated, washed, vacuumed and
resuspended in a total volume of 50ul IX TE buffer.
Both difference products were quantified by measuring absorbance at 260nm using
5ul from each DPI in a total volume of 500ul IX TE buffer. Calculations revealed the
amount of cDNA ranged between 30-45ug for each of the rounds throughout the 3
comparisons, which was well above the recommended 10-20 ug as suggested by Pastorian
(63, 72). Five micrograms from the DPI products were separated on a 2% gel at 75V for
60 minutes, and stained with 5ul ethidium bromide (O.Olmg/ml) to assess size distribution
patterns. Although bands are not expected until the second or third rounds of RDA (72)
visual analysis revealed distinct bands (Figure 2) ranging between 250 and 750 bp, well
within the recommended 150-1000 bp. This was the case in all rounds of the three
comparisons.
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Figure 2: Round One Difference Products (DPI) 1 Day and 6 Weeks

1 day (digested), lday

lOkb

6 weeks (digested), 6 weeks

J. Rounds Two and Three of RDA
In each successive round of RDA, the amplified differentially upregulated products
from the previous round of SH served as the tester for the next round. For example, the
amplified difference products from round one (DPI) became the tester for round two, and
the products from round two became the tester for round three. In rounds two and three the
procedure used for the ligation of primers onto the 5'end of testers for SH and
amplification of difference products was the same as for round one except in round 2,
12/24mer C primers were used, and for round 3, 12/24mer D primers were used. In each
round of SH, the amount of driver (5.0ug) remained constant, while the amount of tester
was decreased from 0.5ug in round one, to .05ug in round two, to .OOlug in round three.
During round two of PCR, the samples were subjected to the same number of cycles as in
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round one; however, in round three, during the second half of PCR, the number of cycles
was increased from 20 cycles to 25 cycles. Following PCR, the amplified hybridized
testers went through the same restriction and purification steps as in previous rounds.
Determination of yield and gel analysis also followed the same steps as in the previous
rounds. The yield for each round was well within the recommendations as was the size
distribution patterns of each of the gels.
Storage of digested cDNA for more than two weeks can result in the ligation of
sticky ends to one another (63). Frequent digests can result in the loss of cDNA yield.
Therefore, since the round three products (DP3) were to be cloned simultaneously, DpnII
digestion of the DP3 products from all three comparisons were conducted together just
before cloning.

Cloning of Subtracted Round Three Difference Products
The pBluescript II SK+ (pBS) Vector (Stratagene #212205) was selected due to its
easy ligation of cDNA inserts at the BamHI site (63). A restriction digest using BamHI
enzyme (lOU/ul, Fermentas), as well as dephosphorylation with calf intestine alkaline
phosphatase enzyme (CIAP, Stratagene #600015), was necessary to prepare the vector for
the cDNA inserts.

Five microliters of the pBS vector, 5ul 10X BamHI buffer, and 5ul

BamHI enzyme (lOU/ul) in a total volume of 50ul was digested at 37° C for 1 hour. This
step was followed by dephosphorylation with 30ul CIAP enzyme, and lOul 10X CIAP
buffer in a total volume of lOOul that was incubated in the TC for 30 minutes at 37° C and
then adjusted to 68° C for an additional 15 minutes. The CIAP catalyzes the removal of
phosphates from the 5' end of cDNA, which prevents re-ligation to the 3' end (78). This
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mixture was extracted with lOOul PCI and chloroform, precipitated, purified with S-300
spin columns, washed, and vacuumed as explained in previous methods. The pBS vector
was resuspended in 5ul of IX TE buffer, and stored at -20° C until its use. One microliter
of pBS vector in a total volume of 50ul IX TE buffer was used to determine yield at A260
followed by running 0.3ug of vector on a 1.2% gel with 6ul ethidium bromide at 85 V for
25 minutes. The gel revealed a successful dephosphorylated linearized pBS Vector that
appeared as a single band located at 3KB.
The final digestion of the DP3 products from the three comparisons was then
carried out using 3ul of DpnII enzyme in a total volume of lOOul in the same manner as in
previous ligations. Digested DP3 products were followed up with extraction using PCI
and chloroform, precipitation, purification, wash, and vacuum of populations followed by,
the resuspension of each DP3 product in 50ul IX TE buffer. Five microliters of each DP3
in a total volume of 500ul TE buffer was used to determine yield at A260. Aliquots of
0.5ug of cDNA from each sample were run on a 1.2% gel at 75V for 60 minutes, and
stained with 5ul ethidium bromide (O.Olmg/ml) as previously described. Results in Figure
3 revealed distinct banding patterns and appropriate size distributions to proceed forward
with the method.
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Figure 3: Round Three DpnII Digestion of All Three Comparisons

1 day:6 weeks Wkb

1 day:6 months Wkb 6 weeks:6 months lOkb

Stratagene recommended that the concentrations of vector and inserts should be
O.lug/ul (78). These concentrations were determined by Anderson to work best when in a
ratio of 1:2 (insert: vector) during the ligation reaction (63). Rather than dilute the whole
cDNA DP3 population and risk degradation, 2ul was aliquoted from the total volume (63).
This aliquot was then diluted to the recommended concentration of O.lug/ul of which 0.5ul
was then combined with l.Oul of vector, 0.5ul T4 DNA ligase, and l.Oul T4 buffer in a
lOul total volume that was incubated at 4° C overnight.
An LB/agar bacterial growth broth comprised of lOg NaCl, lOg Tryptone, and 5g
Yeast, in a total volume of 1 liter of Mohm water at a pH of 7.0 was then mixed with 15g
Agar and autoclaved. The broth was cooled to 55° C followed by the addition of 8ml Xgal (lOmg/ml, Promega), 0.5ml IPTG (lOOmM, Promega), 1.0ml ampicillin (50mg/ml) and
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2.5ml tetracycline (5mg/ml). This was poured into plates and allowed to set overnight at
room temperature according to the XLl-Blue MRP' Supercompetent Cells protocol (79).
The following day the pBS vector-ligated difference products were transformed into
the XLl-Blue MRP' Supercompetent Cells (XL1-cells). A vial of SOC Medium (is a
nutrient rich medium that improves transformation efficiency) was transferred from -20° C
to a 42° C water bath to slowly thaw the SOC. Six 14ml tubes were chilled on ice while
the XL1-cells were removed from -80° C and were slowly thawed on ice. Once thawed,
lOOul of the XLl-cells were transferred into each of the 14ml tubes, followed by 1.7ul BMercaptoethanol (serving as a reducing agent to cleave disulfide bonds). The contents
were stirred gently every 2 minutes for 10 minutes (while on ice) so not to damage the
cells. Next 2ul of pBS vector-ligated cDNA was transferred into the respective
transformation tubes, which were stirred and incubated for an additional 30 minutes. All
six transformation tubes were placed in a rack and heat pulsed in a 42° C water bath for
precisely 45 seconds. Next, 900ul of the pre-warmed (42° C) SOC was transferred into
each of the six 14ml transformation tubes, which were then shaken, at 230 rpm for 1 hour
at 37° C to allow the cells to produce approximately one generation. Next, the Agar treated
growth plates were warmed at 37° C and labeled to include 5 plates for each
transformation, with one serving as a titer plate. Five microfuge tubes for each
corresponding transformation reaction were labeled, and 2ul of transformation mixture was
added to the 6 tubes that were labeled as titer tubes, while 40ul was added to the rest of the
tubes (4 for each transformation). Next, 198ul of SOC was added to the 6 allocated titer
tubes, while 160ul was added to the rest of the tubes for a total of 200ul in each tube.
Finally, 200ul from the tubes were plated onto their respective plates, and allowed to soak
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in for 15-20 minutes. The plates were then inverted, and incubated at 37° C to allow the
colonies to multiply exponentially, overnight. Refrigeration of the plates followed to
enhance the blue/white selection of the clones.
Colonies of pBS vectors containing inserts will remain white because the inserts
disrupt the coding region on the lacZ gene fragment of the vector, and those without inserts
will produce blue colonies (78). The lacIqZAM15 lac gene is carried on the F' episome
region of the XL 1-Blue MRF' Supercompetent Cells and allows for this blue/white
selection (78). Ampicillin together with tetracycline, further selects for colonies that
contain both the pBS Vector and F' episome respectively to help reduce the incidence of
false positives (78). The use of tetracycline was reported by Anderson to reduce the
incidence of false positives after she experienced a large number of false positives
following the hand selection of (white) clones, only to find they contained no inserts (63).
A total of 2304 clones were picked by hand (768 for each comparison) using sterile
toothpicks and placed one in each of the 96-deep well plates containing 400ul Ampicillin2XYT media. These were sealed with Air Pore tape (Rainin) to allow respiration of the
clones, while shaken at 180rpm for 17-18 hours and incubated at 37° C. The next day,
140ul of 60% glycerol was added to each well, and the plates were then sealed, wrapped
and placed in the -80° C freezer to await Rolling Circle Amplification (RCA).
Positive and negative controls were conducted using the XL 1-cells and pUC18
control plasmids supplied by Stratagene to evaluate the blue white selection of the XL1cells and to ensure their quality. Since the pUCl 8 plasmid does not contain inserts, the
colony forming units (cfu), should remain blue for the positive control. This was the case,
with too many cfu present to count (Table 4). As anticipated, the negative control resulted
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in no cfu since pUCl 8 vector was not added to the XLl-cells. Titer plates (presented in
Table 4) were also conducted to estimate the number of cfu for blue (pBS-no cDNA) and
white (pBS-cDNA) inserts, and for the potential number of inserts in each transformation
reaction. The controls correlated well with the outcomes described by Stratagene.

Table: 4: Controls for Blue White Selection of XLl-Cells, pBS Vector & Inserts
#Blue
Colonies in
Titer plate
9
4
3
5
2
2

Titer P l a t e s a n d P o s i t i v e a n d N e g a t i v e C o n t r o l
Total #
# Potential Blue
# Potential White
# White
Colonies in
Colonies in
Colonies in Colonies in
Transformation
Titer Plate
Titer Plate
Transformation
76
4517
38141
85
28104
56
59
2007
99
102
49683
1506
39144
78
83
2509
36
1004
18067
38
16
18
1004
8030

Comparison Aqe
1Day
C-1
C-1
6Weeks
C-2
1Day
C-2
6Months
C-3
6Weeks
6Months
C-3
Average:
Negative Control: Cells without vecto resulted in zero colonies
Positive Control: Cells with vector we re blue and resulted in too many colonies to count

Total # Potential
Colonies in
Transformation
42657
29609
51189
41653
19070
9033

% Contain Inserts
for Titer and
Transformation
89%
95%
97%
94%
95%
89%
93%

The results for the titer plates in Table 4, revealed that on average, 93% of XLlcells contained pBS-cDNA inserts. These findings allowed proceeding to the next step of
purifying and amplifying the cDNA inserts by Rolling Circle Amplification (RCA).

Rolling Circle Amplification (RCA) of Bacterial Cultures
The RCA Tempi Phi 500 Amp kit (Amersham Biosciences, #25-640-50) was
selected to prepare the cDNA inserts for sequencing by releasing them from the XLl-cells
followed by amplification. The protocol was adjusted by Anderson to use half the amount
of the recommended reactants while providing the same results, and doubling the number
of reactions that could be conducted with a single kit (63). The following procedures were
the same throughout for each of the 24, 96-well plates. A cloned 96-deep well plate was
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removed from -80° C and slowly thawed at room temperature for two hours or overnight at
4°C.
With a multi-channel pipetter, 2.5ul of Sample Buffer (5X 0.5ml) and 0.8ul of the
cloned XL 1-cells were added to each well of a new shallow 96-well plate. The plate was
sealed with strip caps, and pulse spun in a plate spinning head in the Beckman/Coulter
Allegra 25R centrifuge, for 25 seconds at 5700 rpm and then placed in the preheated TC at
95° C for precisely 3 minutes to lyse the XL1-cells and release plasmid vector-cDNA
inserts from the cells, without denaturing DNA. The plate was removed and immediately
placed on ice while preparing a master mix of 250ul Reaction Buffer (5X 0.5ml) and lOul
Enzyme Mix (5X 20ul). An aliquot of 2.5ul from the master mix was then added to each
well of the cooled plate bringing the total volume to 5.8ul. The plate was again sealed with
the strip caps, and pulse spun for 25 seconds and placed in the preheated TC at 30° C for 16
hours. The temperature was adjusted to 65° C for 10 minutes to denature the enzyme, and
was then adjusted to 4° C until removal of the plate from the TC. The plate was then pulse
spun for 25 seconds to collect the contents. Ten microliters of Mohm water were added to
each well bringing the total volume to 15.8ul, and the plate was pulse spun again.
The following restriction digestion reaction was conducted to determine whether
the vector was in fact released from the XL 1-cells, and to assess whether the pBS vector
contained an insert. The TC was preheated at 37° C while a master mix of 1 lul Bovine
Serum Albumin (BSA) (lOmg/ml), 1 lOul 10X Multi Core Buffer, 329ul Mohm water, 50ul
Hind III enzyme (lOU/ul), and 50ul Xbal enzyme (12U/ul) were added to equal a total
volume of 550ul. The Hind III and Xbal are six cutter enzymes that recognize and cut 24
bp upstream and 8 bp downstream from the BamHI site respectively. Using a new shallow
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96-well plate, 5ul of the master mix was pipetted into each well with the multi-channel
pipetter. Strip caps were removed from the RCA plate and 5ul from the total volume of
15.8ul was transferred from each RCA well into the respective wells of the new plate
containing the master mix. Strip caps were used to seal the wells, and the plate was pulse
spun for 25 seconds and then placed in the preheated TC at 37° C for 2 hours.
The digestion plate was removed from the TC after 2 hours and pulse spun to
collect the contents. The strip caps were removed to pipette 4ul of gel loading dye into
each well for a total volume of 14ul. The wells were again covered and pulse spun. Using
the multichannel pipetter, 7ul aliquots were transferred row by row from the 96 digested
samples, and were run on a 1.2% gel, with 7.5ul of ethidium bromide in a large
electrophoresis gel bed at 85V for 30 minutes. The gel was photographed under UV light
as previously explained to assess the location of XL1 -cells, pBS Vector and the digested
cDNA inserts. Acceptable gels revealed three main components. The XL1-cells were
located at the wells, while the pBS Vector formed a distinct band at 3000bp. A third band,
the cDNA inserts, was located below lOOObp. To proceed, at least 88 of the 96 pBS
Vectors had to contain cDNA inserts visualized on the gel below lOOObp before the entire
plate could be submitted for sequencing (63).
A new 96-well shallow plate was used to prepare cDNA inserts for sequencing. A
master mix of, 4.8ul M13 reverse primer (M13R) (2uM) was prepared in 451.2ul MOhm
(nuclease free) water. Of the 456ul total volume, 3.8ul aliquots were pipetted individually
into each well. Aliquots of 1.2ul from the thawed and pulsed RCA plate were pipetted into
each well using the multi-channel pipetter. The wells were sealed and the plate was pulse
spun for 30 seconds, wrapped in cellophane and aluminum foil, labeled with a pre-assigned
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ID number and submitted on dry ice to the Hubbard Center for Genome Studies (HCGS) at
the University of New Hampshire for sequencing of the differentially expressed RDA
transcripts in the ABB 130 genetic analyzer. The Ml3 Reverse primer (5'
GGAAACAGCTATGACCATG 3') was chosen to amplify the target inserts from the pBS
Vector (63). The results were provided from the Genome Center in digital file format,
which included the individual sequences, quality scores in "fasta" format, and
chromatograms to help determine the quality of the sequences (63).

Sequence Analysis and Characterization of Differentially Expressed Products
To begin analysis of the 2626 sequences provided by the Hubbard Genome Center,
the VecScreen program within the National Center for Bioinformatics (NCBI) data base,
provided the ability to flank nucleotide sequences for vector contamination or M13R
primer and to determine the quality of the nucleotide sequences. The process began with
uploading a sequence into VecScreen to look for vector contamination within the
nucleotide sequences. The sequences were matched with known vectors in the data base
and reported as strong, moderate, weak, or suspect. Strong matches were always cut at the
recommended nucleotide sequence sites, most often removing both sides of the retained
quality sequence.
DNAClub is an open freeware program created by Xiongfong Chen at
http://128.84.203.244 while a student at Cornell University. This program was used to
highlight and cut the identified vector nucleotide sequences that were flanked by
VecScreen. This program also allowed one to search for the GATC restriction sites and
verify a match with VecScreen before removing nucleotide sequences. In addition, this
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program provided the ability to search for all GATC sites throughout the sequence to
determine whether more than one sequence was ligated together at the sticky ends. This
was the case more often than not, and allowed for individual analysis in a later step to
search for and identify multiple genes within a single sequence.
Matches that were suspect in VecScreen, were cross evaluated using FinchTV
Version 1.4.0. located at www.geospiza.com. Finch TV is a very useful program that
provides a chromatogram of the nucleotide sequence patterns displaying peaks and changes
that help to further confirm the quality of a sequence that is suspect. Patterns that
consistently revealed strong peaks, yet were identified as suspect in VecScreen, were
retained for further analysis. Sequences that revealed small or rounded peaks or many
changes in the size and shape of peaks were considered poor quality and were discarded.
Once sequences were evaluated and determined to be quality sequences, they were
trimmed and saved in a file later to be queried against a database of known gene sequences.
The Basic Local Alignment Search Tool (BLAST) or BLASTn located within NCBI's data
base was used to match quality nucleotide sequences with known genes and identify
potential proteins for the sequences. E-values established in the database were used to
indicate a level of confidence between matches. A typical cutoff used in this lab was e-4 or
less. After much discussion a more conservative cutoff of
e-10- or less was adopted for this research, to indicate greater confidence that a match was
not by chance. Gene sequences meeting the criteria were accepted as quality sequences.
Those that were matched with a known gene sequence and met the e-value were
"identified" genes. Those that were quality sequences but didn't meet the e-value criteria
of a quality match in BLASTn remained "unidentified".
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Sequences that were labeled as "null" had been either Vec-screened and/or
underwent BLASTn and were identified as vector or nothing at all, had a poor
chromatogram, and or a high e-value.

Annotation, Placement. Regulation and Interactions of Genes
The MetaCore Software Program located at www.Genego.com is a licensed online
database that incorporates a systems biology approach to fully annotate and link genes of
interest to hundreds of available metabolic pathway maps. This approach, provides visual
analysis of the placement of genes, their interactions and the cascade of events that result in
a given pathway. Detailed descriptions of the pathways are linked directly to the pathway
maps. In addition, the individual genes in a given pathway map are linked to a wealth of
information regarding annotation, gene-gene interactions, and metabolic functions within a
given pathway. Some of the additional benefits available with MetaCore include, detailed
descriptions of multiple functions that many of the genes are known to participate in, links
to known diseases, pharmaceutical research, NCBI, and Pub Med's database, as well as the
use of E-Z search engines to access gene information. MetaCore also offers the ability to
build direct networks (which include all the genes known to participate between the
selected genes of interest) or indirect networks (only displays selected genes of interest),
and the ability to create custom pathway maps between selected genes (not accessed during
this project).
Once genes were identified in NCBI's BLASTn database, they were then retained
in excel to be later analyzed further for their potential role in initiation and progression.
MetaCore was utilized to fully annotate genes of interest, and to determine any gene-gene
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interactions, and regulation within metabolic pathways in order to, distinguish between
genes potentially involved in initiation and/or progression of atherosclerosis from those of
normal development. Some of the candidate genes were also compared with unpublished
in-vitro and in-vivo work conducted by Anderson (63) in this laboratory and are presented
in Appendices Q - T (pages 147 - 150).

54

CHAPTER III

RESULTS

A total of 2304 cloned DPs were selected for further determination of their
nucleotide sequences. Table 5, includes the raw sequence data, as well as Vector-Trimmed
and BLASTed quality sequences from each of the three RDA comparisons of differentially
upregulated DPs. Of the 2304 possible clones, 70 of the pBluescript (pBS) vectors lacked
cDNA inserts. The remaining 2234 clones, resulted in a total of 2556 quality sequences.
The unusual find of 111% quality sequences was due to occasions when more than one
insert was ligated together at their GATC sticky ends within a pBS vector. Of the total
number of quality sequences that were accepted, 2270 differentially upregulated sequence
tags (ESTs) were identified using BLASTn leaving the remaining 286 sequences as
unidentified.
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Table 5: Raw Data and BLAST Results Summary
PigebnClonjr

RDA
Comparison

QJ

Raw Sequence riata
Breed & Aqe Plate
Mean # bp raw
#NULL
%
&C Ictey
A
558
6
2
B
803
C
889
3
D
673
3
14
Total
384
731
WC6wks

A
B
C
D

Total

384

672
665
667
641
661

2
5
2
0
9

384

635
668
649
702
664

1
4
1
6
12

384

649
672
676
707
676

2
4
1
9
16

384

647
,663
651
655
654

3
2
5
3
13

384

699
635
657
659
663

1
1
1
3
6

2304

675

70

A
B
C
D
RDA
Total
Comparison
C 2

A
B
C
D

Total
WC6wks

RDA
Total
Comparison
C 3

Total
Totals

A
B
C
D

A
B
C
D

# Accepted %
Mean # bp query
# Identified
107
282
73
109
305
76
115
285
93
119
249
99
4%
450
117%
280
341

2%

103
105
113
116
437

114%

311
294
314
312
308

97
104
107
111
419

3%

109
96
97
98
400

107%

316
290
253
274
283

89
75
73J
76
313

4%

100
94
104
96
394

103%

260
255
284
247
262

92
84
92
69
357

3%

101
103
107
114
425

111%

296
283
297
303
29S

96
99
104
107
406

2%

104
114
117
115
450

117%

273
281
270
259
271

3%

2556

111%

275

%

# Unidentified
34
33
22
20
76%
109

%" "*"

24%

96%

6
1
6
5
18

78%

20
21
24
22
87

22%

91%

8
10
12
7
37

9%

96%

5
4
3
7
19

4%

102
111
111
110
434

96%

2
3
6
5
16

4%

2270

89%

286

11%

4%

Table 5 represents the three ages that were compared against one another. Comparison one (C-1) lday
verses 6 weeks (lday:6wks), comparison two (C-2) lday verses 6 months (lday:6mos), and comparison
three (C-3) 6 weeks verses 6 months (6wks:6mos).

KEY: Raw data and BLAST results
Plate = ideal total # inserts per 384 wells/clones per age per comparison
Mean # bp +/- SEM raw = average # bp before Vec trimmed
# NULL: is # of wells or clones that lack inserts
%Nuf is % based on # absent inserts / # wells/clones
# Accepted: = # of quality inserts accepted (after Vec trimmed and BLASTed)
% accepted: is based on actual t inserts accepted / # wells/clones
Mean # bp +/• SEM query: average # bp after Vec Trimmed & before BLASTed
# indentified is # inserts Vec trimmed & BLASTed & identified
% identified: is % based on # accepted (# identified/# accepted)
# unidentified: is # inserts Vec trimmed & BLASTed but remained unidentified (is a quality insert with an e-value of > e-10) these are novel sequences not in data base
% unidentified is % based on # accepted

Presented in the following six tables, are lists of the differentially expressed genes
from each of the three comparisons. Each of the tables, Table 6a and 6b, C-1 (1 day:6
weeks), Table 7a and 7b, C-2 (1 day:6 months) and Table 8a and 8b, C-3 (6 weeks:6
months) include the combined data from the four plates that were analyzed for each age
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comparison, using NCBI's BLAST program, and presents the genes that were differentially
upregulated between the ages compared. The colored asterisks in each of the six tables
represent the rare instances when difference products were upregulated in both ages within
a comparison. Gene's upregulated in this manner are color coded by an asterisk next to
their gene name, so they can be easily tracked between the tables.
Totals for each age compared are located at the bottom of each column. The first
represents the mean base pair length of all the quality sequences that were Vec-Screened
and BLASTed. The "identified" represents the total number of quality sequences that were
identified in BLAST (meeting the e-value cut off of e-10 or <) and includes annotated as
well as non-annotated genes. The unidentified quality ESTs followed since they did not
meet the e-value criteria of acceptance in NCBI. Since the unidentified ESTs did not meet
the e-value criteria, it is not known whether any of the ESTs are the same or are all
different genes. Additional efforts required to identify these ESTs were beyond the scope
of this thesis. The total number of ESTs for an age includes the combined totals of the
identified as well as the unidentified difference products. The total number of identified,
unique, non-redundant sequence tags is represented in each of the tables as, "total number
of identified non-redundant transcripts". Finally, in the instances when the actual "gene
name" for the identified genes was not available, NA was used in the appropriate column.
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Table 6a: Differentially Expressed Genes, Comparison 1 (1 Day Versus 6 Weeks)
Ortholog (C-1 1day Merged plates A-D}
lumican (LUM)
clone ChEST85g22
collagen, type I, alpha 2 (COL1A2)
telokin
actin, alpha 2, smooth muscle, aorta (ACTA2)
similar to SEC61 gamma (LOC776639)
clone ChEST874k20
1B-3866 cytochrome c oxidase subunit I (COI)
BAC clone CH261-10P22
leucine rich repeat containing 17
ATPsynthase FO subunit 8 (ATP8) gene
dermatan sulfate proteoglycan decorin
fdxl gene and 4 orf s
hypothetical LOC424163 (LOC424163)
vascular smooth muscle alpha-actin (ACT-4)
ATP synthase FO subunit 8 and 6 (ATPase 8, 6),
BAC clone TGMCBa-23H12
klral 7 mRNA for lectin-like transmembrane protein, Ly49q1 isoform (CDR-1)
clone 0064p0012D12 putative ribosomal protein
collagen, type VIII, alpha I (COL8A1)
fatty acid binding protein 4, adipocyte (FABP4)
hypothetical LOC424163
fk506 binding protein 9, 63 kDA (FKBP9)
myoglobin gene
NADH dehydrogenase subunit 4 gene
neomycin resistance cassette pNeo4 NeoTet (neoTet)
microsatellite marker vemos44
CR1 gene for chicken repeat 1
has operon deletion mutant
Gene encoding methionine sulfoxide reductase
mitochondrial DNA

Gene Name
LUM
FBLN5
COL1A2, COLA
MYLK
ACTA2
SEC61G
clone ChEST874k20
COI
BACCH261-10P22
LRRC17
ATP8
DCN
NA
ACT-4
ATPase 6
BACTGMCBa-23H12
CDR-1
clone 0064p0012D12
COL8A1
FABP4
FASTKD1
FKBP9
MB
ND4
NEOTET
NA
NA
NA
NA
NA

Copy #
159
87
26
13
10
7
5
4
3
3
2
2
2
424163
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

MEAN |BP)
it.; ' , &[..
UNIDENTIFIED
TOTAL (ESTj of 384 wetts
TOTAL # identified non-redundant transcripts
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I
|

280
341
109
450
31

Table 6b: Differentially Expressed Genes, Comparison 1 (6 Weeks Versus 1 Day)
O r t h o l o g <C-1 S w k s SVSerged p i a t e s A - D )
heat shock protein 9 0 alpha
BAC clone CH261-126J23
gelsolin ( G S N )
clone 0 0 6 4 P 0 0 2 1 C 0 6 spermidine/spermine N1-acetyltransferase
similar to nbosomal protein L3 ( L O C 7 7 1 4 3 2 )
hypothetical L O C 4 1 5 8 9 1 ( L O C 4 1 5 8 9 1 )
myosin heavy chain II smooth muscle ( M Y H 1 1 ) _
clone C h E S T 3 9 8 a 1 6 ( R P L 3 2 )
nbosomal protein L4 ( R P L 4 )
mitochondnon
clone C h E S T 1 8 9 k 1 1
clone C h E S T 1 1 8 | 5
eukaryotic translation initiation factor 3 subunit H ( E I F 3 H )
rho-assoaate coiled-coil forming kinase 1 ( R O C K 1 )
chromogramn B (secretogramn 1) ( C H G B )
D E A D (Asp-Glu-Ala-Asp) box polypeptide 6 ( D D X 5 )
hemoglobin alpha-globin chain
lymphocyte antigen 6 complex locus E ( L Y 6 E )
similar to N P D 0 1 4 protein ( N P D 0 1 4 )
nbosomal protein S 3 A ( R P S 3 A )
splicing factor argmine/senne-nch 10 (transformer 2 homoloq drosophila) ( S F R S 1 0 )
splicing factor argmine/senne-nch 6 ( S F R S 6 )
beta2-microqlobulm
cyclin-dependent kinase inhibitor p27 Kip1
clone C h E S T 1 0 0 7 e 1 0
mitochondnal D N A
mitochondnal D N A
similar to yeast nbosomal protein S 2 8 homologue ( L O C 4 2 7 3 2 3 )
alpha-tropomyostn gene exons 9 c 9d and complete cds alternatively spliced
clone 0 0 6 2 P 0 0 0 1 C 0 1 putative high-mobility group nucleosome binding domain 1 variant 1
beta-actin
acidic (leucine-nch) nuclear phosphoprotein 32 family member A ( A N P 3 2 A )
alpha thalassemta/mental retardation syndrome X-linked ( A T R X )
BAC clone C H 2 6 1 - 1 1 4 A 2 0
clone C h E S T 3 9 8 a 1 6
destnn (actin depolymenzing factor) ( D S T N )
jagged 1 (Alaqille syndrome) (JAG1)
N A D H dehydrogenase (ubiquinone) 1 alpha subcomplex 10 4 2 k D a ( N D U F A 1 0 ) nuclear
similar to B-aqgressive lymphoma 2B
R P S 6 m R N A for nbosomal protein S 6
vimentin (VIM)
similar to collaqen alpha-2(IV) chain ( L O C 4 1 8 7 5 2 )
hypothetical L O C 4 2 3 1 9 2 ( L O C 4 2 3 1 9 2 )
hypothetical L O C 4 2 3 6 0 2 ( L O C 4 2 3 6 0 2 )
hypothetical protein L O C 7 7 0 9 0 9
similar to S D F 3 ( L O C 7 7 1 6 0 8 )
clone 0 0 5 8 P 0 0 1 1 D 0 9 putative beta 1 integnn binding protein 2 vanant 1
12S nbosomal R N A g e n e
B-cell translocation gene 1 anti-proliferative ( B T G 1 )
calmodulin 1 (phosphorylase kinase delta) ( C A L M 1 )
chaperonm containing T C P 1 subunit 8 (theta) ( C C T 8 )
M H C class II associated invariant chain ( C D 7 4 )
clone C h E S T 6 0 8 l 2 2
clone C h E S T 7 5 1 d 6
clone C h E S T 9 8 4 n 1 5
cytochrome oxidase subunit I ( C O I )
sp 2 8 1 5 0 k i n a w a mitochondrial genomic D N A
cleavage stimulation factor 3 p r e - R N A subunit 1 5 0 k D a ( C S T F 1 )
eukaryotic translation elongation factor 1 alpha 1 ( E E F 1 A 1 )
eukaryotic translation tnititiation factor 4 A isoform 2 ( E I F 4 A 2 )
eukaryotic translation initiation factor 5 (EIF5)
F Y N oncogene related to S R C F G R Y E S ( F Y N )
hect domain and RLD 2 ( H E R C 2 )
heterogeneous nuclear nbonucleoprotein D-like ( H N R P D L )
low density lipoprotein receptor-related protein associated protein 1 ( L R P A P 1 )
lumican (LUM)
mitochondnal nbosomal protein L27 ( M R P L 2 7 )
pumiho homolog 2 (drosophila) ( P U M 2 )
ring finger protein 11 ( R N F 1 1 )
nbosomal protein L5 ( R P L 5 )
nbosomal protein L6 ( R P L 6 )
clone 0 0 5 8 P 0 0 3 1 F 0 7 putative nbosomal protein S 3
splicing factor argmine/senne-nch 1 ( S F R S 1 )
T cell receptor delta chain ( T C R D ) pseudogene
W D repeat domain phosphomositide interacting 2 ( W I P I 2 )
clone 0 0 5 8 P 0 0 4 7 C 0 7 putative S N F 7 domain containing 2 vanant 2
clone 0 0 6 9 P 0 0 0 4 A 0 6 transcriptional regulator Id2-like
clone 0 0 6 4 P 0 0 1 0 H 0 5 high-mobility group nucleosome binding domain 1 variant 1-like
clone 0 0 6 1 P 0 0 3 1 D 1 1 m a t n x G l a - l i k e
steroid dehydrogenase
invanant chain (h)
encoding methionine sulfoxide reductase

Geeie Name
HSP90AA1
BAC C H 2 6 1 - 1 2 6 I 2 3
GSN
SAT1
RPL3
MYH11
RPL32
RPL4
16SrRNA
clone C h E S T 1 8 9 k 1 1
clone C h E S T 1 1 8 | 5
EIF3H
ROCK1
CHGB
DDX5
HBA
LY6E
NPD014
RPS3A
SFRS10
SFRS6
B2M
CDKN1B
clone C h E S T 1 0 0 7 e 1 0
COM
ND4
RPS28
TPM1
clone 0 0 6 2 P 0 0 0 1 C 0 1
ACTB
ANP32A
ATRX
BAC C H 2 6 1 - 1 1 4 A 2 0
clone C h E S T 3 9 8 a 1 6
DSTN
JAG1
NDUFA10

Copy*
67
49
43
34
39
415891
13
9
9
9
7
6
5
5
5
4
4
4
4
4
4
4
4
3
3
4
3
3
3
3
2
2
2
2
2
2
2
2
2

PARP14
RPS6
VIM

2
2
2
418752
423192
423602
770909
771608

clone 0 0 5 8 P 0 0 1 1 D 0 9
12S rRNA
BTG1
CALM1
CCT8
CD74
clone C h E S T 6 0 8 l 2 2
clone C h E S T 7 5 1 d 6
clone C h E S T 9 8 4 n 1 5
COI
COIN
CSTF1
EEF1A1
EIF4A2
EIF5
FYN
HERC2
HNRPDL
LRPAP1
LUM
MRPL27
PUM2
RNF11
RPL5
RPL6
RPS3
SFRS1
TCRD
WIPI2
clone 0 0 5 8 P 0 0 4 7 C 0 7
clone 0 0 6 9 P 0 0 0 4 A 0 6
clone 0 0 6 4 P 0 0 1 0 H 0 5
clone 0 0 6 1 P 0 0 3 1 D 1 1
NA
NA
NA
MLAN

IBP}

z~
^
UNIDENTIFIED
T O T A L (EST1 of 384 wells
T O T A L # identified n o n - r e d u n d a n t t r a n s c r i p t s

59

308
419
18
437
82

Table 7a: Differentially Expressed Genes, Comparison 2 (1 Day Versus 6 Months)
Ortholog (C-2 1day plates A-D)
collagen, type I, alpha 2 (COL1A2)
clone ChEST874k20
fibulin 5 (FBLN5)
similar to SEC61 gamma(LOC776639)
keratin sulfate proteoglycan lumican
nephroblastoma overexpressed (NOV)
FK506 binding protein 9, 63 kDa (FKBP9)
telokin myosin, light chain kinase (MYLK)
clone 0062P0005D06 putative 40Sribosomalprotein S8
fibronectin 1 (FN1)
clone 0063P0029G01 putative RHoA GTPase variant 3
ATP synthase FO subunit 8 (ATP8)
cytochrome c oxidase subunit I (COI)
mitochondrial genomic DNA
collagen, type III, alpha 1 (COL3A1)
leucine rich repeat containing 17 (LRRC17)
ras homolog gene family, member A (RHOA)
clone 0058P0007G11 putative peroxiredoxin 1 variant 3
16S ribosomal RNA
calmodulin 1 (phosphorylase kinase, delta) (CALM1)
carboxypeptidase E (CPE)
mitochondrion
PG-M mRNA for proteoglycan
ribosomal protein L7 (RPL7)
hypothetical LOC424163
clone 0061P0024E07 putative sm like protein U6 snRNA-associated Sm-like protein
clone 0063P0030D07 putative solute carrier family 25 member 6 variant 1
clone 0063P0009H02 putative proteosome maturation protein
clone 0058P0011D09 putative beta 1 integrin binding protein 2 variant 1
BAC clone CH261-10P22
BAC clone CH261-147F20
BAC clone CH261-79I12
non-muscle caldesmon
cell division cycle 2, G1 to S and G2 to M (CDC2)
similar to Methylosome subunit plC1n (chloride conductance regulatory protein IC1n)

Gene Name
COL1A2
clone ChEST874k20
FBLN5
SEC61G
LUM
NOV
FKBP9
MYLK
RPS8
FN1
RhoA GTPase-like
ATP8
COI
COIN
COL3A1
LRRC17
RHOA
clone 0058P0007G11
16SrRNA
CALM1
CPE
ND4
PG-M
RPL7

clone ChEST433n1
cloneChEST587b19
type VI collagen alpha-2 subunit
dermatan sulfate proteoglycan decorin
destrin (actin depolymerizing factor) (DSTN)
clone 0062P0005H11 putative eukaryotic translation initiation factor 1 variant 1
H3 histone, family 3B (H3.3B)
similar to otoancorin (LOC771927)
clone 0063P0009H02 putativee proteosome maturation protein
ornithine decarboxylase antizyme 1 (OAZ1)
similar to yeastribosomalprotein s28 homologue (LOC427323)
ribosomal protein S3A (RPS3A)
actin, alpha 2, smooth muscle, aorta (ACTA2)
cytochrome oxidase II

clone ChEST433n1
cloneChEST587b19
COL6A2
DCN
DSTN
EIF1
H3.3B
KDELR2
clone 0063P0009H02
OAZ1
RPS23
RPS3A
ACTA2
COM

Copy #
158
21
15
12
10
9
7
5
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
424163

clone 0061P0024E07
clone 0063P0030D07
clone 0063P0009H02
clone 0058P0011D09
BAC CH261-10P22
BAC CH261-147F20
BAC CH261-79I12
CALD1
CDC2
CLNS1A

MEAN |BP)
Z^, "' '£X'
UNIDENTIFIED
TOTAL fESTi of 384 weils
TOTAL # identified non-redundant transcripts
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283
313
87
400
49

Table 7b: Differentially Expressed Genes, Comparison 2 (6 Months Versus 1 Day)
Gene Name
HSP90AA1
MYH11
BACCH261-117C7
CANX
ACTA2
LUM
MYLK
16SrRNA
CD36
EN01
clone 0057P0001H01

Ortholog (C-2 6mos plates A-D)
heat shock protein 90 alpha
similar to myosin-11 (Myosin heavy chain, gizzard smooth muscle) (LOC777204)
BAC clone CH261-117C7
calnexin (CANX)
actin, alpha 2, smooth muscle, aorta (ACTA2)
lumican (LUM)
myosin, light chain kinase (MYLK)
16S ribosomal ma
CD36 molecule (thrombospondin receptor) (CD36)
mma for tau-crystallin/alpha enolase
clone 0057P0001H01 calmodulin variant 1-like
cytochrome oxidase subunit II (COM)
Rho-associated, coiled-coil containing protein kinase 1 (ROCK1)
12Sribosomalma
ATP synthase F0 subunit 8 (ATP8)
clone 0058P0017H07
similar to CD59 protein (LOC423148)
mitochondrial genomic DNA
mitochondrial DNA
phosphodiesterase 5A, cGMP-specific (PDE5A)
clone 0058P0057E07 ribosomal protein L32-like
similar to bullous pemphigoid antigen 1, 230/240kDa (LOC421884)
acyl-CoA synthetase long-chain family member 1 (ACSL1)
beta-actin (ACTB)
acidic (leucine-rich) nuclear phosphoprotein 32 family, member A (ANP32A)
similar to asponn (LOC415954)
BAC clone CH261-138K4
BAC clone CH261-187N23
clone Pgp29 microsatellite sequence
similar to CLIP-associating protein 1; multiple asters 1 (LOC420724)
clone ChEST163a24
clone ChEST189k11
cloneChEST398a16
clone ChEST417p21
clone IMAGE:8236308

ACSL1
ACTB
ANP32A
ASPN
BACCH261-138K4
BACCH261-187N23
clone Pgp29
CLASP2
clone ChEST163a24
clone ChEST189k11
clone ChEST398a16
clone ChEST417p21
clone IMAGE:8236308

cytochrome c oxidase subunit I (COI)
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, x-linked (DDX3X)
eukaryotic translation initiatin factor 4A, isoform 2 (EIF4A2)
fatty acid binding protein 4, adipocyte (FABP4)
mitochondrion
similar to phospholipase C beta 4, transcript variant 2 (LOC416730)
UNK clone TGMCBa-14H12

COI
*
DDX3X
EIF4A2
FABP4
ND5
PLCB4
UNK clone TGMCBa-14H12

Copy#
213
27
23
9
7
7
7
6
6
5
3
3
3
2
2
2
2
2
2
2
2

con

ROCK1
12S rRNA
ATP8
clone 0058P0017H07
CD59
COIN
ND4
PDE5A
RPL32
421884

MEAN
:

7« •

UNIDENTIFIED
TOTAL (EST) of 3B4 wells
TOTAL # identified non-redundant transcripts

61

262
357
37
394
42

Table 8a: Differentially Expressed Genes, Comparison 3 (6 Weeks Versus 6 Months)
Ortholoq {C-3 6wk A-D compared)
clone 0064P0021C06 spermadine/spermine N1-acetyltransferase variant 1-like
BAC clone CH261-126J23 from chromosome ul
similar to yeast ribosomal protein S28
ribosomal protein S3A (RPS3A)
clone 0063P0030D07 putative solute carrier family 25 member 6 variant 1
qelsolin (GSN)
similar to ribosomal protein L3 (LOC771432)
prohibitin 2 (PHB2)
similar to coactosin-like 1 (dictyostelium) (LOC768420)
nucleoside diphosphate kinase
finished cDNA, clone ChEST14214
NADH hydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42kDa (NDUFA10),

Gene Name
SAT1
BAC CH261-126J23
RPS28
RPS3A
SLC25A6
GSN
RPL3
PHB2
COTL1
NDPK
SERPINF2
NDUFA10

ras homoloq qene family, member A (RHOA)

RHOA

9

ribosomal protein L9 (RPL9)
S-phase kinase-associated protein 1 (SKP1)
eukaryotic translation initiation factor 3, subunit H (EIF3H)
clone 0058P0007G11 putative peroxiredoxin 1 variant 3
similar to SDF3 (LOC771608)
BAC clone CH261-77K20
cytochrome oxidase subunit II (COII), mitochondrial
collaqen, type I, alpha 2 (COL1A2)
clone 0061P0016C08 putative actin related protein 2/3 complex subunit 2
actin, beta (ACTB)
acidic (leucine-rich) nuclear phosphoprotein 32 family, member A (ANP32A)
clone ChEST611b2
clone 0062P0005H11 putative eukaryotic translation initiation factor 1 variant 1
similar to B-aqqressive lymphoma 2B (LOC424266)
clone 0061P0001E09 putative Yip1 domain family member 1
mitochondrion
chaperonin containinq TCP1, subunit 8 (theta) (CCT8)
cyclin-dependent kinase inhibitor p27 Kip1
clone 0061P0031D11 matrix Gla-like
ribosome bindinq protein 1 homoloq 180kDa (doq) (RRBP1)
ribosomal protein L4 (RPL4)
ribosomal protein S23,11 days embryo whole body cDNA, RIKEN full-lenqth

RPL9
SKP1
EIF3H
PRDX1
SERPINF1
BACCH261-77K20
COII
COL1A2

9
6
5
5
5
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2

vimentin (VIM)
hypothetical protein LOC770045
clone 0061P0022F12 putative creatine kinase B variant 1
clone 0064P0012G12 RIKEN cDNA 0610039A15-like
similar to adenylate kinase (EC 2.7.4.3) (LOC428227)
chromosome 12 open readinq frame 49 (c12orf49)
chaperonin containinq TCP1, subunit 6A (zeta 1) (ccT6A)
clone 0058P0030G01
clone 0065P0012D05
clone ChEST1004o7
cloneChEST5e12
similar to collaqen alpha-2 (IV) chain
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 (DDX5)
DnaJ (Hsp40) homoloq, subfamily A, member 1 (DNAJA1)
destrin (actin depolymerizinq factor) (DSTN)
GNAS complex locus, transcript variant 2 (GNAS)
similar to qlycoqen synthase kinase 3 beta (LOC418335)
lectin associated matrix protein (hLAMP-1)
similar to microfibrillar associated protein 5 (LOC418256) MFAP5
proline-rich nuclear receptor coactivator 1 (PNRC1)
rinq finqer protein 11 (RNF11)
ribosomal protein L5 (RPL5)
ribosomal protein S6 (RPS6)
transmembrane emp24 protein transport domain containinq 5 (TMED5)
alpha-tropomyosin, clone CC401

Copy #
74
34
25
25
21
•• 20
18
17
16
15
15
14

100190509
ACTB
ANP32A
clone ChEST611b2
EIF1
PARP14
100190677
16S rRNA
CCT8
CDKN1B
clone 0061P0031D11
RPBP1
RPL4
RPS23
VIM

2
770045
100190470
100190503

AK2
C12orf49
CCT6A
clone 0058P0030G01
clone 0065P0012D05
clone ChEST1004o7
cloneChEST5e12
COL4A2
DDX5
DNAJA1
DSTN
GNAS
GSK3B
hLAMP-1
MFAP5
PNRC1
RNF11
RPL5
RPS6
TMED5
TPM1
MFAN top}
i'

UNIDENTIFIED
TOTAL (EST) OF 384
TOTAL # identified non-redundtant transcripts

62

295
406
19
425
60

Table 8b: Differentially Expressed Genes, Comparison 3 (6 Months Versus 6 Weeks)
Ortholog (C-3 6mos A-D compared)
heat shock protein 90kDa alpha (cytosolic), class A member 1 (HSP90AA1)
lumican (LUM)
eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2)
actin, alpha 2, smooth muscle, aorta (ACTA2)
myosin, heavy chain 11, smooth muscle (MYH11)
fibroblast myosin light chain kinase
enolasel, (alpha) (EN01)
BAC clone CH261-117C7
acyl-CoA synthetase long-chain family member 1 (ACSL1)
ATP synthase FO subunit 8 (ATP8)
BAC clone CH261-126J23
clone ChEST85g22
16S nbosomal RNA gene, partial sequence; tRNA-leu gene, complete sequence;
NADH dehydrogenase subunit 1 (ND1) gene
similar to 0TTHUMP00000028984 (LOC418017)
hypothetical LOC419017, transcript vanant 1 (LOC419017)
BAC clone CH261-16J12
BAC clone CH261-19B3
BAC clone TAM31-16o5
BAC clone TGMCBa-49H12
CD151 molecule (Ralph blood group) (CD151)
clone 0061P0022F12 putative creatine kinase B variant 1
mitochondnon
mitochondrial genomic DNA
ZMUC 125434 ornithine decarboxylase (ODC)
odd-skipped related 1 (drosophila) (OSR1)
GTP-specific succinyl-CoA synthetase alpha subunit (SCS)
clone 0063P0006F01 ubiquitin C variant 5-like

Copy#

Gene Name
HSP90AA1
LUM
EIF4A2
ACTA2
MYH11
MYLK
EN01
BACCH261-117C7
ACSL.1
ATP8
BAC CH261-126J23
FBLN5

175
104
35
32
32
21
6
4
3
2
2
2

ND1

2
418017
419017

BACCH261-16J12
BACCH261-19B3
BACTAM31-1605
BACTGMCBa-49H12
CD151
CKB
COM
ND4
ODC
OSR1
SCS
UBC
MEAU IBP)
UNIDENTIFIED
TOTAL |ESTS of 384
TOTAL # identified non-redundant transcripts

271
434
16
450
27

Chi square analysis was initially used to determine statistical differences (using a pvalue of < 0.05) and was required to establish regulation patterns between the ages
compared, prior to uploading into MetaCore. Because the RDA method in and of itself
enriches only for sequences that are differentially expressed, genes that were upregulated
between the comparisons were significant by nature of the method. This ability of the
RDA method to detect and selectively enrich transcripts of low copy number speaks for the
level of sensitivity of the method (71) and negated any further reason for using chi square
analysis to assist in the interpretation of the results.
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The largest number of identified genes (presented in Table 9) was observed at 6
months of C-3 with 434 gene transcripts followed by 419 genes at 6 weeks of C-l. The
greatest number of unidentified transcripts, (109) was observed at 1 day of C-l, followed
by 87 transcripts at 1 day of C-2. In C-3, only 16 unidentified transcripts were found at 6
months, which was the lowest number of unidentified transcripts of all the ages
compared. This is perhaps because more work to identify genes, has been completed on
older vertebrates as compared to younger vertebrate animals. In C-l and C-3, both 1 day
and 6 months respectively contained the greatest number (450) of identified and unidentified expressed sequence tags (ESTs) combined. The largest number (83) of unique,
non-redundant transcripts was observed at 6 weeks in C-l when compared to 1 day. In
contrast, 27 genes at 6 months of C-3 was the lowest number of non-redundant transcripts
found in an age group compared.
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Table 9: Number of Transcripts from Greatest to Lowest by Comparison and Age
Comparision
C-3
C-1
C-3
C-2
C-1
C-2
Comparison
C-1
C-2
C-2
C-3
C-1
C-3
Comparison
C-1
C-3
C-1
C-3
C-2
C-2
Comparison
C-1
C-3
C-2
C-2
C-1
C-3

Age
6 months
6 weeks
6 weeks
6 months
1 day
1 day
Age
1 day
1 day
6 months
6 weeks
6 weeks
6 months
Age
1 day
6 months
6 weeks
6 weeks
1 day
6 months
Age
6 weeks
6 weeks
1 day
6 months
1 day
6 months

Total Number of Identified Genes
434
419
406
357
341
313
Total Number of Unidentified Transcripts
109
87
37
19
18
16
Total Number of Expressed Sequence Tags (ESTs)
450
450
437
425
400
394
Total Number of Identified Non-Redundant Gene Transcripts
82
60
49
42
31
27

When distinguishing between genes involved in the disease process, and those that
were expressed as a result of normal development, the genes that were expressed in the
highest number of copies were not necessarily the primary focus. Copy number provides
one perspective into the understanding of which genes may be key players participating in
atherosclerosis. In fact, as demonstrated in monogenic diseases, a single gene may be
responsible for kicking off a cascade of events. Given the extensive time required to
evaluate each of the 291 differentially expressed, non-redundant transcripts in this
experiment, it became necessary to develop criteria to effectively address the current
hypothesis and select the most likely candidates involved in atherosclerotic disease.
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Genes that were differentially upregulated at 1 day, 6 weeks, and 6 months when
compared to each of their respective ages are presented in Tables 10,11, and 12, and
comprised the first criteria of distinguishing between genes that are potentially involved in
initiation and those that participate in progression. Genes that were differentially
upregulated specifically at 1 day when compared to 6 weeks and 6 months are regarded as
representing the earliest stage of the disease. This may in fact be the most important stage
when distinguishing initiation from that of progression. Table 10 provides a combined list
of the 55 genes that were differentially upregulated at only 1 day when compared to 6
weeks and 6 months. The 7 genes that were differentially upregulated at

1 day in both

C-l and C-2 may actually represent the gene or genes that are related to initiation of
atherosclerosis. The genes that were exclusive to 1 day in this case include, SEC61
Gamma (SEC61G), FK 506 binding protein9 (FKBP9), clone ChEST874k20, BAC
CH261-10P22, Leucine rich repeat containing 17 9LRRC17), Decorin (DCN), and
hypothetical protein LOC424163.
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Table 10:
Genes Differentially Upregulated at 1 Day When Compared to 6 Weeks & 6 Months
Qrftioiog ( W Way versus 6weeksj

Gene Name

similar to SEC61 gamma (LOC776639)
clone ChEST874k20
BAC done CH261-10P22
leucine nch repeal containing 17
deimatan sulfate proteoglycan deconn
hypothetical LOC424163 (LOC424163)
vascular smooth muscle alpha-actin (ACM)
ATP synthase FO subumt 8 and 6 (ATPase 8,6),
BAC done TGMCBa-23H12
Wra17 mRNA for ledm-like transmembrane protein, Ly49q1 isoform (CDR-1)
done 0064pD012D12 putative nbosomal protein
collagen, type VIII, alpha I (C0L8A1)
hypothetical LOC424163
W binding protein 9 63 kDA (FKBP9)
myoglobin gene
neomycin resistance cassette pNeo4 NeoTel (neoTet)
microsatellite marker vemos44
CR1 gene for chicken repeat 1
fdxl gene and 4 orf s
has operon deletion mutant
Gene encoding methionine sulfoxide reductase
mitochondnal DNA

SEC613
clone CrES174<2C
BACCr261-"CP22
JiRC'T

DCN
424-63
ACT-4
ATPase 6
BAC TGMCBa-23H12
CDR-1
done0064p0012D12
C0L8A1
FASTKD1

FKB
MB
NEOTET

NA
NA
NA
NA
NA
NA

Copy!

Orthoiog (C-2 Way versus Smomfa)

7
5
3
3
2

clone ChEST874k20
similar to SEC61 gamma(LOC776639)
nephroblastoma overexpressed (NOV)
fk506 binding protein 9,63 kDA (FKBP9)
done 0062P0005D06 putative 40S nbosomal protein S8
fibronectm 1 (FN1)
done 0063P0029G01 putative RHoA GTPase variant 3
collagen, type III, alpha 1 (C0L3A1)
leucine nch repeal containing 17 (LRRC17)
done 0058P0007G11 putative perouredoxin 1 vanant 3
caitjoxypeptidaseE(CPE)
PG-M mRNA for proteoglycan
nbosomal protein L7(RPL7)
hypothetical LOC424163
done 0061P0024E07 putative sm like protein U6 snRNA-associated Sm-like protein
done 0063P0030D07 putative solute earner family 25 member 6 variant 1
done 0063P0009H02 putative proteosome maturation protein
done 0058P0011D09 putative beta 1 integnn binding protein 2 variant 1
BAC done CH261-10P22
BAC done CH261-147F20
BAC done CH261-79I12
non-muscle caldesmon
cell division cyde 2, G1 to S and G2 to M (CDC2)
similar to Methylosome subumt pICIn (chloride conductance regulatory protein IC1 n)
,(l(C1n)) (chloride channel, nudeotide sensitive 1A) (LOC425500)
>neChEST433n1
|doneChEST587b19
| type VI collagen alpha-2 subunit
Idermatan sulfate proteoglycan deconn
H3 histone, family 3B (H3 3B)
similar to oioanconn (L0C771927)
done 0063P0009H02 putativee proteosome maturation protein
ornithine decarboxylase anbzpe 1 (0AZ1)
similar to yeast ribosomal protein s28 homologue (LOC427323)

Gene Name

Copy*

cfcneChESTP4k20
SEC61G

NOV
FKBPS
RPS8

FN1
RhoA G T P a s e *
C0L3A1
LRR01?
clone 0058P0007G11

CPE
PG-M
RPL7

21
12
9
7
4
4
4
3
3
2
2
2
2

424*63
done0061P0024E07
clone 0063P0030D07
clone 0063P0009H02
done0058P0011D09
EACCH2W0P22
BACCH261-147F20
BACCH261-79I12
CALD1
CDC2
CLNS1A
clone ChEST433n1
clone ChEST587b19
COL6A2

DCN
H33B
KDELR2
clone 0063P0009H02
0AZ1
RPS23

Table 11 represents the 60 genes that were differentially upregulated at 6 weeks
when compared to 1 day and the 47 genes differentially upregulated at 6 weeks in C-3.
Since these genes were not found to be upregulated until 6 weeks of age, they are likely
contributors in the progression of atherosclerosis. Of the 107 genes that were differentially
upregulated at 6 weeks, only 16 were differentially upregulated at 6 weeks when compared
to both ages in C-l and C-3. They appear to be distinct only to 6 weeks and include
Gelsolin,(GSN), Spermidine/spermine Nl-acetyltransferase (SATl), Ribosomal protein L3
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(RPL3), Ribosomal protein L4 (RPL4), Eukaryotic translation initiation factor 3, subunit H
(EIF3H), Dead (Asp-Glu-Ala-Asp) box polypeptide 6 (DDX5), Cyclin-dependant kinase
inhibitor p27 kipl (CDKN1B), Ribosomal protein S28 (RPS28), Tropomyosin-alpha
(TPMl), Similar to B-aggressive lymphoma / Poly (ADP-ribose) polymerase (PARP14),
Ribosomal protein S6, (RPS6), Vimentin (VIM), Chaperonin containing TCPl, subunit 8
(CCT8), Ring finger protein 11 (RNF11), Ribosomal protein L5 (RPL5), and clone
0061P0031D11.
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Table 11:
Genes Differentially Upregulated at 6 Weeks When Compared to 1 Day & 6 Months
Ortholog |C-1 fiweeks versus 1eay)

Gene Name

gelsolm (GSN)

GSN

4 3 l d o n e 0064P0021C06spemiadine/spemiine N1-acetyltransferase variant Hike SAT*

clone 00&4P0D21CO6 spermidine/spermine N1-acetyltransferase

3AT1

34j|similarto yeast nbosomal protein S28 homologue (LOC427323)

R°S28

similar to nbosontal protein L3 (LOC771432)

RPJ

39 JJdone 0063P0030D07 putative solute earner family 25 member 6 vanant 1

SLC25A6

13JJ gelsolm (GSN)

GSN

hypothetical LOC415891 (LOC415891)

Copy # l O r t h o l o g (C-3 Sseeks versus

415891

faonths)

Gene Name

nbosomal protein L4 (RPU)

RPL4

sfesimilarto nbosomal protein L3 (LOC771432)

doneChEST118|5

doneChEST118|5

5Pprohibitin2(PHB2)

PHB2

eukaryotic translation initiation factor3 subumt H (EIF3H)

EIF3H

5Psimilarto coadosin-like 1 (dictyostelium) (LOC768420)

C0TL1

chromogranin B (secretogramn 1) ICHGB)

CHG8

DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 (DDX5)

DCXE

hemoglobin alpha-globm chain

HBA

lymphocyte antigen 6 complex locus E JLY6E)

LY6E

similar to NPD014 protein (NPD014)

NPD014

splicing factor arginine/serine-ncti 10 (transformer 2 homolog drosophila) (SFRS10)

SFRS10

splicing fedor argmine/senne-nch 6 (SFRS6)

SFRS6

doneChEST1007e10

doneChEST1007e10

bela2-m:croglobulin

B2M

cydrrvdependent kinase inhibitor p27 Kip1

CDKN'B

similar to yeast nbosomal protein S28 homologue (LOC427323)

RPS26

alpha-tropomyosm gene, exons 9c 9d, and complete cds alternatively spliced

TPM*

4
4
4
4
4
4
4
4
3
3
3
3
2
2
2
2
2
2
2

clone C362P0D01031 putative high-mobility group nudeosome binding domain 1 vanant 1done0062P0001Cu1
alpha lhalassemia/mental retardation syndrome X-linked (ATRX)

ATRX

BACdoneCH261-114A20

BACCH261-114A20

lagged 1 (Alagille syndrome) (JAG1)

JAG1

similar to B-aggresswe lymphoma 2B

PaPP 4

RPS6 mRNAfor nbosomal protein S6

RPS6

vimentin (VIM)

VIM

Copy«

R°L3

nucleoside diphosphate kinase

NDPK

finished cDNA done ChEST14214

SERPINF2

nbosomal protein L9(RPL9)

RPL9

S-ptiase kinase-associated protein 1 (SKP1)

SKP1

eukaryotic translation initiation factor 3 subunit H (EIF3H)

EIF3H

done 0058P0007G11 putative peroxiredoxin 1 vanant 3

PRDX1

similarto SDF3 (LOC771608)

SERPINF1

BACdoneCH261-77K20

BACCH261-77K20

done 0061P0016C08 putative actin related protein 2/3 complex subunit 2

done 0061P0016C08

similar to B-aggressive lymphoma 2B (LOC424266)

PARP14

done 0061P0001E09 putative Yip1 domain family member 1

done 0061P0001E09

chaperonin containing TCP1 subunit 8 (theta) (CCT8)

CCT8

cydin-dependent kinase inhibitor p27 Kip1

emm

done 0061P0031D11 matnx Gla-like

done0:«1F0031C11

nbosome binding protein 1 homolog 180kDa (RPBP1)

RPBP1

nbosomal protein L4 (RPL4)

PPL4

vimentin (VIM)

VIM

hypothetical prolan L0C770045

770045

done 0061P0022F12 putative creatine kinase B vanant 1

doneOO61P0O22F12

similar to collagen alpha-2(IV) chain (L0C418752)

418752

done 0064P0012G12 RIKEN cDNA 0610039A15-like

done0064P0012G12

hypothetical LOC423192 (LOC423192)

423192

similar to adenylate kinase (EC 2 7 4 3) (LOC428227)

AK2

hypothetical LOC423602 (LOC423602)

423602

chromosome 12 open reading frame 49 (c12orf49)

C12orf49

hypothetical protein LOC770909

770909

chaperonin containing TCP1, subunit 6A (zeta 1) (ccT6A)

CCT6A

similarto SDF3 (LOC771608)

771608

done 0058P0030G01

done QD58P0O3CGO1

B-cell translocation gene i anti-prolrferative (BTG1)

BTG1

done0065P0012D05

done0065P0012D05

chaperonin containing TCP1, subunit 8 (theta) (CCT8)

CCT8

doneChEST1004o7

done ChEST1004o7

MHC dass II associated mvanant chain (CD74)

CD74

done ChEST5e12

done OiEST5e12

clone ChEST608i22

done ChEST608i22

similar to collagen alpha-2 (IV) chain

C0L4A2

clone ChEST751d6

done ChEST751d6

DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 (DDX5)

SX5

clone ChEST984n15

done ChEST984n15

DnaJ (Hsp40) homolog subfamily A member 1 (DNAJA1)

DNAJA1

cleavage stimulation factor, 3' pre-RNA subunit 1 50kDa (CSTF1)

CSTF1

GNAS complex locus transenpt vanant 2 (GNAS)

GNAS

eukaryotic translation elongation factor 1 alpha 1 (EEF1A1)

EEF1A1

similarto glycogen synthase kinase 3 beta (LOC418335)

GSK3B

eukaryotic translation initiation factor 5 (EIF5)

EIF5

lectin associated matnx protein (hLAMP-1)

hLAMP-1

FYN oncogene related to SRC FGR, YES (FYN)

FYN

similarto microfibrillar associated protein 5 (LOC418256) MFAP5

MFAP5

hed domain and RLD 2 (HERC2)

HERC2

proline-nch nudear receptor coadivator 1 (PNRC1)

PNRC1

heterogeneous nudear nbonudeoprotein Dfike (HNRPDL)

HNRPDL

nng finger protein 11(RNF11)

"NF'1

low densriy lipoprotein receptor-related protein associated protein 1 (LRPAP1)

LRPAP1

nbosomal protein L5 (RPL5)

=?L5

mitochondnal nbosomal protein 127 (MRPL27)

MRPL27

nbosomal protein S6(RPS6)

SPS6

pumilio homolog 2 (drosophila) (PJM2)

PUM2

transmembrane emp24 protein transport domain containing 5 (TMED5)

TMED5

ring finger protein 11 (RNF11)

RNF1I

alpha-tropomyosm done cC401

TPM"

nbosomal protein L5 (RPU)

RPL5

nbosomal protein L6 (RPL6)

RPL6

clone 0058P0031F07 putative nbosomal protein S3

RPS3

splicing factor, argmine/senne-nch 1 (SFRS1)

SFRS1

T cell receptor delta chain (TCRD) pseudogene

TCRD

WD repeat domain, phosphoinositide interacting 2 (W1PI2)

WIPE

clone 0058P0047C07 putative SNF7 domain containing 2 vanant 2

clone 0056P0047C07

clone 0069P0004A06 transcnptional regulator Id2-like

done0069P0004A06

clone 0064P0010H05 high-mobility group nudeosome binding domain 1 vanant 1-like

done 0064P0010H05

clone 0061P0031D11 matnx Gla-like

done:06'P0O31D^

steroid dehydrogenase

NA
NA
NA

mvanant chain (li)
encoding methionine sulfoxide redudase
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74
25
21
20
18
17
16
15
15
9
6
5
5
5
4
3
3
2
2
2
2
2
2
2

Thirty-seven genes were differentially upregulated at 6 months when compared to 1
day (C-2) and 6 weeks (C-3) of age respectively and are listed in Table 12. These are
related to disease progression since they were not differentially upregulated in the previous
ages. Of the 37 genes only 3, BAC CH261-117C7, Enolase 1 (ENOl) and Acyl-coA
synthetase long chain family member 1 (ACSL1) were differentially upregulated
exclusively at 6 months when compared to both 1 day and 6 weeks.

Table 12:
Genes Differentially Upregulated at 6 Months When Compared to 1 Day & 6 Weeks
Oittiolog (C-2 tenths yesus iday)
BAC done CH261-117C7
calnexin (CANX)
CD36 molecule (thromfcospondinreceptor)(CD36)
mrna for tau-crystallin/alpha enolase
clone 0057P0001H01 calmodulin variant Hike
done0058P0017H07
similar to CD59 protein (LOC423148)
phosphodiesterase 5A, cGMP-specific (PDE5A)
similarto bullous pemphigoid antigen 1,230/240kDa (LOC421884)
acyl-CoA synthetase long-chain family member 1 (ACSL1)
similar to asporin (LOC415954)
BAC done CH261-138K4
BAC done CH261-187N23
done Pgp29 microsatellite sequence
similarto CLIP-assodating protein 1; multiple asters 1 (LOC420724)
clone ChEST163a24
doneChEST417p21
clone IMAGE8236306
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, x-linked (DDX3X)
mitochondnon
similar to phospholipase C beta 4, transcript variant 2 (LOC416730)
UNKdoneTGMCBa-14H12

Gene Name

Copy*'

Ortholog ( W tenths versus fiweeks}

3ACCH261-17C7
CANX
CD36

23 enolase 1, (alpha) (ENOl)
9 BACdoneCH261-117C7
6 acyl-CoA synthetase long-chain family member 1 (ACSL1)

ENOl
done0057P0001H01
done0058P0017H07
CD59
PDE5A
421884
AC3J
ASPN
BACCH261-138K4
BACCH261-187N23
done Pgp29
CLASP2
clone ChEST163a24
doneChEST417p21
donelMAGE:8236308
DDX3X

5
3
2
2
2

16S liposomal RNA gene, partial sequence; tRNA-leu gene, complete
sequence; NADH dehydrogenase subunit 1 (ND1) gene
Similarto 0TTHUMP00000028984 (LOC418017)
hypothetical LOC419017, transcript variant 1 (LOC419017)
BAC clone CH261-16J12
BAC done CH261-19B3
BAC done TAM31-16o5
CD151 molecule (Ralph blood group) (C0151)
done 0061P0022F12 putative creaine kinase B variant 1
ZMUC125434 ornithine decarboxylase (ODC)
odd-skippedrelated1 (drosophila) (0SR1)
GTP-spedfic sucdnyl-CoAsynthetase alpha subunit (SCS)
done 0063P0006F01 ubiquitin C variant Wike

Copy!
Gene Name
ENC"
6
EACCH26--117C7
4
3
ACS.'

ND1

2

418017
419017
BACCH261-16J12
BACCH261-19B3
BACTAM31-16o5
CD151

CKB
ODC
0SR1

SCS
UBC

ND5
PLCB4
UNKdoneTGMCBa-14H12

The following bar graphs, Figures 2a - 2af provide a pictorial representation of
genes in a manner that was similar to those listed in tables 10,11, and 12. In addition,
however, the bar graphs were developed to visually display the regulation patterns of only
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those genes that were differentially expressed in more than one age comparison, either at
the same age or at different ages therefore comprising the second criteria. They were then
grouped as participating in either initiation or progression of atherosclerosis. Given the
three age comparisons, seven different patterns of regulation were possible and are laid out
in Table 13.

Table 13: Patterns of Genes Differentially Expressed in Age Comparisons
Genes Differentially Expressed in More Than One Age Comparision
1day
Pattern #
6weeks
6months
# of Genes
Figures
—
—
1
7
3a-3g
t
—
—
2
15
4h-4w
T
—
—
3
3
5x-5z
t
—
4
10
6aa-6jj
T
t
—
5
5
7kk-7oo
T
T
—
6
10
8pp-8yy
T
T
7
6
9zz-9af
t
t
t

Of the 291 genes that were originally identified by BLASTn, 57 genes were
grouped into one of the seven patterns. While it is interesting to look at the change in
patterns of expression throughout the three comparisons, it is important to keep in mind
that the differential expression is unique between the ages compared and cannot necessarily
be compared to another comparison (age group) or across comparisons. The following
Figures 4a - 4af represent the upregulation pattern of a given gene within an age group
compared, as well as patterns of expression across comparisons.
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Figures 4a - 4af: Upregulation of Genes Within and Across Comparisons:
Figure 4a: Sec61 Gamma Subunit (SEC61G) Figure 4b: Clone ChEST874k20
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Figure 4d: Decorin (DCN)
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Figure 4e: FK506 Binding Protein 9

Figure 4f: Leucine Rich Repeat

(FKBP9)

Containing 17 (LRRC17)

3
25
2

1 5

/

M

s

*
*

1
05
A

1Day

6wks

1Day

6mos

6wks

C_1
1Day

6mos

72

^.fc
C_1
6wks

I^SWKI^&^~
C_2
1Day

C_2
6mos

C_3
6wks

C_3
6mos

Figure 4g: BAC CH261-10P22

Figure 5h: Gelsolin (GSN)
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Figure 5i: Ribosomal Protein L3 (RPL3)
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Figure 5j: Spermidine/Spermine
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Figure 5k: Ribosomal Protein S28 (RPS28) Figure 51: Chaperone Containing TCPl,
subunit 8 (theta) (CCT8)
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Figure 5m: DEAD (Asp-Glu-Ala-Asp) box Figure 5n: Eukaryotic Translation
polypeptide 5 (DDX5)
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Figure 5o: B-aggressive Lymphoma 2B
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Figure 5p: Ring Finger Protein (RNFl 1)
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Figure 5q: Ribosomal Protein L4 (RPL4)
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Figure 5r: Ribosomal Protein L5 (RPL5)

RPL4
^ • s .

*B

!„„

1
0 9-

74

Figure 5s: Ribosomal Protein S6 (RPS6)

Figure 5t: Alpha-Tropomyosin 1 (TPMl)
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Figure 5v: Cyclin Dependant Kinase

Figure 5u: Vimentin (VIM)

Inhibitor p27 Kipl (CDKN1B)

iy\

4£Z

|i

j«s:

^\
S
.

-IT-

•i,.,

A ... .:
i
-'jt»_.A

0

0

C_2
1Day

C_2
6mos

rrr

C_1
1Day

L ° _J
C_3
6wks

C_3
6mos

Figure 5w: Clone 0061P0031D11

Figure 6x: BAC clone CH261-117C7

Clone0061P0031D11

CH261-117C7

£

0
C_1
1Day

1

1
C_1
6wks

0
C_2
1Day

0
C_2
6mos

|I
C_3
6wks

_ o

15|

>
C_1
1 Day

C_3
6mos

75

CM
6w ks

C_2
1 Day

C_2
6mos

C_3
6w ks

C_3
6rros

Figure 6z: Acyl-CoA synthetase long-

Figure 6y: Enolase (ENOl)
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Figure 7cc: Eukaryotic translation
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Figure 7ee: Ribosomal Protein S23

Figure 7ff: Clone 0058P0011D09
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Figure 7gg: Calmodulin 1 (CALMl)

Figure 7hh: Ribosomal Protein S3A
(RPS3A)

Figure 7ii: Destrin (DSTN)

Figure 7jj: Acidic (leucine rich) nuclear
phosphoprotein 32, member A (ANP32A)
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Figure 8kk: Fatty Acid Binding Muscle,

Figure 811: Fibulin 5 (FBLN5)

Protein 4 (FABP4)
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Figure 8mm: Myosin Light Chain Kinase

Figure 8nn: ATP Synthase FO Subunit 8
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Figure 8oo: Actin, alpha 2, Smooth
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Figure 9qq: Ribosomal Protein L32

Figure 9rr: 12S Ribosomal rRNA
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Figure 9tt: RHO Associate Coiled-Coil
Forming Kinase 1 (ROCK1)
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Figure 9ww: Eukaryotic Translation
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Figure 9yy: BAC Clone CH261-126J23)

Figure lOzz: Cytochrome Oxidase III
(COIII)
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Figure lOab: 16S Ribosomal rRNA

Figure lOac: NADH Dehydrogenase
Subunit 4 (ND4)
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Figure lOad: Cytochrome Oxidase II (COII)

Figure lOae: Lumican (LUM)

Figure lOaf: Cytochrome Oxidase 1 (COI)
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While examining the differential upregulation of genes within the comparisons, the
seven patterns of expression that were possible when distinguishing between initiation and
that of progression can be explained as follows. The first pattern, reflects genes that were
differentially upregulated exclusively at 1 day when compared to the other two ages.
Genes exhibiting this pattern are presented in Figures 4a-4g and may be the most
important genes when looking at whether these genes play a role in initiation of the disease.
The second pattern of expression was observed in Figures 5h-5w. In this pattern, genes
were differentially upregulated at 6 weeks when compared to both 1 day and 6 months,
suggesting early progression. The third pattern observed in Figures 6x-6z, include genes
that were differentially upregulated exclusively at 6 months, which is suggestive of later
progression. A fourth pattern that was observed in Figures 7aa-7jj involved genes that
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were differentially upregulated at both 1 day and 6 weeks. Although this pattern may be
slightly ambiguous, since they were upregulated at both 1 day and 6 weeks it is possible
that they serve in initiation of the disease and may participate in early progression. The
fifth pattern of expression presented in Figures 8kk-8oo reflected genes that were
differentially upregulated at both 1 day and 6 months. This was rather interesting
suggesting several possibilities. The differential upregulation at 1 day suggests genes are
involved in initiation. Since they were upregulated again at 6 months, however, this may
indicate that these genes are involved in both initiation and progression, or that their role
was simply that of normal development. Since this pattern does not fit the pattern laid out
in the objectives, these genes were not considered further for purposes of this thesis.

The

sixth pattern of expression (Figures 9pp-9yy) in which genes were differentially
upregulated at both 6 weeks and at 6 months of age, indicated involvement in progression
of the disease. The final and seventh pattern of expression included genes that were
differentially upregulated in all of the three the ages (Figures lOzz-lOaf). The regulation
of these genes, presented an ambiguous situation and resulted in not placing them in either
initiation or progression.
When looking more closely at the regulation of the genes, beginning with the first
pattern of expression, in Figure 4a, SEC61G gene was differentially upregulated at 1 day
when compared to 6 weeks and 6 months of the first two comparisons respectively. This
was also the case for ChEST874k20, LOC424163, DCN, FKBP9, and LRRC17 and BAC
CH261-10P22 in Figures 4b-4g.
Genes fitting the second pattern, included GSN, RPL3, SAT1, RPS28, CCT8,
DDX5, EIF3H, PARP14, RNFl 1, RPL4, RPL5, RPL6, TPMl, VIM, CDKNIB, and clone
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0061P0031D11 represented in Figures 5h-5w respectively and were differentially
upregulated at 6 weeks when compared with both 1 day and 6 months (in C I and C_3).
In the third pattern, (Figures 6x-6z), CH261-117C7, ENOl, and ACSL1 were
differentially upregulated at 6 months when compared to both 1 day and 6 weeks
respectively. In the fourth pattern, Collagen type 1, alpha 2 (COL1A2) in Figure 7aa, was
upregulated at 1 day when compared to both 6 weeks and 6 months in C_l and C_2. It was
also differentially upregulated at 6 weeks when compared to 6 months in C_3. Figure 7bb
shows thatNADH hydrogenase (ubiquinone) 1 alpha subcomplex, 10 (NDUFA10) was
upregulated in both reciprocal ages at 6 weeks when compared to 1 day, and at 1 day when
compared to 6 weeks in C-l. It was also upregulated at 6 weeks when compared to 6
months. Figures 7cc-7ee revealed the differential upregulation of, Eukaryotic translation
initiation factor 1(EIF1), Ras homolog gene family, member A (RHOA) and Ribosomal
protein S23 (RPS23) at 1 day when compared to 6 months in C-2, and at 6 weeks, when
compared to 6 months in C-3 yet no difference in upregulation was observed in C-l.
Figures 7ff and 7gg showed Clone 0058P0011D09, and Calmodulin 1 (CALM1), were
differentially upregulated at 6 weeks in C-l as well as at 1 day in C-2. Figures 7hh-7jj
reflect the upregulation of Ribosomal protein S3 A (RPS3A), Destrin (DSTN), and Acidic
(leucine rich) nuclear phosphoprotein 32, member A (ANP32A), at 6 weeks when
compared to both 1 day and 6 months respectively, and were also upregulated at 1 day
when compared to 6 months in C-2 thus concluding genes that fit the fourth pattern of
expression. In the fifth pattern of expression, Figure 8kk, Fatty acid binding muscle
protein 4 (FABP4) was differentially upregulated at 1 day when compared to 6 weeks, and
at 6 months when compared to 1 day, yet no difference in regulation appeared between 6
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weeks and 6 months in C-3. Fibulin 5 (FBLN 5) (Figure 811) was differentially
upregulated at 1 day when compared to both 6 weeks and 6 months and was also
differentially upregulated at 6 months when compared to 6 weeks. This same pattern of
regulation that was exhibited by FBLN 5 was also observed for Myosin light chain kinase
(MYLK), ATP synthetase FO subunit 8 (ATP8), and Actin, alpha 2, smooth aorta
(ACTA2) (Figures 8mm-8oo) except that, they were also upregulated at 6 months when
compared to 1 day in C-2.
Genes that fit the sixth pattern of expression included, Actin, beta (ACTB,)
Ribosomal protein L32 (RPL32), 12S ribosomal rRNA (12SrRNA), Clone ChEST 189kl 1,
RHO associate coiled-coil forming kinase 1 (ROCK1), Clone ChEST 398al6, Heat shock
protein 90 AA1 (HSP90AA1), Eukaryotic translation initiation factor 4A (EIF4A2),
Myosin heavy chain 11, smooth muscle (MYH11) and CH261-126J23 (Figures 9pp-9yy).
In Figure 9pp, ACTB was differentially upregulated at 6 weeks when compared to both 1
day and 6 months, and at 6 months when compared to 1 day in C-2. The genes in figures
9qq-9uu were all upregulated at 6 weeks when compared to 1 day, and were up again at 6
months when compared to 1 day, yet there was no difference in regulation between 6
weeks and 6 months in C-3. HSP90AA1, EIF4A2, and MYH11 (Figures 9w-9xx), were
all upregulated at 6 weeks when compared to 1 day, and at 6 months when compared to
both 1 day and 6 weeks.
The final pattern of regulation, exhibited by genes in Figures lOzz-lOaf was rather
ambiguous as stated previously, and therefore prevented their placement in either initiation
or progression of the disease. Genes that comprised this seventh pattern included
Cytochrome oxidase III (COIII), 16S ribosomal rRNA (16S rRNA), NADH dehydrogenase
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subunit 4 (ND4), Cytochrome oxidase II (COII), Lumican (LUM), and Cytochrome
oxidase I (COI).
Once the 57 genes fitting the 7 different patterns of regulation were made known,
they were then entered into MetaCore to determine their primary function. Although
genes' fitting patterns five and seven were excluded from further analysis based on the
hypothesis, they were included in this step with the hope of providing some understanding,
as to why the seven groups of genes were differentially upregulated at the time points
reflected by the seven patterns of regulation. These genes were laid out in table format
according to the 7 types of expression patterns in Table 14.
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Table 14: Primary Function of Genes Fitting 7 Patterns of Differential Upregulation
Seven Patterns of Expression: Gene Function According to MetaCore
Pattern # & Age
Differentially Upregulated

#1: t 1 day

Figure

Gene Name

Function

2a
2b
2c
2d
2e
2f

SEC61G
ChEST874k20
LOC424163
DCN
FKBP9
LRRC17
BACCH261-10P22

Transporter/Translocator
?
?

3j
3k
31
3m
3n
3o
3p
3q
3r
3s
3t
3u
3v
3w

GSN
RPL3
SAT1
RPS28
CCT8 (TCP theta)
DDX5
Elf3H
PARP14
RNF11
RPL4
RPL5
RPS6
TPM1
VIM
CDKN1B(p27KIP1)
Clone 0061P0031D11

calcium modulation dependent & regulating proteins, muscle contraction
Ribosomal production
Transporter/transloactor
Ribosomal production
Chapterone
Mitochondrial energy production, mRNA splicing, translation
Translation
Transcription & translation
Protein-protein interactions
Ribosomal production
Ribosomal production
Ribosomal production
Muscle contraction, calcium modulation dependent & regulating proteins
Cytoskeletal elements
cell cycle, kinase
?

4x
4y
4z

CH261-117C7
EN01
ACSL1

?

5aa
5bb
5cc
5dd
5ee
5ff
5gg
5hh
5ii

5ii

COL1A2
Connective tissue / matrix integrity
NDUFA1D
Mitochondrial energy production
EIF1
Translation
RHOA
Signal transduction, muscle contraction
Ribosomal production
RPS23
Clone 0058P0011D09 ?
Calcium modulation dependent & regulating proteins, muscle contraction
CALM1
Ribosomal production
RPS3A
DSTN
Cytoskeletal elements & organization, muscle contraction
ANP32A (PHAP1 (pp32 Cell growth, regulation & differentiation, tumor suppressor, transcription

6kk
6II
6mm
6nn .
6oo

FABP4 (A-FABP)
FBLN-5
MYLK
ATP8
ACTA2

Lipid metabolism
Adhesion molecule
Calcium modulation dependent & regulating proteins, muscle contraction, kinase
Mitochondrial energy production
Cell motility, muscle contraction, cytoskeletal elements

7pp
7qq
7rr
7ss
7tt
7uu
7w
7ww
7xx
7yy

ACTB
RPL32
12SrRNA
Clone ChEST189k11
ROCK1
Clone ChEST398a16
HSP90AA1
EIF4A2
MYH11
CH261-126J23

Cell motility, muscle contraction, cytoskeletal elements
Ribosomal production
Ribosomal production
?
Adhesive molecule, kinase
?

8zz
8ab
8ac
8ad
8ae
8af

COIN
16SrRNA
ND4
CON
LUM
CON

Mitochondrial energy production
Ribosomal production
Mitochondrial energy production
Mitochondrial energy production
Proteoglycan
Mitochondrial energy production

2g
3h
3i

#2: t 6 weeks

#3:t 6 months

#4: 11 day & I 6 weeks

#5:

11 day & t 6 months

#6: t 6 weeks & t 6 months

#7: t 1 day, t 6 weeks & I 6 months
o

Proteoglycan
muscle contration, receptor, immunity
?
?

Glycolysis, cell growth, regulation, differentiation, immunity
Lipid metabolism

Chaperone, protein folding
Translation
Muscle contraction
?

According to MetaCore, of the original 57 genes, 46 of them that fit patterns one,
two, three, four, and six, were annotated and remained genes of interest. Given the
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extensive amount of time that would be necessary to fully characterize each of these
candidate genes, and in light of the expectations of this project, it was decided that only
genes that were differentially upregulated exclusively as laid out in Tables 10,11, and 12
would be further analyzed with the assistance of MetaCore's database.
Of the 55 genes that were differentially upregulated at lday (Table 10), only the 7
genes that were differentially upregulated exclusively at 1 day when compared to both
6weeks and 6months respectively were analyzed further for their potential role in initiation
of atherosclerosis in the discussion. In addition, 107 genes were differentially upregulated
at 6weeks, while 37 genes were differentially upregulated at 6months (Tables 11 and 12,).
Of those, only the 16 genes that were differentially upregulated exclusively at 6weeks
when compared to both lday and 6months respectively (Table 11), and the 3 genes that
were differentially upregulated exclusively at 6months when compared to both lday and
6weeks (Table 12), were analyzed further for their potential role in progression. Genes
fitting this criterion were then researched further in hopes of understanding their potential
role in initiation and progression of atherosclerosis, and are presented in Table 15. These
genes will be discussed further in Chapter four of this report. Some of these annotated
genes were placed in available pathway maps in MetaCore, and are located in the Appendix
section.

87

Table 15: Genes Upregulated Exclusively at 1 Day, 6 Weeks, and 6 Months When
Compared to Their Respective Ages.
Annotation of Genes Differentially Upregulated Exclusively When Compared to Both Respective Ages
Function According to MetaCore
Age
Gene Name
1 day
SEC61 G
FKBP9

DCN

Protein transport protein, necessary for protein translocation in the endoplasmic reticulum and is the central component of the
protein translocation apparatus of the endoplasmic reticulum (ER) membrane
Associates with ryanodine receptor (RYR-2) in cardiac muscle SR & may play unique physiological role in excitation-contraction
coupling in cardiac muscle
Bone proteoglycan II may affect the rate of fibril formation Small cellular or pericellular matrix proteoglycan that is closely related in
structure to biglycan protein Is a component of connective tissue, binds to type I collagen fibrils plays a role in matrix assembly & is
capable of suppressing the growth of various tumor cell lines

6 weeks

SAT1

The L3 protein is a component of the large 60S subunit of cytoplasmic nbosomes, that catalyze protein synthesis Ribosomes
consist of a small 40S subunit and a large 60S subunit Together these subunits are composed of 4 RNA species and approximately
80 structurally distinct proteins
The L4 is a componet of the large 60S nbosomal subunit of cytoplasmic nbosomes
This gene encodes a nbosomal protein that is a component of the large 60S nbosomal subunit The protein belongs to the L18P
family of nbosomal protein that interacts specifically with the beta subunit of casein kinase II Vanable expression of this gene in
colorectal cancers, compared to adjacent normal tissues has been observed,
This gene is a componet of the 40S nbosomal subunit of cytoplasmic nbosomes May play an important role in controlling cell
growth and proliferation through the selective translation of particular classes of mRNA Belongs to the S6E family of nbosomal
proteins It is the major substrate of protein kinases in the ribosome, with subsets of five C-terminal serine residues phosphorylated
by different protein kinases
The S28 gene encodes a nbosomal protein that is a component of the 40S subunit located in the cytoplasm
Is a transporter that binds and undergoes conformational changes Catalysis of 2ndary active transfer of sulfate from one side of
membrane to the other up its concentration gradient

EIF3H

Is involved in translation of proteins in the cytoplasm

RPL3
RPL4

RPL5

RPS6
RPS28

DDX5

CDKN1B

TPM1

PARP14

RNA-dependent ATPase activity The rate of ATP hydrolysis is highly stimulated by single-stranded RNA May be involved in premRNA splicing DEAD box proteins are characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA
helicases They are implicated in a number of cellular processes involving alteration of RNA secondary structure such as translation
initiation, nuclear and mitochondnal splicing and nbosome and spliceosome assembly Some members of this family are believed to
be involved in embryogenesis spermatogenesis and cellular growth and division
Is an important regulator of cell cycle progrssion Involved in G1 arrest Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes
Positive regulator of cyclin D-dependent kinases such as CDK4 Regulated by phosphorylation and degradation events Positive
regulation of cellular and developmental processes
Binds to actin filaments in muscle and non-muscle cells Plays a central role in association with the troponin complex, in the calcium
dependent regulation of vertebrate striated muscle contraction Smooth muscle contraction is regulated by interaction with
caldesmon In non-muscle cells is implicated in stabilizing cytoskeleton actin filaments This gene is a member of the tropomyosin
family of highly conserved widely distnbuted actin-binding proteins involved in the contractile system of striated and smooth muscles
and the cytoskeleton of non-muscle cells
Enhances STAT6-dependent transaction (By similanty) Has ADP-nbosyltransferase activity Poly(ADP-nbosyl)ation is an
immediate DNA damage-dependent posttranslational modification of histones and other nuclear proteins that contnbutes to the
survival of injured proliferating cells

GSN

Vlmentins are class-Ill intermediate filaments found in vanous non-epithelial cells, especially mesenchymal cells Along with actins
and microtubules (tubulins) the intermediate filaments represent a third class of well-charactenzed cytoskeletal elements
Mmolecular chaperone assist the folding of proteins upon ATP hydrolysis Known to play a role in vitro in the folding of actin and
tubulin Also, known as chaperonin containing TCP1, subunit 8 (theta)
Contains a RING-H2 f nger motif which is known to be important for protein-protein interactions Has been shown to be induced by
mutant RET proteins (MEN2A/MEN2B) The germline mutations in RET gene are known to be responsible for the development of
multiple endocrine neoplasia (MEN)
Calcium-regulated actm-modulating protein that binds to the plus (or barbed) ends of actin monomers or filaments preventing
monomer exchange (end-blocking or capping) It can promote the assembly of monomers into filaments (nucleation) as well as sever
filaments already formed

EN01

Multifunctional enzyme that, as well as its role in glycolysis plays a part in various processes such as growth control hypoxia
tolerance and allergic responses May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve
as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons Stimulates
immunoglobulin production May be a tumor suppressor

ACSL1

Activation of long-chain fatty acids for both synthesis of cellular lipids and degradation via beta-oxidation is an isozyme of the longchain fatty-acid-coenzyme A ligase family Converts free long-chain fatty acids into fatty acyl-CoA esters and thereby plays a key
role in lipid biosynthesis and fatty acid degradation

VIM
CCT8

RNF11

6 months
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CHAPTER IV

DISCUSSION

In the WC pigeon, spontaneous atherosclerosis develops in the absence of known
risk factors (49) making it an excellent model in which to study underlying genetic factors
associated with atherosclerosis. In this study, two hundred and ninety one non-redundant
genes were differentially upregulated at 1 day, 6 weeks, and 6 months of age in the celiac
bifurcation of the WC pigeon. When considering the placement of genes that were
differentially upregulated at each of the three ages, previous research demonstrates that
initiation occurs early on. In fact, Santerre reported that in the WC pigeon, spontaneous
atherosclerosis occurs as early as 1 day (80). Therefore, genes that were differentially
upregulated at 1 day were considered to participate in initiation of atherosclerosis.
While the actual point at which initiation occurs is less defined, by 6weeks of age
the biochemical and morphological hallmarks demonstrate that progression of the disease is
well under way (57). In addition, reports suggest that factors responsible for initiation are
independent of those that are responsible for progression (81). With that said, the initiating
event in the WC sets in motion the documented cellular, biochemical, and molecular
changes that ensue marking the disease progression (50). Based on these studies, genes
that were differentially upregulated at 6 weeks and 6 months of age were considered more
likely to participate in the progression of atherosclerosis.
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Only a subset of the genes most likely to be involved in the disease, that were
upregulated exclusively and annotated in MetaCore, were chosen from each of the three
age groups to be analyzed further for their potential role in initiation and progression of
atherosclerosis. It is important, not to lose sight of the fact that many of the genes of
interest may actually be involved in normal development. In light of this, efforts were
made to distinguish between genes involved in normal healthy development and those
involved in the pathogenic state.
Of the 7 genes that were differentially upregulated exclusively at 1 day, only 3
genes were fully annotated in MetaCore and include, SEC61G, FKBP9, and DCN.
According to MetaCore, SEC61G is the central component of the protein translocation
apparatus which is necessary for translocation of proteins in the endoplasmic reticulum
(82).

FKBP9 associates with ryanodine receptor (RYR-2) in cardiac smooth muscle

sarcoplasmic reticulum and may play a unique role in excitation contraction coupling in
cardiac muscle. FKBP9 also has the potential to contribute to the immunosuppressive and
toxic effects of FK506 (an immunosuppressive drug) and rapamyacin (an
immunosuppressant) (82, 83). In a study conducted to explore novel genetic causes of
inherited cardiomyopathies in one kindred (4 generations, 32 individuals), linkage was
established to a novel locus on chromosome 7 (7pl2.1-7q21) which included the candidate
genes SEC61G and FKBP9, although no disease causing mutations were identified (84).
The third gene fully annotated in MetaCore, DCN, is recognized as bone
proteoglycan II (82). DCN is a component of connective tissue and binds to type I collagen
fibrils (COL1A2). The gene COL1A2 which codes for Type I collagen fibrils was also
differentially upregulated at 1 day when compared to 6 weeks and again when compared to
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6 months, and is also known to play a role in matrix assembly (82). DCN is also capable of
suppressing the growth of various tumor lines (82). A study, conducted to assess the
relationship between proteoglycans and calcification of cultured bovine aortic SMCs
revealed that there was a significant increase in DCN, peaking by 7-10 days and decreasing
by day 14, although it remained elevated when compared to control cells (85). The
researchers also reported that over expression of DCN enhanced the calcification of tissues
as seen in sheets of arterial SMCs and in colocalized regions of atherosclerotic plaques in
arteries (85).
Immunofluorescence of human carotid artery segments, obtained from autopsy or
from surgery, revealed that in non-atherosclerotic arteries, DCN was detected only in the
adventitia (86). On the other hand, in arteries that contained atherosclerotic lesions, DCN
was present primarily in the layer of the intima close to the media with less in the
subendothelial part of the intima (86). In addition, this study found that while type I and III
collagen in the arterial intima associates with DCN, group II secretory nonpancreatic
phospholipase A2 (snpPLA2) binds preferentially to DCN which enhances snpPLA2
activity, and may contribute to the pathogenesis of atherosclerosis by modifying
lipoproteins and releasing inflammatory lipid mediators at sites of lipoprotein accumulation
(86). While it is not known precisely whether SEC61G and FKBP9 are responsible or
involved in initiation of atherosclerosis, research strongly implicates DCN as a major
player in atherosclerosis, although a specific role in initiation remains unclear at the present
time.
At 6 weeks, 15 of the 16 genes that were exclusive to this age were annotated in
MetaCore. Five of these included genes responsible for ribosomal production. The first
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three, RPL3, RPL4, and RPL5, are all components of the large 60S subunit of cytoplasmic
ribosomes while RPS6 and RPS28 belong to the small 40S subunit of cytoplasmic
ribosomal proteins. RPL3 belongs to the L3P family of ribosomes and is suggested to
contribute to tat-mediated transactivation by binding to RNA which then activates
translation (82) [Appendix D]. While RPL4 belongs to the L4E family of ribosomal
proteins (82), a study by Zengel et al., found that RPL4 regulates the SIO operon of
Escherichia coli by inhibiting translation of the proximal gene and by stimulating
premature termination of transcription within the SIO leader (87). According to MetaCore,
ribosomal protein L5 belongs to the L18p family of ribosomal proteins in the cytoplasm
(82). Ribosomal S6 belongs to the S6E family of ribosomal proteins and may be key in
controlling cell growth and proliferation through selective translation of particular classes
of mRNA. It is a major substrate of protein kinases in the ribosome, with subsets of five Cterminal serine residues that are phosphorylated by different protein kinases (82). RPS28
belongs to the S28E family of ribosomal proteins (82) [Appendices D, and K].
Interestingly, RPS28 and RPL3 were also differentially upregulated exclusively at 6
weeks in the WC when compared to the SR as shown in Anderson's unpublished in-vivo
RDA work (63) [Appendix S]. While RPL3 was upregulated differentially at 6 weeks in
both this work and in the in-vivo work, it was also downregulated by 6 months of age in the
WC in both bodies of work. This was also the case in Anderson's in-vitro work (which
represents that of a compressed time-frame of approximately 2-3 years) [Appendix Q].
There, RPL3 was upregulated significantly in the SR when compared to the WC. These
patterns appear to support the ultrastructural work conducted by Cooke where he found that
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free ribosomes gradually decreased in the aorta of the spontaneously atherosclerotic WC as
they developed unlike those of the SR (88).
In support of Cooke's findings, while many different ribosomal genes were
differentially upregulated at each of the three ages throughout the three comparisons, most
of the ribosomal genes that were upregulated at 6 weeks in this study were down by 6
months of age in the WC. More specifically, 10 different ribosomal genes were
upregulated at 6 weeks of age when compared to 1 day [Appendix D], and 8 different
ribosomal genes were upregulated at 6 weeks when compared to 6 months in the WC.
However, in the reciprocal age comparisons, there was no increased regulation of
ribosomal genes at 1 day or at 6 months when compared to 6 weeks. It was suggested by
Anderson that, although the changes in regulation could not be explained, it is possible that
the WC is attempting to compensate for ribosomal degradation by increasing synthesis by 6
weeks, followed by sharp a decline as the WC ages (63). This seems reasonable, given that
this was the case in this current work and was also reported by Cooke, although future
work will be needed to discern whether the changes in regulation by 6 weeks are due to the
disease progression or other mechanisms that are unrelated to the disease.
Also of interest is that many of the genes that were differentially upregulated at 6
weeks were also involved in both transcription and translation, protein folding and
transport. EIF3H was also upregulated exclusively at 6 weeks. While the exact role of
EIF3H was not determined it is involved in translation of proteins following transcription
(82). It also seems reasonable to suggest that the increased regulation at 6 weeks may be
due at least in part to some of the increased synthesis of extracellular materials that occur
during early progression of atherosclerosis. For example, DDX5 was also upregulated
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exclusively at this age. It is an RNA helicase that is implicated in a number of cellular
processes involved in altering the RNA secondary structure such as translation initiation,
nuclear, and mitochondrial splicing, as well as ribosome and spliceosome assembly (82).
DDX5 is known to encode a dead box protein, which is an RNA-dependent ATPase, and a
proliferation-associated nuclear antigen, that is specifically known to react with the simian
virus 40tumor antigen, and may also be involved in pre-mRNA splicing (82).
Inhibitor p27 Kipl (CDKN1B) is a positive regulator of cellular and developmental
processes that impact cell cycle progression (82). It is involved in Gl-arrest and is a potent
inhibitor of cyclin-E and cyclin-A CDK2 complexes. It is also a positive regulator of
cyclin-D-dependant kinases such as CDK4 that is regulated by phosphorylation and
degradation events (82). According to Lauter et al., CDKN1B is a dependant kinase
inhibitor which serves to repress the function of cyclin-dependent kinases, necessary for
cellular progression through Gl to S-phase of the cell cycle (89). CDKN1B expression
has been shown to be decreased in various tumor types including colon cancer (89) and
may explain the decreased regulation by 6 months.
Molatore et al., also reported that CDKN1B acts as a tumor suppressor to regulate
the suppression of Gl to S-phase by regulating the activity of cyclin E and cyclin A CDK2
(90). In addition to its negative role in cell cycle progression, it is involved in cell
migration, neuronal differentiation and apoptosis (90). A study by Nowel et al., found that
CDKN1B was downregulated while p52 was upregulated in early stage fallopian tube
carcinoma (FTC) when compared to normal fallopian tube tissues (91).
Immunohistochemistry results revealed that the decreased protein expression of
CDKN1B in FTCs continued as the cancer progressed (91). In addition, when SMCs are
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bound to fibronectins and proteoglycans in atherosclerotic plaques, CDK2 inhibitors such
as P27Kipl are downregulated to promote SMC proliferation (34). Based on these studies,
there may actually be a relationship between the decreased regulation of CDKN1B by 6
months of age in the WC, the progression of atherosclerosis, and the mechanisms involved
in tumor progression although future work will be needed to fully discern this.
Poly (ADP-ribose) polymerase or PARP14 was also exclusively upregulated at 6
weeks of age. PARP14 is known to enhance STAT6-dependent transcription factor, while
STAT6 acts in response to cytokine and growth factor activity (82). PARP14 responds
immediately to DNA damage following posttranslational modification of histones and
other nuclear proteins in order to collectively contribute to the survival of injured
proliferating cells (82). Research by Agarwal et al., demonstrated the enzymatic DNA
repair activity of PARP14 in male germ cells, during spermatogenesis (92). There,
increased levels of PARP14 were present in mature spermatozoa, in response to strand
breaks in DNA as a result of oxidative stress, chromatin remodeling and cell death (92).
This response of PARP14 to DNA damage was associated particularly with inflammatory
cytokines, and with oxidative stress that was connected with protein modification due to
biological or chemical stressors (92). During atherosclerosis, cytokine production is
dramatically increased. Cells such as T-cells, macrophages, endothelial cells, and SMCs in
particular, produce such cytokines as platelet derived growth factor, macrophage inhibitory
factor (MIF+), interferon gamma (IFNy) and monocyte chemoattractant protein (MCP-1)
(34). It is therefore possible that, the increase in PARP14 by 6 weeks of age, may be in
response to an increase in cytokine production known to occur during atherosclerosis.
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Ring finger protein (RNF11) contains a RJNG-H2 finger motif and a PY motif,
which is known to be important for protein-protein interactions (82). RNF11 has been
shown to be induced by mutant rearranged transformation (RET) proteins, also known as
multiple endocrine neoplasia (MEN2A/MEN2B). The germline mutations in the RET gene
are known to be responsible for the development of multiple endocrine neoplasias (82).
Immunohistochemical analysis of RNF11 protein revealed that RNF11 was markedly
overexpressed in breast cancer, and to a lesser extent in pancreatic and prostate cancers
(93). It is believed that RNF11 may function as an adaptor molecule for the recruitment of
specific substrates to E3 ligase complexes for ubiquitination and subsequent degradation by
26S-proteosome (93). Li et al., concluded that RNF11 is likely involved in multiple cancer
related cellular processes such as gene transcription, protein ubiquitination and
ubiquitination associated events related to receptor endocytosis and protein sorting (93).
Gelsolin (GSN) is a calcium-regulated, actin-modulating protein that binds to the
plus (or barbed) ends of actin monomers or filaments, preventing monomer exchange (endblocking or capping). It can promote the assembly of monomers into filaments as well as
sever filaments already formed (82). Nishio et al., found that gelsolin has multiple
regulatory activities, including cytoskeletal remodeling and ion channel regulation (94).
They also found that GSN mRNA levels are elevated while plasma concentration levels of
GSN are decreased in patients with ischemic heart disease and in animal models of heart
failure. As a result, they suggested that GSN plays a key role in cardiac remodeling (94).
Work conducted by Li et al., suggests a link between GSN and induction of apoptosis
following MI (95). They detected enhanced expression of gelsolin in human heart failure,
and in dilated and ischemic cardiomyopathy (95). Li et al., also found that cells with
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gelsolin are likely to produce more actin-barbed ends and actin monomers, which bind to
deoxyribonuclease (DNase I), a key enzyme responsible for DNA degradation following
the stimulus generated by MI, which tries to attenuate enhanced activation of promoting
cell death by apoptosis (95). Following microarray gene expression analysis of 22,283
human genes, it was found that GSN was markedly increased in human heart failure of
both dilated and ischemic cardiomyopathy phenotypes (95). Immunoblotting revealed that
GSN protein was also increased following MI in mouse models (95). In mice, COL1 Al
and COL3A1 were also higher in GSN +/+ hearts than GSN-/- hearts which is believed to
be pro-apoptotic(95). This relationship was not the case however, for Gelsolin at 6 weeks
in that COL1 Al and COL3A1 were down by this age in the WC, possibly suggesting loss
of regulation of apoptosis. Also, GSN, which is a substrate of caspase-3, -7+ -9 is
frequently downregulated in human cancers, that are able to escape apoptosis (95).
Caspase-3 is considered a key mediator of apoptosis in mammalian cells (96). In cells that
were exposed to Fas receptor, there was an increased presence of GSN cleaved fragments
through caspase-3 which then led to apoptosis of the cells (96).
Chaperonin containing TCP1, subunit 8 (CCT8) according to MetaCore is a
cytosolic chaperone protein that assists in protein folding upon ATP hydrolysis (82). Invitro it was shown to be involved in the folding of tubulin and actin, which interestingly
ACTB was also upregulated at this age (82). The presence of CCT8 at 6weeks of age may
actually be in response to the increased regulation of the many non-redundant genes that
were presented in Table 9 of the results. CCT8 may also be associated with the folding of
Vimentin (VIM), which was also exclusively upregulated at this age. According to
MetaCore, VIM, like actins and microtubules, are class III intermediate cytoskeletal
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filaments, which are all associated with one another in various capacities (82) [Appendices
B and L]. VIM is found primarily in mesenchymal cells, displaying tissue specific patterns
of expression associated with cell integrity (97). Unlike actins and microtubules however,
VIM provides resiliency to cells during times of mechanical stress. (97).
In a study by Goldman et al, Vim-free cells were shown to be more fragile, pointing
to the structural role that VIM plays (97). It appears that VIM in an attempt to deal with
stress inducing alterations associated with disease progression, is attempting to offset the
morphological alterations that are observed in the cytoskeleton (98). As noted in the
literature, these changes are thought to be in response to the shift in SMCs to the synthetic
state, which is also known to increase the proliferative index of ECM, further
compromising the integrity of atherosclerotic tissue (34). These changes were followed by
increases in Chondroitin 6-sulfate and Chondroitin 4-sulfate, both glycosaminoglycans
(GAG) that remain elevated at 6months. This is believed to precede and be at least
partially responsible for the uptake of lipid in the cells, and further progression of
atherosclerosis (16, 34). Each of these findings are believed to facilitate lipid accumulation
and hypoxic stress, both contributors to the disease progression (16, 57). Given all that is
in transition during this stage, it seems reasonable to suggest that the increased regulation
observed by all these genes at 6 weeks, occurs in response, at least in part to some of the
regulatory changes and stressors placed on aortic tissues during early progression.
Tropomyosin (TPM1) was also exclusively upregulated at 6weeks. It functions in
both muscle and non-muscle cells and is a member of the tropomyosin family of highly
conserved actin binding proteins(82) [Appendices B and C]. TPM, which is regulated by
caldesmon binds to and stabilizes cytoskeletal actin filaments during SMC contraction (82).
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Rong reported a decrease in both TPMl as well as ACTA following cholesterol loading in
SMCs, which he reported to be the result of a shift from the healthy contractile state to the
synthetic state (39). It is well established that ACTA levels as well as other SMC
differentiation markers, decrease in-vivo in response to atherosclerosis and or vascular
injury (36, 99). Work conducted by Kashiqada et al., reported that a shift from
differentiated SMCs, to dedifferentiated SMCs led to the phenotypic modulation of TPMl
causing it to shift from a SMC type to a fibroblastic type 1 and 2 (100).
A shift in regulation between ACTA and ACTB was observed at 6weeks in this
current research. Here ACTA was up at lday and again by 6months, while ACTB was not
upregulated until 6weeks and remained up at 6months. Interestingly, Anderson found an
inverse relationship between ACTA and ACTB (63). The results from her work suggest
that higher levels of ACTA represent normal contractility, while increased regulation of
ACTB represents a loss of contractility in the SMC (63). She proposed that decreased
ACTA and TPMl, in parallel with increased ACTB, signal a loss of muscle contraction
(63).
It is possible that the upregulation of TPMl at 6weeks in the current results had not
yet caught up with the changes in regulation between ACTA and ACTB. The increased
regulation that was observed by TPMl exclusively at 6weeks may actually reflect a
compensatory mechanism of the WC, to at least initially maintain some sort of regulation
during the transition from the contractile state to the synthetic state (100).
Spermidine/spermine Nl-acetyltransferase (SAT1) was also upregulated
exclusively at 6weeks and is a member of the family of sulfate/anion transporters.
According to MetaCore, SAT1 functions as a sodium-dependent amino acid transporter,
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which participates in many reactions such as the uptake of nutrients, detoxification, energy
production, and neurotransmitter cycling (82) [Appendices M and N]. In multiple studies,
SATl was upregulated during times of stress. Babbar reported that, increases in the
cytokine, tumor necrosis factor alpha (TNFalpha), resulted in increases in SATl which
encodes a rate-limiting polyamine catabolic enzyme, reducing intracellular polyamine
contents in lung cancer cells (101). SATl has also been associated with decreased cell
growth and apoptosis (101). A study by Wang et al showed that, over expression of SATl
resulted in rounding up and loss of cell anchoring, along with alterations in the morphology
of actin-containing filopodia (102). In another study SAT2, not SATl, was shown to have
a high affinity for I-proline transport in vascular SMCs while SATl was found exclusively
in brain cells (103). These findings conflict with Babbar's work, as well as the results of
this current research, and Anderson's work, which all found that SATl was upregulated in
the WC when compared to the SR. Perhaps the increased cytokine production in response
to disease progression of atherosclerosis, as reported by Doran, may explain the increased
regulation of SATl at 6 weeks.
While it is interesting that many of the genes that were upregulated at 1 day and at 6
weeks were associated with transcription, translation and changes in cell integrity, a
number of the genes were also associated with decreased immune function, increases in
cytokine production, inflamation, and progression of some tumor lines and cancers. It is
also interesting that 6 of the genes that were differentially upregulated in the WC, were
reportedly expressed in multiple tumor lines and cancers. While it is not known at this
point, whether this is due to the large amount of work that has been conducted on tumors
and cancers, this pattern does seem to raise interest in Benditt's monoclonal theory of
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atherogenesis (104). It is also possible that the increased regulation at 6 weeks was an
early compensatory mechanism to control some of the negative downstream affects
following initiation and even early progression, especially those in response to stress and
cytokine production. It is also important to note that 6 of the 15 genes that were
upregulated exclusively in the WC and analyzed here, were also upregulated in the WC
when compared to the SR in Anderson's unpublished in-vivo work. Those genes include
CCT8, VIM, TPM1, RPL3, RPS28, and SAT1, which are presented in Appendix A.
Future work will be needed to fully understand the mechanisms, in which these genes are
involved.
At 6 months of age, genes that were differentially upregulated exclusively include
ENOl and ACSLl. The first gene, ENOl is a multifunctional enzyme that participates in
the later steps of glycolysis to convert 2-phosphoglycerate to phosphorenolpyruvate (82)
[Appendices E, F and J]. It is also known to participate in many additional metabolic
functions such as the regulation of growth, response to hypoxic conditions, and
immunoglobulin production (82). Unpublished in-vitro SMC work conducted previously
in this lab revealed that ENOl was differentially upregulated (30:0) in the WC when
compared to the SR (63) [Appendix Q]. Additional in-vivo work revealed however, that
ENOl was not differentially upregulated at 6months when compared to the SR [Appendix
T]. This appeared to confound ENOl as a major gene of interest in the progression of
atherosclerosis, although it is quite possible that this type of regulation of ENOl in-vitro
indicates that ENOl is acting at the level of the SMC. Since this was in-vitro, it may also
indicate that the increased regulation of ENOl occurs much later than 6months of age.
Research shows that SMCs have been shown to be the first cells present in locations
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destined to develop atherosclerotic plaques (34, 39, 105), and that intrinsic properties of
SMCs are intimately implicated with the regulation of the disease (49). Since ENOl was
also associated with hypoxic stress according to MetaCore, and given that one of the
characteristics of atherosclerosis is that of hypoxic stress, coupled with the role of SMCs,
ENOl appears to remain a primary gene of interest involved in atherosclerotic progression.
In regards to energy production, Hajjar et al showed that the WC totally lacked ATP
regulation of NADH transhydrogenation by 6weeks of age, and by 6months had lower P/O
ratios as compared to the SR, suggesting uncoupled respiratory-chain phosphorylation (17),
which may in part explain the increased regulation of ENOl. While examining the
differences in energy production between both breeds, Zemplenyi revealed there were
differences in the amount of arterial enzymes that were produced between WC and SR
pigeons at 5-8 weeks of age. His findings demonstrated that there was in fact a clear shift
in the WC from oxidative phosphorylation to glycolysis at the level of the arterial wall
(106). Zemplenyi suggested that this hypoxic shift predisposed the WC to atherosclerosis.
He also found that lipoamide dehydrogenase, a component of the pyruvate dehydrogenase
complex was significantly lower in the WC when compared to the SR (106). The
decreased amount of lipoamide dehydrogenase in the presence of acetyl CoA slowed down
the conversion of pyruvate to oxaloacetate markedly slowing down the ICrebs cycle. There
was also an increase in the amount of phosphofructose kinase, which is the rate-limiting
step of glycolysis in the WC at this age. This effect was however believed to be a
secondary effect resulting from the decreased rate of the Krebs cycle (106).
Work conducted by Santerre found that respiratory control ratios in the WC were
high at lday, dropping to low levels by 3-6 months unlike the SR, where respiratory ratios
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increase as the SR grows and develops (80). Zemplenyi also found that tissue hypoxia not
only forces glycolysis to become the primary energy pathway but it also contributes to the
accumulation of lipids and the synthesis of arterial connective tissue apparatus (106).
Hajjar et al showed that tissue hypoxia occurs later, following a rise in GAGs (64). By 1224 weeks, they were able to demonstrate that the 0 2 tension in the medial layer of WC was
lower than that in the SR and in younger WC pigeons (64). By 6 months, increases in
chondroitin 6-sulfate and other GAGs were present which have been correlated with lipid
accumulation (16).
As stated previously, acyl-CoA synthetase long-chain family member 1 (ACSL1)
was also differentially upregulated exclusively by 6months. ACSLls are membrane bound
long chain synthetases that trap fatty acids on the cytosolic side following passive diffusion
across the plasma membrane (107) [Appendices G and I]. This timing of the increased
regulation of ACSL1, according to MetaCore, occurs in response to an increase in the
synthesis of lipids, and appears to correlate well with the build up of lipids observed by
Zemplenyi, and the rise in GAGs reported by Hajjar et al. Increases in ACSL1 are also
known to occur in response to beta-oxidation of fatty acids, which must first be converted
to fatty acyl-CoA in the cytosol using ACSL1 [Appendix H]. These are then transported
into the mitochondria assisted by the carnitine shuttle to then undergo beta-oxidation to
their two carbon units. Un-published in-vitro work in this lab revealed that ACSL1 was
also differentially upregulated when compared to the SR, which correlates well with the
energy changes that occur as a result of the disease progression. This loss of regulation in
energy metabolism represents a shift from oxidative phosphorylation to glycolysis as the
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dominant energy pathway by 6 months in the WC, and that it may actually be at the level of
the SMC.

Limitations
While the RDA method is quite effective at presenting only genes that are
differentially expressed between two similar populations, limitations do exist within the
context of this project. Given the narrow selection process of analyzing only genes
differentially upregulated exclusively at 1 day, a number of potential genes of interest were
excluded, reducing the chances of finding a gene responsible for initiation.
Such a small amount of starting material that was used from the original pool of
cDNA at the onset of RDA, may also have limited the selection process of potential genes
throughout, especially since only lng was used during the third rounds of SH. While the
goal of the RDA method was to remove genes common between both populations, it was
observed following Rounds 3, that electrophoresis gels revealed some of the bands were
less defined than in the previous round. As a result, questions were raised whether actual
quality difference products were removed, therefore reducing potential genes of interest at
all of the ages. The small amount of cDNA that was used originally could further reduce
the chances of finding a gene of interest. The other point to keep in mind is that, the
amount of total RNA that was collected prior to RDA represents only a snapshot in time.
Despite these limitations, the level of sensitivity of the RDA method is impressive in that it
can select for genes differentially upregulated, of low copy number and then amplify them,
without prior knowledge of their sequence, and with a low number of false positives (72).
In addition, of the 286 quality sequences that were unidentified, 68% were
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upregulated at 1 day alone [Appendices O and P]. This fact alone makes it likely that the
gene(s) associated with initiation remain unknown. Given the RDA method, the
parameters of selection, and the large number of unidentified genes that remain, it is quite
probable that additional gene(s) of interest associated with initiation and progression
remain elusive.
Future work that encompasses a wider scope of analysis, and includes more
complex and detailed investigation of additional candidate genes may be helpful in
identifying genes responsible for atherosclerosis. Additional research is also needed to
identify the 196 unidentified quality ESTs that were upregulated at 1 day. It is also quite
possible that the gene (s) of interest lie in this group of ESTs. Given all these limitations,
and in light of the technology that is currently available, the RDA method is still the best
method we have at this point in time.
When considering the genes that were not placed in either initiation or progression,
new research demonstrates that genes share dual roles. It is also possible that the two
processes of initiation and progression, may not be distinct from one another (or at least for
some of the genes) as reported by Herndon et al. Some of the genes that were differentially
upregulated at 1 day, and again at 6 months may actually share this duality. For example,
genes that were differentially upregulated at 1 day may reflect initiation, yet when they
were differentially upregulated at 6 months, they may in fact reflect normal development,
or progression of the disease. According to Seroude, changes in gene regulation are
associated with the rate of physiological aging as opposed to chronological aging (108).
Interestingly, aging is associated with the same highly dynamic regulatory changes
observed during development, and these same regulatory changes that occur during aging,
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also occur in response to stress (108). In fact, both the up and downregulation of genes
whose expression changed during aging, also changed when exposed to oxidative stress
(109). All told, it is the combination of genes and their regulation that impacts the
downstream effects (108). In light of this and the current findings, future work will be
required to sort through all the genes that were differentially upregulated at more than one
age.
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CONCLUSIONS

A number of candidate genes were differentially upregulated at 1 day. More
importantly seven genes were differentially upregulated exclusively at 1 day, therefore
placing them as potentially being involved in initiation of atherosclerosis in the WC pigeon
under the conditions evaluated in the hypothesis. However, given the tight parameters of
this hypothesis, while SEC61G, FKBP9 and DCN were correlated with atherosclerosis they
could not be definitively assigned a significant role in initiation.
At 6 weeks and at 6 months, seventeen candidate genes were differentially
upregulated exclusively, and were analyzed for their role with progression of
atherosclerosis. The genes included RPL3, RPL4, RPL5, RPS6, RPS28, EIF3H, DDX5,
CDKN1B, PARP14, RNF11, GSN, CCT8, VIM, TPM1, SAT1, ENOl, and ACSL1. The
events associated with these genes include increases in ribosomal biogenesis in response to
increased protein synthesis, transcription, translation, splicing associated with transcription
and translation, regulation of cell cycle progression, immune and inflammatory functions,
stress associated with protein translation and modification. Several genes were also
involved in ubiquitination and degradation, cytoskeletal remodeling and apoptosis,
increases in chaperonin protein involved in the folding of newly translated proteins,
decreases in cellular integrity, changes in muscle contraction, and increases in a transporter
gene that was also upregulated in response to cellular stress, and increased regulation of
cell cycle.
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Finally, changes in energy metabolism were apparent by 6 months of age reflecting
a shift from oxidative phosphorylation to glycolysis in the WC pigeon, as well as increases
in lipid synthesis and degradation. These findings concur with previous studies which
strongly suggest that this energy shift is a major event in the development of
atherosclerosis in the WC pigeon.
Future work will be necessary to fully analyze the functional role for each of the
major candidate genes associated with initiation and progression of atherosclerosis, as well
as for the many additional genes of interest that were not analyzed based on the current
hypothesis. Also, many more unidentified quality transcripts were differentially
upregulated at 1 day than at any other age according to the e- value criteria of acceptance.
It will therefore be essential to identify and further annotate the quality sequences that were
retained so that they can then be analyzed for their potential role in initiation of
atherosclerosis.
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APPENDIX A: GENE FUNCTION ACCORDING TO METACORE
Table 1: Genes Upregulated or Downregulated Exclusively in WC and in WC When
Compared to SR

Genes Upregulated or Downregulated exclusively in the WC in this Current Body of Work and in Anderson's Work
Function According to MetaCore
Ortholoq
Age
Gene Name
Function(s)
Uprequlated
The L3 protein is a member of the larges 60S subunit of cytoplasmic ribosomes
responsible for catalyzinq protein synthesis.
6weeks
RPL3
Ribosomal Protein L3
The S28 is a component of the small 40S subunit of cytoplasmic ribosomes
responsible for catalyzinq protein synthesis.
6weeks
RPS28
Ribosomal Protein S28
Assists in the folding of proteins upon ATP hydrolysis. Known to play a role, invitro, in thefoldinq of actin and tubulin
6weeks
CCT8
Chaperonin Cbntaininq TCP1, subunit 8
Are class II intermediate filaments found in various non-epithelial cells,
especially mesenchymal cells. Along w/ actins and tubulins, it represents a
6weeks
third class of well characterized cytoskeletal elements
VIM
Vimentin
Binds to actin filaments in both muscle and non-muslce cells. Plays a role, in
association with the troponin complex. In the calcium dependent regulation of
vertebrate striated muscle contraction. In SMC contraction is regulated by
interaction with caldesmon. In non-muscle cells is implicated in stabilizing
cytoskeleton actin filaments.
6weeks
TPM1
Tropomyosin, Alpha
Is a member of a family of slfate/anion transporter genes. Functions as a
sodium-dependent amino acid transporter. Plays an essential role in the
uptake of nutrients, production of energy, chemical metabolism, detoxification,
6weeks
Spermadine/Spermine N1-Acetyltransferase variant 1-like and neurotrnsmitter cycling.
SAT1

6months

EN01

6months
ACSL1
Downrequlated

Enolase, Alpha

Multifunctional enzyme, that in addtion to its role in glycolysis, participates in
regulation of growth, hypoxic conditions, and immunity. Has the ability to serve
as a receptor and activator of plasminogen on the cell surfaces of such celltypes as leukocytes and neurons. Stimulates immunoglobulin production.

Acvl CoA Synthetase Long Chain Family Member 1

Is an isozyme of the long-chain fatty-acid-coenzyme A ligase family. Converts
free long-chain fatty acids into fatty acyl-CoA esters, and thereby plays a key
role-in lipid biosynthesis and fatty acid deqredation.

6months

EIF1

Eukaryotic Translation Initiation Factor 1

6months

RPS3A

Ribosomal Protein S3A

Is necessary for scanning and is involved in initiation site selection. Promotes
the assembly of 48S ribosomal complexes at the authentic initiation codon of a
conventional capped mRNA
The S3A protein is a member of the small 40S subunit located in the cytoplasm
responsible for protein synthesis
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APPENDIX B: METABOLIC PATHWAY - VIM & TPMl
Figure B.l: C-1 (lday-red versus 6weeks-blue)
VIM & TPMl Upregulated at 6weeks
Development-Regulation of Epithelial-to-Mesenchymal Transition (EMT)
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APPENDIX C: METABOLIC PATHWAY - TPMl
Figure C.2: C-1 (lday-red versus 6weeks-blue)
TPMl upregulated at 6weeks
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APPENDIX D: METABOLIC PATHWAY - RPL3 & RPS28
Figure D.3: C-1: (lday-red versus 6weeks-blue)
RPL3 & RPS28 Upregulated at 6weeks
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APPENDIX E: METABOLIC PATHWAY - ENOl
Figure E.4: C-2: (1 day-red versus 6months-blue)
ENOl Upregulated at 6months
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APPENDIX F: METABOLIC PATHWAY - ENOl
Figure F.5: C-2: (1 day-red versus 6months-blue)
ENOl Upregulated at 6months
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APPENDIX G: METABOLIC PATHWAY - ACSLl
Figure G.6: C-2: (lday-red versus 6months-blue)
ACSLl Upregulated at 6months
Glucose Metabolism
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APPENDIX H: METABOLIC PATHWAY - ACSLl
Figure H.7: C-2: (lday-red versus 6months-blue)
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APPENDIX I: METABOLIC PATHWAY - ACSLl
Figure 1.8: C-2: (lday-red versus 6months-blue)
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Regulation of Lipid Metabolism
rj»»e»f£*<w-»-»»"
#*H M

-«>tpi(Jma«bol«iN»ta.PPW!!,RXR*«IV0f»

ACSfX 1 "

1 iTTSil

SattrrafioTatty
acid biosynthesis

^ ^

FADS

#

AG

j£g£

FaMtofSpl CnA

PalmEtid

#

ac£T
p

ACSLS

iTft

©

ACSU

FADff
1 14 19TT

C8I S3 octadeca
6 9 dienwl CoA
182n-9

1 14 191 Q t e o , n & H 8 1 n S

PalmiEyl CoA
1«B

#v

#

#
#

ELOVi

#

ial

2%.!

&

#

,K

#
ELOVLS

#
3 oto Eicosatioyl
Cos,

3 0X0 Cciadwsancvi CoA,

<»

3 a>ts DocssaWil"

enoy! C o ^

® ^^^
3 hysfrtWf WcosanoylCcA

3 hydroxy
©Srtadssanoyt-CoA

3 hiMJmxy(8Z.11Z) istosa
811 dwisyl-CoA

iff

4TI

41

(Ei rclab»c 2*
enoyl-CcA

TER

#

#

#

(E) Doi»sa-2

(2E4Z11Z) eicoss
1811 tragwrt-CoM*

(E Elfosa 2 enoyl-CoA

1 31 CoA 18 0

129

eicosanG^I

'31

Docasonoyl
SOS, 22 0

1 d1

(8Z11ZJ-BEOSa 811 1
lenoyl- GoA 20 2 n-9

APPENDIX J: METABOLIC PATHWAY - ENOl
Figure J.9: C-3 (6weeks-red versus 6months-blue)
ENOl Upregulated at 6months
Transcription Role of Akt in Hypoxia Induced HIFl Activation
no«ia-d?pend*nt HIFl destruction *'3"T "
-:-

.

" " ^ " % . ', Prolonged hypoxia results ' ;i*w% HIF actuation in prolonqed hypoxia l.«'?-;#- i . :-"• -.'
iJP'mJintheinactivationofA.kt
-, ">*•>••• ..„„„„,„*'",„»,!•*''•*•;••"•••
• •

P«lrwp5,5)PS; and actuation of GSK3

f '

,,.*^„_: 5 « • * *

VS&F-ft
ia»j<4

\
3 T ! ?

w

#

#

',

J j

HSF70

*' #
m «

TCT1

NCOA^RCI)'
PDKiPDPKI}

AkTjPKBJ

Epo

*<»J»
' VHL

#'

AF»ff \

#

#

•

#

^

©

* .« .

#

©
APEX*

Cul2IRte1-E3
lijase
\

•>•

fArOWBS

GSK3beta

-J

-^GSK3bata

HIF1A

HtF-1

#

#

m

#

" Gfufl

' #

\j #

ALD0

(353

| Protein degradation J { \
in protsasome ; f :
ARD1

Heme oxygenase

NIP3

jrHIFfA"

I

n i ^ j?

p§3-depertdert apopfesis

/
HIF-prol/l hydroxylase

130

APPENDIX K: METABOLIC PATHWAY - RPL3, RPS28,
Figure K.10: C-3 (6weeks-red versus 6months-blue)
RPL3, RPS28, Upregulated at 6weeks
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APPENDIX L: METABOLIC PATHWAY - VIM
Figure L . l l : C-3 (6weeks-red versus 6months-blue)
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APPENDIX M: METABOLIC PATHWAY - SATl
Figure M. 12: C-3: (6weeks-red versus 6months-blue)
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APPENDIX N: METABOLIC PATHWAY - SATl
Figure N.13: C-3: (6weeks-red versus 6months-blue)
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APPENDIX O: Table 2: C-l Unidentified Transcripts lday versus 6weeks
Comparison

jjiffi

Age

Size (#bp)

C 1 1 Day A

A01

323

C 1 1 Day A

A06a

355

C 1 1 Day A

A06b

195

C 1 1 Day A

A07

323

C 1 1DayA

A08

322

C 1 1DayA

B01b

247

C 1 1 Day A

B02

183

C 1 1DayA

B03

430

C 1 1DayA

B05

307

C 1 1DayA

B07

323

C 1 "IDayA

B10

259

C 1 IDayA

B11

323

C 1 IDayA

C04b

243

C 1 IDayA

C05

147

Sequences
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGGAAGTTGGACGCTATGA
GAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAGCACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCAAATGTG
TTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATTGGTAGATATATCAGTTTATA
TATGACCTCCGAGGATC
GATCAACCAAAGCCTTAAGGAGAACATAGGGAACGAAAATATGAATTATACTGCATCACTTGTAATTCAACCAAATACGTGGGAAATTCAGTTGGCAAGGAA
AGGGAGTAGAATAATGTGTGAAATGTTCGACTACGTATCCCCTTTCCAACCATTAAAGCTAATGTCAGTAAATTTTGGTCAACCCAAGAAGAATATTCATTCA
TCCAGCCTGATGATGGCTTCTTTTAGGCTGCTTTAAATTTTTGTTTTCAACAGACGTCTAATTTGCTGTGTGCCAAGTCACATCTTCCAGACTGTGTGCTGC
ATGTACGTGCACAATGGAGGCTGGAAGATGAAAGGAAGGCACAGGATC
GATCAAGTGCTTATATTGGAAACATAAATCTACTTCCAGTCCTGTTCCTAATATATTTGTGTAAATGAAGAATGCTGCATTTCAGTCTCTTGTGGCCATATTTT
TGGTGGTGGCCTGAAAGGCTCCACTAAAGGAGACATCAGCAGTGAATGTCAGAGCATCAGAGAGTGAAATATCCCTGGAATGTGAAGTGCC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGCGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCGAATGTGT
TCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATG
TATGACCTCCAAAGATC
J
GATCCCTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATACTTCTTTCCATTAGGT
CCCAGCTGTGGTATAGAACACATTGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTGGGTGGGGGATGGCATATGAAGTCTAATTT
TGCCGTCCATGAGGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCTACTCATCTCGAATTCAGAA
GCAAACAAACTGATC
GAGGTGAACCCACTGATTCCGTATTCAAATCACCCTATCGCTACCGGGGACATTAAGGGGGGGCCCGAACCAATTCGCCCCTAGAGATCGCAATACTCAC
GCTCACTTGGCTCGTTTTCAAGGCCGGTTGGGAAACCCGGCGTGCCCACTAACCCCCCCCGCCATCCCCTTTCCCAGCGGGCGTAAATTCAATTTGCCCC
ATCCCATCCCTCCCCAAAGCGGCTCACCCTAAAAGCAAAGGGCACGG
GATCCTCTATGTTTCGTTTTGGCACACACTTGTTGAGAGTGGAAAGGTGGAGTGAGGCCACTGTTACATTAGACAAGTGAAAAGTAAGAAGAGGATAATAC
TTAGGTTCGCACTTTAATCTCAGAATTAAACCAAACCTTGCATTCAAAGTAGATTTTTCTTTTTAAGTGGTGGTAGTTGATC
ATTCAAAGGGCGAATTAACCCTCACTAAAAGGGACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAAAAAGTGGAGCAATGTTACTCGCAGCC
CTACCTCTTAAGCTAGGCGGCTATGGCATCATGCGAGTTACCCTCCTAATAAACCCCACCGCCAACCACCTATACTACCCATTCATTACCTTAGCCCTATGG
GGCGCCCTAATAACTAGCTCAATCTGCTTGCGCCAAACGGACCTAAAGTCCCTCATTGCCTACTCTTCCGTTAGCCATATAGGCCTAGTCATCGCTGCAAG
CATAATTCAAACCCACTGAGCATTCTCAGGCGCAATACTCCTTATAATCTCACACGGACTAACCTCTTCCATACTATTCTGCCTGGCTAACACAAACTACGAA
CGAACACATAGCCGAATCTTGATC
GATCAAGTGCTTATATTGGAAACATAATCTACTTCCAGTCCTGTTCCTAATATATTTGTGTAAATGAAGAATGCTGCATCTCAGTCTCTTGTGGCCGTATTTT
TGGTGGTGGCCTGAAAGGCTCCTCTAAAGGAGACATCAGCAGTGAATGTCAGAGCATCAGAGAGTGAAATATCCCTGGAATGAGAAGTGCCAAGGGGTTT
TAACTTCCCCAGATTTCTCTGCATGTGCCATGATGCATGGGAGATGTCAGGTTACCCTTTGTTCCAAACTTATCTTCTCAGATGATAAACTTTTCTGTCTGAT
C
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATTATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGTCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCGAATGTGT
TCTATACCACAGCCGGGACCTAATGGAAAGAAATATATCCGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATA
TATGACCTCCAAGGATC
GATCAGACTAACTCCCCAACACAGTTCAGTCTTTTTTTCTTCTCTTTCTCTGCTAGCTATAAGTAAGTGCTGAGTATAGGCCTACCCATCCAGATTTCTGATA
GTTAAAATGAAAGAAACTGAATGCCACCCTCATTGACTAGCCTCAGAAATTTGTTTTCAACTTTTCACTGCCTTCCTTGGATGCACAGAGGAATTTAGAAGC
CCAGACTCTAAGATAAAGAAAAATCACTTTGAAATGGGACACAAGCTGTGGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGTGGTTTAACATAACTTTTGCAGGAGTGAGAAAGCTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCCACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCGAATGTGT
TCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCCCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATA
TATGACCTCCAAGGATC
GATCAGTTTGGTTTGCTTCTGATTCGAGATGAGTGGATTAGTGAAAATCATGGGGAGGTTAACATACTTTTGCAGGAGTGAGAAAGTTGGACCTATGAGAG
CTTCATGACAGCAAATTAGACTTCTATGCCATCCCCTACCACCACTGCGAATTCCATGGACTCTTAAGAGGAGCTCTCAGAGCGATGTGTTTCTTACCCAGC
TGGACCTAAGGAAAAAAAAACGTATCTCAAATTTCTATTT
GATCCTCCAGAAGAAAGATTGGAGACGCCCAGGGTCACTATGGCGGCAGAGGAACCTGGGTGTGCCGGCTCTGTTGTCTTTCATCGCAAACTTAAGGCCA
TAGTCCGATGCACACTTCTGGGGGCAGTTCCCAGCCCTTTGCTGATC

APPENDIX O: C-l Unidentified Transcripts lday versus 6weeks (continued)
Comparison
Ass®

'ZW'.'

C 1 1DayA

C09

323

C 1 IDavA

C11

555

C 1 1Day A

D01

323

C 1 1Day A

D04

323

C

1 1 Day A

D10b

323

C

1 1DayA

E01b

243

C 1 IDavA

E03

323

C 1 1 Day A

E07a

227

C 1 1 Day A

E07b

147

C 1 1 Day A

E08

327

C

1 1 Day A

E10

323

C

1 1 Day A

F03

323

C 1 1 Day A

F06

433

C 1 1 Day A

FIO

23

C 1 1DayA

G07

323

C 1 1 Day A

G08

237

®iK® <#&|3)

Sequences
GATCCTTGGAGGTCATATATAAACAGGTATATCT-ACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGGTATATTTCTTTCCATTAGGT
CCCAGCTGTGGTATAGAACACATTCGCTCTGAGAGGTTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAGTCTAATT
TTGCTGTCCACGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCTCGAATTTAGA
AGCAAACAAACTGATC
GATCTATTCACCTGCTGTTCTGCTGCTCCACCTGCCCCGTCGCCTCACTACCTGGTCCAGCCGTTCAGCTGGGATGACTCATCTCTGCACGAGTACATTGT
TAAATGATGTATTTTCAGGGGTTTGTTTCTGCAAAAGCAGAAGGAAGGATAAAGACCTTTCCTTAATACCACATCACTTACTTTGTTTGCCTCCCTCCTTTGC
CTTTTTTGAAGCAGAAAAAGCACAGTGGCTGAATCCTTCAGGCTTCTGAATGCCAGGCTAATGTGCAATTCCCCGCTTCGTAATGAAAGGCATCATAAGTCA
AGGGCATCTGCATCATCCTCCCCCAGATAACAGTTTACTGAAGCAGTGAAAGGGAAAGAGCTTTCAAAGTTTGTTGCAAAAATTTCAGATCTTAGCCACTGG
AATACAGGCACAAACTTCCCTTTATGTGTGACCTTGCTGGGTGCCAGCTGGTATACTATCAGATGCTATTTAAAAAAGAAACAAACAAACAAAAACAAAGCC
ATGGCTTTTTTTTCCCACCTGAGACCATTGTCTTTGAAGTTGATC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTAGGTC
CCAGCCGTGGTATAGAACACATCCGCTCTGAGTGGCTTCCTCTTTCAGAGTTCCATGGTAATTCGCAGTGTTGGTAGGGGATGGCATATGAGGTCTAATTT
TGCTGTCCATGAAGCCCTCATAGTGTCCAACTTTCTCACTCCTGCGAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCTCGAATTCAGAA
GCAAACAAACTGATC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCCTTCCATTAGGTC
CCAGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCCCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTACGGGATGGCATATGAAGTCTAATTT
TGCCGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCACCTCGAATTCAGAA
GCAATCAAACTGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGGTGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCGAAAGTGT
TCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATAT
ATGACCTCCAAGGATC
GATCAACAACTAGTTGCTTATCCAGGTTTCAGTCTCCACAGCAGAGTTTTGCTTTCTCCTTTATTTGTGCACTAGAAAGTGAAGTTGTTTTCTTCCCCTGCTT
CCTCCAAGAAGAAGAATGGAAGGCAAATAAATAGTAGAGAATACAGCCATCAAGTTTGAGAGATGACCTTTACACTTCTATGGCATTTGCAACCTACAACCT
TGCCTTCCCCACTTCCACTGGCTACAGCTAACATGATC
GATCAGTTTGTTTGCTTCTGAGTTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGATTTAACATAACTTTTGCAGGAGTGAGAAAATTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCAAATGTGT
TCTGTACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATA
TATGACCTCCAAGGATC
GATCTTCACCATACCTTGATATTTCATTCTTGGGACTAGGCTGATAGATGATTTCAACTGCTCTGACAGGGCCATGCTAGATGTATCTGTGCTCTCTACCTG
AAGCACACACTCGGGGGATGCTTCCAATTTTCTCTGTTTATTGTGGATTTGCAAGGATAAACAAGGACACTGACCGCTTCCCCGGGGGTGCAGGAATCTTT
AAAGCCCTGTAAGAATACCGCAACAACTCAATAGGGGGCCCGGCATCCACCTTGCCCTATGGGGAGTCGTATTACTTGCTGAGTGCGGGCGTCGTTTTGA
GGCCTGCAGAGGGGAAAAAGCCTGGGGCTACCCAAATGGTGGCCCTTTAAGTACACCCCCCATTCACCCAGTGGCTCAATCACGAAGACGGCCTCCTTA
CTCAAACATTTATACAGTTGTGCCACCTGAATGGCCAGTTCCACACTCCCTGAAGGGGCAAGATATCTCATCCCCGGGGTGGGTTACATTCAATATCAACG
CTACGATGCCAGCGCCCTCGAGGGGGGGTCCTGTACCCA
GATCTTCACCATACCTTGATATTTCATTCTTGGGACTAGGCTGATAGATGATTTCAACTGCTCTGACAGGGCCATGCTAGATGTATCTGTGCTCTCTACCTG
AAGCACACACTCGGGGGATGCTTCCAATTTTCTCTGTTTATTGTGGATTTGCAAGGATAAACAAGGACACTGACCGCTTCCCCGGGGGTGCAGGAATCTTT
AAAGCCCTGTAAGAATACCGCAAC
AAGGGAGCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCACTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATT
AGGTCCCAGCTGTGGTATAGAACACATTTGCTCTGAGGGGCTTCCTCTTTCAGAGTCCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAGTCT
AATTTTGCTGTCCATGAAGCTCTCATAGTGTCCAACATTCTCACTCCTGCAAAAGTTGTGTTAAACCTCCCATGATTTTCACTAGTCCAACTCATCTCGAATG
CAGAAGCAAACAAACTGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGAAGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCGTGGAACTCTGAAAGAGGAAGCCTCTCAGAGCGAACGTGT
TCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTGGATATATCTGTTTATA
TATGACCTCCAAGGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGTACTCTGAAAGTGGAAGCCTCTCAGAGCAATTGTGTT
CTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTACCCAAGTCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATAT
ATGACCTCCAAGGATC
GATCAGCAAAGGGCTGGGAACTGCCCCCAGAAGTGTGCACTGGACTATGGCCTTAAGTTCGCGATGGAAGACAACAGAGCCAGCACACCCAGGTTCCTC
TGCCACCATAGTGACCCTGGGCATCTCCAATCTTTCTTCTGGAGAGTCAGGCTGGACAGCAGAGCAATACTGTCCCACCTTACTTCCCACGATTCTTCTGG
ACCTGGCAGCTGTGAAGTGCTCCCATTTTCTGCATTTTACATGCACCCTGTAGACCAAGCAGACTGCAGTCATTGAGGAAATCTATGATAGAAATGGGAAT
GGGACTGCAGGAGGCTTTCAGGTGAATAGTTTCTAACTAGTTGTGAAATTCTTCAGCGGGAAGGGAACGTGCAAGTGCTGCAGAGGCAATATAGCCAGCT
TTACATCATTGCCCAAGCCCATAACCATGATC
GATCCTTGGAGGTCGTATATGAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATGTATTTCTTTCCATTAGGT
CCCAGCTGTGGTATAGAACACATTTGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGMGTCTAATT
TTGCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCTCGAATTCAGA
AGCAAACAAACTGATC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATGGAGATACAGATATATTTCTTTCCATTAGGTC
CCAGCTGTGGTATAGAGCACATTCGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAGTCTAATTT
TGCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACACCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCTCGAATTCAGAA
GCAAACAAACTGATC
GATCCAGAGGAGAGCTCACAAAGAACAGATAATGTTAGATGAGTGTAGATAACAGCCTTCTTTCTTTGACAAAAATACCAGTTTTCATTTTTTAAATGTGCCT
ATG AAGATAAGAAAATGTC C ATTTTGATC

APPENDIX O: C-l Unidentified Transcripts lday versus 6weeks (continued)
Comparison

v

C 1 1 Day A

G11

323

C 1 1 Day A

H02b

320

C 1 1DavA

H07

323

C 1 IDayA

H08

323

C 1 1 Day B

A01

323

C 1 1 Day B

A06b

261

Sequences
GATCCTTGGAGGTCATATATAAACAGATATATCTGCCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTAGGTC
CCAGCTGTGGTATAGAACACATTTGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAGTCTAATTTT
GCTGTCCATGGAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATAATTTTCACTAACCCAACTCATCTCGAATTCAGAAG
CAAACAAACTGATC
GATCCCTAGGGGTTGAGGGTATCCGACATGGGTGACAGAATAGCACTTTTCAAATGAACTAAATATAGGAGAGTTTACTTATTTTACTCTGTTCCTGCTGTC
CCTGGTGTGGACAAAAACGCATGGGCTGAGGGAGGACCGCAAGATCAGAGATCAATGGCAGGTCTCATGAGGAATTGGAAAGGGAATATAAGGTCTGAAT
TTGCTGTTCTTGCTGCTCTCATTTCTCCAAATCATTTCACTCAI I 1 1 CTCGGTATTCAGATGCTCTGTGCTATTGGGTATTGAACACTATGGTCTATACAGAA
GCTACTGCAATAACC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTAGGTC
CCAGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCCTATGAAGTCTAATCT
TGCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCTCTCCTGCAAAAGTTATGTTAGACCTCCCATGATTTTCACTAATCCAACTCATCTCGAATTCAGAA
GCAAACAAACTGATC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCAATCCATTTGTCTATAGACATAGATATGGATAGAGATATAGATACATTTCTTTCCATTAGGTC
CCAGCTGTGGTATAGAACACATTTGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAGTCTAATTTT
GCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCGAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCTCGAATTCAGAAG
CAAACAGGCTGATC
GATCAGTTTGTTTGCTTCTGAACTCGAGATGAGTTGGATTAGAGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGTGAAAGTTGGACACTATGAG
AGCTTCATGGACTGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCAAATGTGTT
CTATACCACAGCTGGGACCTAGAGGAAAGAAATATATCCGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATAT
ATGACCTCCAAGGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCCCAGAGCGAATGTGT
TCAATACCACAGCCGGGACCTAATGGGAAAGAAATATATCTGTATCTCTATCCATATC

C 1 1 Day B

A07

197

GATCCAAATGTGGCTGTAAACTGCGACAGGGTTAGGATGGAGGTACTCAAAAGGAAATGGAGGATGTCTTCACGGTTCCCACCAGACATCTGAATGTATGT
C I A I C I G I C I 1 CA1 C 1 G 1 G(J 1AAAGUGUACG 1 1 GCCGTAAGACATAGCGTGGGGTTGGTGTTGTTTTTATAACTCCACTCAAAGACATTGTTGA 1 C

C 1 1 Day B

A08

302

C 1 1Day B

A11

309

C 1 1Day B

B02

323

C 1 1 Day B

B03

323

C 1 1 Day B

B04

246

C 1 1 Day B

B07b

490

C 1 1 Day B

B10

322

C 1 1 Day B

D03b

590

C 1 1 Day B

D06

237

Age

Stsse <#bp)

GATCAGATTGCAGGAAGGTGACTGCTACTGTGCATTCTTGAACGCAATGGTATGTGATGCCATCTCTGAGCTGTGACAGTTTCTGTTGCCTATGTGTTGAG
TATATGCACCAGCTGCAGCATGGCCTTCCACTGATTGCTCCTCCAGTGAGATGGGAACCCCAGTGGAGATTCCTTACTGTGTTGGCTATGGTTTTTCAGAA
CGCATTATTTTATGTGTGTGTACGTAAAGGAAAATGCAATAGCTATGATAGCACCCTGAGCTGTGTTTTCCTAGTAGCTGTCTCTGTCAGCAATTTGATC
GATCAGACAGAAAAGTTTATCATCTGAGAAGATAAGTTTGGAACGAAGGGTAACCTGACATCTCCCATGCATCATGGCACATGCAGAAGAAATCTGGGGAA
GTTAAAACCCCTTGGCACTTCTCATTCCAGGGATATTTCACTCTCTGATGCTCTGACATTCACTGCTGATGTCTCCTTTAGAGGAGCCTTTCAGGCCACCAC
CAAAAATATGGCCACAAGAGACTGAAATGCAGCATTCTTCATTTACACAAATATATTAGGAACAGGACTGGAAGTAGATTTATGTTTCCAATATAAGCACTTG
ATC
GATCCTTGGAGGTCATGTATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATACGGATAGAGATACAGATATATTTCTTTCCATTAGGT
CCGAGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAGTCTAATT
TTGCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCTCGAATTCAGA
AGCAAACAAACTGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTACGAG
AGCTTCATGGTCAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCAAATGTGTT
CTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTACCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGGTATATCTGTTTATAT
ATGACCTCCAGGGATC
GATCTCAGCCTGAGGGCAAAGGTAAGTATGAGACAGGGAAGAATATATCCATGGTGTATAGCACTAAGGGGACACTGTTTTTGAGTGTGCTCTGGCAAGG
CCGGGTTTGCCAGCCTGACAGAGCATAGATTTAGCCCTGGATC
GATCATTAGAATTAAATATCTGAGTAATGGGGCTTCCCACATTCCGTTTTTTAAAAACTATATCTGATTTAACACCTCTAAAAATTCTTCTTGCATCTCAATAC
CTTTGTTTAATCTGATATTTAGAGAATTTCGTATGATAGGTAATCAACAGCAAATATAACTGTGGTTGAGTTCTGTACTTAGAAATCATGTAAAGCTAAGAAAT
GCATTTGTTTGTTTTTAAAAAGTCTTAAAATCCTTTGGGTTCCTATAAAATCAAACCAATATCTTGGCATTCTCAACCACAAGAGGGCATCCATGCTTGCAAC
C 1 UA 1 CACCCA 1 AAAGCCCA 1 AA 1 G 1 1 1 1 1 C 1 1 (J 1 AU 1 1 CUAU 1 AUU 1 UAAU 1 1 1 UA 1 UA1A1ACA 1 I U I G I UUUU
GATCCTTGGAGGTCATGTATGAACAGACATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTAGGT
CCAGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAGTCTAATTT
TGCTGTCCATGAGGCTCTCATAGTGTCCGACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCTCGAATTCAGAA
GCAAACAAACTGATC
GATCAAAAACCCTAAACTCCATCCTAAAGCCACAGCGCATCTTTTCTCAACAAAAAATGACGAAAGAAATTTCTAAAGCCTATCAGAGTTTTTTCTTGCATAT
G l I A I 1 1 AA 1 AUCAGA1 G 1 1AAC1CAU1 I A I A I C A G I 1GACAAAG1U1 I U U G I 1 1 1 1 1 1 1 1 1 C 1 U 1 AAACCG 1 UCCAAAACACCA 1 I A I I A I A I I A I 1 1 1 ACCA
AGAAATAAAGGCAGTTGTGTTCAACTGTAGGGCAATGGCCTTTTATTTTTACTTGTAGTCAGAGTTAGAAAGCTGTTACTGTTACTCACAAGGAACAAAACA
G I I G I I A I I A I I ACCCAAGAAAAAAAC 1 GA 1 U 1 1 GA 1" 1 1 1 1 AGCGU 1 U 1 1A 1 GC 1 UGA 1 GAG 1 1 1 1 1 UA 1 1 I I GGA 1 C
GATCATAAACAAGTTACCCCCTGCAATGTGCTTTCTGCCTCCATTTTGCAGAATTGGCAGTTCTAACTCAATTTGTTGAACAACAGCAGGCAGCTAATACTA
TTATTATTTTACAATCAGCTGGAAAAATAAATGACTTCTTTGATACTGCATTGTATGATACTGATGGTGTGGTTGAAATTAGTTCAGATAGAAACCCTCTAAAG
CTTAGGGGCGGAGGCAGGGGTGGTTAAGATC

APPENDIX O: C-l Unidentified Transcripts lday versus 6weeks (continued)
Comparison <„
Sise (#i»p)

Age

C 1 1 Day B

D10b

610

C 1 1 Day B

E06b

323

C 1 1 Day B

E07

309

C 1 1 Day B

EOS

323

C 1 1 Day B

E10

322

C 1 1 Day B

E11

322

C 1 1Day B

F02

237

C 1 1Day B

F03

323

C 1 1 Day B

F10

321

C 1 1Day B

F11

323

C 1 1 Day B

G01a

323

C 1 1 Day B

G06b

323

C 1 1 Day B

G08

243

C 1 1 Day B

G09

323

C 1 1 Day B

G11

323

C 1 1 Day B

H01a

323

Sequence's
GATCAACCAAAGCCTTAAGGAGAACATAAGGAACGAAAATATGAATTATACTGCATCACTTGCAATTCAACCAAGTACGTGGGAAATTCAGCTGGCAAGGAA
AGGAAGTAGAATAATGTGTGAAATGTTCGGCTACGTATCCCCTTTCCAACCATTAAAGTTAATGTCAGTAAATTTTGGTCAACCCAAGAAAAATATTCATTCA
TCCAGCCAGATGATGACTTCTTTTAGACTGCTTTAAATTTTTGTTTTCAACAGACGTCTAATTTGCTGTGTGCCAAGTCACATCTTCCAGACTGTGTGCTGCA
TGTACGTGCACAATGGTGGCTGGAAGATGAAAGGAAGGCACAGGATCAGACAGAAAAGTTTATCATCCGAGAAGATAAGTTTGGAACGAAGGGTAACCTG
ACATCTCCCATGCATCATGGCACATGCAGAAGAAATCTGGGGAAGTTAAAACCCCTTGGCACTTCTCATTCCAGGGATATTTCACTCTCTGATGCTCAGACA
TTCACTGCTGATGTCTCCTTTAGGGGAGCCTTTCGGGCCACCACCAAAAATGTGGCCACAAGAGACTGAAATGCAGCATTCTTCATTTACACAAATATAT
GATCAGTTTGTTTGCTCCTGAATCCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGGAAGTTAGACACTATGA
GAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCGAATGTG
TTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGAATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTAT
ATATGACCTCCAAGGATC
GATCAAGTGCTTATATTGGAAACATAAATCTACTTCCAGTCCTGTTCCTAATATATTTGTGTAAATGAAGAATGCTGCATTTCAGTCTCTTGTGGCCATATTTT
TGGTGGTGGCCTGAAAGGGTCCTCTAAAGGAGACGTCAGCAGTGAATGGCAGAGCATCAGAGAGTGAAATATCCCTGGAATGAGAAGCGCCAAGGGGTT
TTAACTTCCCCAGATTTCTTCTGCATGTGCCATGATGCATGGGAGGTGTCAGGTTACCCTTTGTTCCAAACTTATCTACTCAGATGATAAACTTTTCTGTCTG
ATC
GATCCTTGGAAGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTAGGTC
CCAGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAGTCTAATTT
TGCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCTCGAATTCAGAA
GCAAACAAACTGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGCTGGATTAGTGAAAATCATGGGAGGGCAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTCCGTATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCAAATGTGT
TCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCCATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATA
TATGACCTCCAAGGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGTGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAGA
GCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCCACCAACACTGGGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCGAATGTGTT
CTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATAACTGTTTATAT
ATGACCTCCAAGGATC
GAAAGCATTCTTTCACTATCATCAGCTAGGAACCTAGGCTATTTTCATTAAGTCTTCATTTTTGATATGAATATTGTATGAATATTTTTGTTTAAAATATGTTAA
ATGAAGATAAGAAAATGTCCATTCTGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGCCTTCCCCTACCAGCACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCAAATGTGT
TCTATACCACAGCTGAGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTTTAGACAAATGGATAGATAGGTAGATATATCTGTTTATAT
ATGACCTCCAAGGATC
GATCCTTTTGGGCGCTTCTGAATTCGAGATGACCCGGATTGGTGAAAATCATGGGAGGTTTAACATGCCTTTTGCAGGAGTGAGAAAGTTGGGCACTATGA
GAGCTTCACGGAAGTGGAATTAATACTCATATGCCATCCCCTATGTGACGGCGAAATACCATGAAAATCTGAAAGAGGAAGCCTCTCACATCAAATGTGTTA
TATACCACGCTGGGGACCTAATGGAAAAAAATATATCTGTATCTCTATCCATAAGGGGGGGTATGGACCCATATTTAGATAAGTAGATATATCTGTTTATATA
TGACCTGGAAGGATCCCCCCGGCTGCATGAATGGGAAAACAATGTTATTAATACCGTTAACC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTAGGGC
CCAGCTGTGGTATAGAACACATTTGCTCTGAGAGGCTTCCTCTTTCGGAGGTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGGATATGAAGTCTAATTT
CGCTGTCCATGAAGCTCTCCTAGTGTCCAACTTTCTCACTCCCGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCTCGAATTCAGAA
GCAAACAAACTGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCGTGGGAGGTTTAACATAACTTTTGCAGGAGTGAGGAAGTTGGGCACTATGA
GAGCTTCGTGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCGAATGTG
TTCTATACCACAGCTGGGACCTAATGGAAAGAAATGTATCTGTATCCCTATCCATATCTATGACTATAGACAAATGGATAGATAGGCAGATATATCTGTTTAT
ATATGACCTCCAAGGATC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTAGGTC
CCAGCTGTAGTATAGAACATATTCGCTCTGAGAGGCTTCCTCCTTCAGAGTTTCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAGTCTAATTTT
GCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCTCGAATTCAGAAG
C AAAC AAATT G ATC
GATCAACAACTAGTTGCTTATCCAGGTTTCAGTCTCTACAGCAGAGTTTTGCTTTCTCCTTTATTTGTGTACTAGGAAGTGAAGTTGTTTTCTTCCCCTGCTT
CCTCCAAGAAGAAGAATGGAAGGGAAATAAATAGTAGAGAGTACAGCCATCAAGTTTGAGAGATGACCTTTACACTTCTACGGCATTTGCAACCTACAACCT
TGCCTTCCCCACTTCCACTGGCCACAGCTAACATGATC
GATCAGTTTGTTTGGTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGGAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCAAATGTGT
TCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATAT
ATGACCTCCAAGGATC
GATCAGTTTATTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAACACCATGGAACTCTGAAAGAGGAAGCCTCTCAGGGCAAATGTGT
TCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAAACAAATGGATAGATAGGTAGATATATCTGTTTATAT
ATGACCTCCAAGGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATAAGTTGGATTAGTGAAAATCATGGGAAGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGGAAGAGGAAGCCTCTCAGAGCGAATGTGT
TCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCCGTATCTCTATTCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCCGTTTATA
TATGGCCTCCAAGGATC

APPENDIX O: C-l Unidentified Transcripts lday versus 6weeks (continued)
Comparison
Age

Size (#bp)

C 1 1DayB

H06

323

C 1 1 Day B

H08

247

C 1 1DayB

H09a

290

C 1 1DayB

H10a

170

C 1 1DayB

H10b

167

C 1 1DayC

A01

322

C 1 1 Day C

A05

323

C 1 1DayC
C 1 1DayC

A11b
C03

241
44

C 1 1DayC

C06b

309

C 1 1DayC

C07

323

C 1 1DayC

D05

287

C 1 1 Day C

D09

238

C 1 1DayC

E07a

369

C 1 1 Day C

F03a

31

Sequences
GATCAGT1TGTTTGCTTCTGMTTCGAGATGAGTTGGACTAGTGAAAATCATGGGAGGTTTAACGTAACTTTTGCAGGAGTGAGTAAGTTGGACACTATGAG
AGCTTCATGGACAGCGAAATTAGACTTCATATGCCATCCCCTACCAGCACTGCGAAATACCATGGAACCCTGAAAGAGGAAGCCTCTCAGAATGAATGTGT
TCTATACCACAGCCGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATA
TATGACCTCCAAGGATC
GATCMTAGTCAATATTGCCAGGGCTTAGCTGCCTTGCTTCTACCTAATTTTTACCCTTGCATGTCACAATAAAACCCAATGTGGAAGGCCCTCCAGGATAT
GGAGGGGGAGAAAGCACGAGAMCCATACCTACTGTCMTGTTGTCTGCTTTTTMTAMCMTATGTTTTGAAAATTCAAGCACTCAGGTAGGTTTGTAAA
TTGGATGGAGATGTCTAAGTCCCTGTAAAATTGAGCATTGATC
GATCAATCAAACCCTTAAGGACAACAAGGGCTCTGAAGGGTTAATTACTATCTCTCTGTCATTACCCTGCGAAGAAGGTAGGAAGCTCAGGTGGTAGGAGA
CGCATGCACMTGAAAAGGGAAAGGMTTCCACTTTTCTGGCATAAATAAATCCATTTGTGTGCATTGAAGAGAATTGCAGCAGAGGAAGAGGTCTTCACAT
ACAACCCCAGACTGAACAGTGTAAGGTGTGCTCCCTGTAAGAGGAAGCTAGCAGCCCCTCCAGAGGGAAAGTGGCAGCTTTAGGATC
GATCCTACTTGTAGCTACAACCTCTGACGAACAGAGGAGCAGTGTCTCTCATACAGCAAGGCMGCTGATGTCTATAAGCCAAAAGGGTATGTGAAAAGGG
TATTCAGCTCTTTTCACACACACACACACACACACACACTAAAAGGACTCAAGTCTGCTTTCTGAGATC
GATCACCAAAAGAAAACCTACCTTCCTGGCTGAAGTCCATTAGGGAAGCCCCCAATAAAACCTTCCAAGTACCTGTCATCTCTGGTGTCTAGAGCTTTATAC
AGGACCCAAGAGTCCAGGCTGCAGATGCGTGATATGGGCTGCTCATGGAAGAGTAGGCTAGGATC
GATCAGTTTGTTTGCTTCTGAATTGGAGATGAGGTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAATATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCGAATGTATT
CTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATGGGTAGATATATCTGGTTATAT
ATGACCTCCGAGATC
GATCAGTTTG7TTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAMTCATGGGAGGTTTMCATAACTTTTGCAGGAGTGAGAAAGTTGGACACTACGAG
AGCTTCATGGTCAGCAAAA7TAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCAAATGTGTT
TTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTGTAT
GTGACCTCCAAGGATC
GATCTTAACCTTATCTGCCTCCACCCCCAAGCTTTAGAGGGTTTCTATCTGAACTAATTTAAACCACACCATCGAAGTCATACAATGCATTATCAAAGAAGTC
CTTACTTTTTCCAGCTGATTAAAAAAAMTMTATTATTATCTGCTTGCTGTTGGTCAACAAATTGAGTAATAACTGCCAATTCTGCAAAATGGAGGCAGAAAA
CACTTTGCCCGGGGTAACTTGGAAATGATTGATC
GATCCACAAGGCCCCCAAGAGCACCAGGGTTGACTTTTGTGATC
GATCAAGTGCTTATATTGGAAACATAAATCTACTTCCAGTCCTGTTCCTAGTATATTTGTGTAGATGAAGAATCCTGCATTTCAGTCTCTTGTGGCCATATTT
TTGGTGGTGGCCTGAAAGGCTCCTCTAAAGGAGACATCAGCAGTGAATGTCAGAGCATCAGAGAGTGAAATATCCCCGGAATGAGAAGTGCCAAGGGGTT
TTMCTTCCCCAGATTTCTTCTGCATGTGCCATGATGCATGGGAGATGTCAGGTTACCCTTTGTTCCAMCTTATCTTCTCAGATGATAAACTTTTCTGTCCG
ATC
GATCAGTTTGTTTGCTTCCGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGrrTAACATAACCTTTGCAGGAGTGAGAAAGTTGGACACTATGA
GAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCCACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCAAATGTG
TTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATA
TATGACCTCCAAGGATC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTAACTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTAGGTC
CCAGCTGTGGTATAGAACACATTTGCTCTGAGAGGCTTCCTCTrTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAGTCTAATTTT
GCTGTCCATGAGGCTCTCATAGCGTCCAACTTTCTCACTCCTGCAGAAGTTATGTTAAACCTCCCATGATTTTCACTGATC
GATCAAAATGGACATTTTCTTATCnCATnMCATATTTTAMCAAAAATATTCATACMTATTCATATCAAAAATGGAGACTTAATGAAAATAGCCTAGGTTC
CTAGCTGATGATAGTGAAAGAATGCTTTCTGGCACATTTAAAAAAATGAAAACTGGTATTrTTGTCAAAGAAAGAAGGCTGTTATCTACATACATCTAACATT
ATCTGTTCTTTGTGAGCTCTCCTCTGGATC
GATCTTAMTGGTTTATTTGAGGAMCTGCMGTTMTTGCCACCAGACATATCAGGCMGTCTTTCTCCAAGGGGTTTTCCCTGTGATGAGACTGACATCA
MTTTTACTGTGAGCTATTTATTCTACTCCTTTGAAAATTCAGTCCTATATGCAAACTGAAGAAAMGAAMCTTCCCATTGAAAATGGGTGTTGCACTCTGA
ATAATGTACTCAGAACATTTTCTTCAACAGACAGGGTTACCAGCTGTAGACAGGCACATTTCCAAATAACATGACATTAAAGGAACCCAGTCACATGAAACT
GCAATTGTTAACAATGTTACAGGCAAGTTACTGAACTTGTATTGGTCAAATCATTTAAGATC
GATCATATCTGTGTGGGCAGAAAGCCAGTTTTTCCTCGGAAAGTTTCCAGCCAACCCTTTGGGGCAACAGTTATCTTACTGGGATGGTGGTGTTACGGTGC
CTGATC

APPENDIX O: C-l Unidentified Transcripts lday versus 6weeks (continued)
Comparison
Size (#bp)

Age

C 1 1 Day C

F05

323

C 1 1DayC

F10

277

C 1 1 Day C

G01

643

C 1 1 Day C

G01a

322

C 1 1DayC

G01b

325

C 1 1 Day C

G03

119

C 1 1DayC

G08a

323

C 1 1 Day C

G10

323

C 1 1 Day C

G11a

321

C 1 1DayC

G11c

234

C 1 1 Day C
C 1 1DayC

H02
H12

247
83

C 1 1 Day D

A03

308

C 1 1 Day D

A12

193

C 1 1 Day D

B01

360

C 1 1DayD

B02

431

Sequences
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAGTCGCGGGAGGTTTAACATAACCTTTGCAGGAGTGAGAAAGTTGGACACTATGA
GAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCCACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCGGAGCAAATGTG
CTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTTTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATA
TATGACCTCCAAGGATC
GATCCTTGGAGGTTATATATAAACAGATATATCAACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTAGGTC
CCAGCTGTGGTATAGAACACATTTGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAGTCTAATTTT
GCTGTCCATGAAGCTCTCATAGCGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATC
GATCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTAGGTCC
CGGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCTTACAGAGTTCCATGGTATTTCGCAGTGTAGGTAGGGGATGGCATATGAAGTCTAATTCT
GCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCTCGAATTCAGAAG
CAAACAAACTGATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACTGATATATTTCTTT
CCATTAGGTCCCAGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTACTTCGCAGTGTTGGTAGGGGATGGCATATGA
AGTCTAATTTTGCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCTCATGATTTTCACTAATCCAAACTCATCTC
GAATTCAGAAAGCAAACAAACTGATC
GATCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTAGGTCC
CGGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCTTACAGAGTTCCATGGTATTTCGCAGTGTAGGTAGGGGATGGCATATGAAGTCTAATTCT
GCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGA I I I I CACTAATCCAACTCATCTCGAATTCAGAAG
CAAACAAACTGATC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACTGATATATTTCTTTCCATTAGGTC
CCAGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTACTTCGCAGTGTTGGTAGGGGATGGCATATGAAGTCTAATTT
TGCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCTCATGATTTTCACTAATCCAAACTCATCTCGAATTCAGA
AAGCAAACAAACTGATC
GATCTTCTGGGCTAGCCTTAAGAGTCCTCATTTTCTGTGAGGGAATGTTCATATTGACTCACCAACAAGTCAAGGTCTCTCAAACTTTGAGGAACTTTCCTT
TGGGGGCACCCCTGATC
GATCAGTTTGTTTGCTCCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAAC I I I I GCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACCTCATATGCCATCCCCTACCGACACTGCGAAATACCATGGAACCCTGAAAGAGGAAGCCTCTCAGAGCAAATGTGT
TCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATAT
ATGACCTCCAAGGATC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGGTATATTTCTTTCCATTAGGTC
CCAGCTGTGGTATAAAACACATTCGATCTGAGAGGCTTCCTCTrTCAGAGTTCCATGGTATTTCGAATTGTTGGTAGGGGATGGCATATGAAGTCTAATTTT
GCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTTACTCCTGCAAAAGTTATGTTAAACTTCCCATGATTTTCACTAATCCAACTCATCTCGAATTCACAAG
CAAACAAACTGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGGGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACGGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGGACTCTGAAAGAGGAAGCCTCTCAGAGCGAATGTGT
TCTATACTACAGCTGGGACCTAATGGAAAGAAATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATATAT
GACCTCCAAGGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGTGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTATCAACACTGCGAAATACCATGGTACTCTGAAAGAGGAAGCCTCTCAGAGCAAATGTGTT
CTATACCACAGCTGGGACCTAATGGAAAGA
GATCAATAGTCAATATTGCCAGGGCTTAGCTGCCTTGCTTCTACCTAATTTTTACCATTGCATGTCACAATAAAACCCAATGTGGAAGGCCCTCCAGGATAT
GGAGGGGGAAAAAGCACAAGAAACCATACCCACCGTCAATGTTGTCTGCTTTTTAATAAACAATATGTTTTGAAAATTCAAGCACTCAGGTAGGTTTGTAAA
TTGGATGGAGATGTCTAAGTCCCTGTAAAATTGAGCATTGATC
UA I C I UCOA I I I C I AAGUAAAGGC I I I I I G I I GAAAI GC I I I I I G I I I G I I CAI I I G I I I CACACC I CAGC I I I I A I I I GA I C
GATCAAGTGCTTATATTGGAAACATAAATCTACTTCCAGTCCTGTTCCTAACATATTTGTATAAATGAAGAATGCTGCATTCCAGTCTCTTGTGGCCGTATTT
TTGGTTGTGGCCTGAAAGGCTCCTCTAAAGAGACATCAGCAGTGAATGTCAGAGAATCAGAGAGTGAAATATCCCTGGCCCGAGAAGTGCCAATGGGTTT
TAACTTCCCCAGATTTCTTCTGCATGTGCCATGATGCGGGGGAGATGTCAGCTTACCCTTTGTTCCAAACTCATCTTCTCAGATGATAAAC I I I I CTGTCTG
ATC
GATCAGGTCCTCCAAGGCAGTCATGATAAATCAATTACTTGCAATCGTGTGTGCTAGCTATTCATATATAGGTGGGACAGTACCAGTTTTTAGCCAAATATT
TACTGATTTTATTTCTGATACCAAAACATTTCTCAGCTGAATATAATTCAACGCAGCTTAAAGATGCAGCACATCTTTCTACCACCAGATC
GATCCACATGTAAGGAGGTAAGTATGTAAAGTAGTCAGTTAGAATGCAACCATCTATGTATAATTArrrrCTTGCTTCCTATTTTCAATTGTCATTGTCTAGAA
ATGTGTCAGAGGCAGTAGTTACCTGGCAACATGCTATAGTGTTGATAAGCTCTGGTTTGCTGCTTGGTCTAATGGGTAAAAGCAGACAAATCTACTACCTG
GATGAAGGGTGAGTAGCCAGGCCAGCAGCTACCCAAATTACCACAGCCAGTTCTCAGTCAGTGGGGCTCTGAGAGTTTATTCCAACAGATATATTGTACCA
GATAGAGTATGTGATGGGTCTATGATGGTGTAATTATTTTATTCTGCCGTGATC
GATCAGCAAAGGGCTGGGAACTGCCCCCAGAAGTGTGCATTGGACTATGGCCTTAAGTTTGCGATGAAAGACAACAGAGCCAGCACACCCAGGTTCCTCT
GCCACCATAGTGACCCTGGGCATCTCCAATCTTTCTTCTGGAGAGTCAGGCTGGACAGCAGAGCAATACTGTCCCACCTTACTTCCCACGATGCCCCTGG
ACCTGGCAGCTGTGAAGTGCTCCCATTrTCTGCATTTTACATGCACCCTGTAGACCAAGCAGACCGCAGTCATTGAGGAAATCTATGATAGAAATGGGAAT
GGATTGCAGAAGGCTTTCAGGTGAATAGTTTGTAACTAGTTGTGAAATTCTTCAGCGGAAGGGAATGTGCAAGTGCTGCAGAGGCAATATAGCCAGCTTTA
CATCATTGCCCAAGCCCTTAACCATGATC

APPENDIX O: C-l Unidentified Transcripts lday versus 6weeks (continued)
Comparison
Age

Size (#bpi

C 1 1 Day D

B05

237

C 1 1 Day D

B09

322

C 1 1 Day D

B11

237

C 1 1 Day D

D02c

96

C 1 1 Day D

D05b

108

C 1 1 Day D

D05c

253

C 1 1 Day D

D09c

109

C 1 1DayD

E12

323

C 1 1 Day D

F03

323

C 1 1 Day D

G04b

309

C 1 1 Day D

G04c

116

C 1 1 Day D

G08

323

C 1 1 Day D

G11

323

C 1 1 Day D

G12

99

C 1 1 Day D

H09c

144

C 1 1 Day D

H10

570

Sequences
GATCAAAATGGACATTTTCTTATCTTCATTTAACATATCTTAAACAAAAATATTCATACAATATTCATATCAAAAATGAAGACTTAATGAAAATAGCCTAGGTCC
CTAGCTGATGTTAGTGAAAGAATGCTTTCTGGCACATTTAAAAAATGAAAACTGGTATTTTTGTCAAAGAAAGAAGGCTGTTATCTACATTCATCTAACATTAT
CTGTTCTTTGTGAGCTCTCCTCTTGATC
GATCATTTTGTTTGCTTCTGATTCAAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCGGGAGCGAGAAAGTTGGACACTATGAGG
GCCTCATGGACATCAAAATTACACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCAAATGTGTTC
TATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATGGACAAATGGATAGATAGGTAGATATATCTGTTTATATA
TGACCTCCAAGGATC
GATCCAGAGGAGAGCTCACAAAGAACAGATAATGTTAGATGAATGTAGATAACAGCCTACTTTCTTTGACAAAAATACCAGTTTTCATTTTTTAAATGTGCCA
GAAAGCAI I C I I I C A C I A I C A I C A G C I A G G A A C C I A U U C I A I I I ICAI I I A G I C I ICAI 1 1 1 I U A I A I U A A I A I I U I A I G A A I A I 1 1 1 I G I 1 I A A A A I A I U I IAA
ATGAAGATAAGAAAATGTCCATTTTGATC
GATCCGTCGACTCGAGGTGGCCAGATACCAATCGACCTATATGAGTCGAATACGGCGCTCACGGCGTTGTTTTCAAGCCGTGCTGGGAAACCGGGT
GATCAATGCTAAAGGTGATAAGAAAGTTCACAGTCACCCTGCAGCGAACGGTCTTACATGTCCCTGGGAGAAGATTAGAAATTGAGAACTAAGAAGCCCGT
GCGGATC
GATCCCCCTGGCGAGAATCATAAGAGGTCAAGCTTTTCCATACGTCGACTCAATGGGGGGCCTGTACTCAATTCGACTTTATTGAGTCATTTACAGCACTC
ATTGGACGTCGATTACACGTCGTGCTGGAACACCGTGTGCTAGCATCTAATTAGCTGAGCACATCGCCATTCAGGTGGGCCATATCCAATGCCCTATGTAG
CCTATCAAAGGGGCAAAAGCGGGATATGTAACGTTCGGGCCTGGTAAACCC
GATCGGCGTCCAGGTTCGTGGCAGGGCCACAGCGCAGAGAGAGAAGCCTAAGTATTGCACCGGCTGGATGCAAGGGTTTCCGTTGTACATTCATTCAAT
CTGGCCGATC
GATCAGTTTGTTTGCTTCTGAATTCGTGATGAGTTGGATTAGTGAAAATCATGGGAGGGTTAACTTAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
GGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCGAATGTGT
TCTATACCACAGCTGGGACCTAATGGAAAGGAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATATATCTGTTTATA
TACGACCTCCAGGGATC
GATCCTTGGAGGTCACATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTAGGTC
CCAGCTGTGGTATAGAACACATTTGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGGAGTCTAATTT
TGCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCTCGAGTTCAGAA
GCAAACAAACTGATC
GATCAAGTGCTTATATTGGAAACATAAACCTACTTCCAGTCCTGTTCCTAATATATTTGTGTAAATGAGGAATGCTGCACTTCAGTCTCTTGTGGCCACATTT
TTGGTGGTGGCCTGAAAGGCTCCTCTAAAGGAGACATCAGCAGTGAATGTCAGAGCATCAGAGAGTGAAATATCCCTGGCCTGAGAAGTGCCAAGGGGTT
TTAACTTCCCCAGATTTCTTCTGCATGTGCCATGATACATGGGAGATGTCAGCTTACCCTTTGTTCCAAACTTATCTTCTCAGATGATAAACTTTTCTGTCTG
ATC
GATCAGTTTGTTTGCTTCTGAAATTCGAGATGAGTTGGATAAGTGAAAAATCATGGGAGGTTTAAACATAACTTTTGCAGGAGTGAGAAAAGTTTGGACACT
ATGAGAGCTTCAGG
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCAAATGTGT
TCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAGATGGATAGATAGGTAGATATATCTGTCTATA
TATGACTTCCAAGGATC
GATCAGTTTGTTTGCTACTGAATTCGAGATGAGTTGGATTAGTGTAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTATGAG
AGCATCACGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCGAATGTGT
TCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGGTAGATAGGTAGATATATCTGTTTATA
TATGACCTCCAAGGATC
GATCTGCATAGCTACCTGACTCACTGGGGGAAATCTGATGTAGGGCTGTCTCACAGAAATACTGCCTGGTTTCAGAACAATTTAGTATCTCACTTGATC
GATCTCACTCTTACGGGTCTAACGTATATCTCCTGGATATTGAACCCGTTGCTGGGAGGGGAGGGGAGGTCTTGTTCCATCATGAATCTGGCACGTCTGTA
TCGCAGGAGGTTAGCCGAGGCCATACGAATAGAACAGGCGGTA
GATCCTCCCCGTTTGTGGGTGTAAACTCCCCTATTCTCCTGGGATATTTAAATTTGGAAGATGCAATGTGCTCGTGGGGATTCTGGTTTCACATTCATTCAT
AAGATGGCAGCATGTGCTAACCGCCCGGAAGTTATGTCCCTCAGGCTGGATACGGGGGGTGAAAACTAGACCCCCTCGCCCGCTCGGACTCGCAAAGAA
GCTTAGCGAAGCTGCCTACCTCCATGGCAGGACCGTGACCTAAATCAGCCTCCAGTTAGTCGGATAGTCCCCGCTGCTGAGCAGTCAACTACAGCGACTG
AACTGGGCAAAGCGAGCGGTTTTAATTGATCATCTTGCACTCTTGCCCTGTCCCCAGGGGTGTAGAATTCAGATGACGCTCTGAATACCGTCACATCGTGG
GGGGCCTGATGCAAATCGGCTCTACTCAGACTGTACACTAAGTCACGGGGCGTGGTGTTACCGCATGATGCGAAACTTGCGTGCCAATACGCCTGTAGCA
TTTCCTTCTCATGCGATACGAATGCGGGCGGTCATCGAATCTACGTAAGTATGGTACGCCTTGACGCA

APPENDIX P: Table 3: C-2 Unidentified Transcripts lday versus 6months
Comparison
Ssse <#lap)

Age

C 2 1 Day A

B03

379

Sequences
GATCAAAAAGGGAAAATGCTTTAAAATGTGGGGGACTTGTTAGGTTGAAACTTGTTTATAAGTGACTTTGACTTGTTGTCTGAAAATTCATATATACCA
TACTGGGACTCTTTTTTGTTATACTCAAATTGCTGCAGGTGTAAAAGTGTCTCTTTGAAGTGTATTGTGGCCTCGAGGAAGTTTTAATCAATGAGGTGA
ACTTCATTAAAACAAAAGACTGCTACTTTTATGATGCCCAGTCCCAGTGTCTGGCTTACCTAGAAGCACTGACAAGTAGTGTTGTGCCAAAAGACTGA
TTTATATCTTCCCTCTTGATGTCACACCCAGCTGTCAGCCAGGGAGAATGGTAGGGGAAAACACACTTATCCTGTCTTGGATC
GATCCCAATGAGCTGTCACAGGAGCACCAACGTATTACAGCATAACGCCAGATGCTGCTTCTTATGCCTATAGAGAGCGGTTGAATTCAGTATGGTA
TGGCATCTTTTCACTGTGAACCTTCATGAGTTTTCCTAGATATTCTTCCAGTCGCATTACCACAAACCTTTTGGTTCCAAAGTGTAGATGAAAATTGCA
ACTGGCTTCAATAAAAAGCACATGATAAAGGCAGGATATAACCACTTTGAAGGAATTGCAGCATGGGTTTGAAAAATGTCTTAATATCCTCCTCCTCTT

C 2 1 Day A

B07

388

GATCAAATGAACACAGTTCCTGCAGTGTAGGCAAGAACTATTCACCTCAGGTTATGATTAAATCCTCTAGACAATGGATTTATTAAACTGTAATCCCCA
TACCTCTATTGGCAGTCTCTTCTCTTTGCTGCCTCAACATTCTCATCCGTACAGCATTTATA I I I I CAAAACAAATAAAAACAAAAAAACCCTCCCTTTG
C 2 1Day A

C02b

317

C 2 1Day A

C06b

365

C 2 1Day A

C07b

292

C 2 1Day A

C10

323

C 2 1 Day A

C12b

259

C 2 1 Day A

D04

323

C 21DayA

D05

323

C 2 1 Day A

F01

323

C 21DayA

F02

323

C 2 1 Day A

F03

265

C 2 1Day A

F05

322

C 21DayA

F07b

403

C 2 1 Day A

F10b

363

C 2 1Day A

G02b

436

TTTTC C C TTAAAG AAAGT
CAAAACTTAGAATGTCCTGCCTCACCCACAGC11 AAGCA1 G1 GGA1 CAG111 G71TGCTTCTGAATTCGAGATGAGTTGGAG1 A G ! GAAAATCATGGG
AGGTTTAACATAACTTTCGCAGGAGTGAGAAAGTTGGACGCTATGAGAGCTTCATGGACAGCGAAATTAGACTTCATATGCCACCCCCTACCAACACT
GCGAAATACCATGGAATTCTGAAAGAGGAAGCCTCTCAGAGCAAATGTGTTCTATACCACAGCTGGACCTAATGGAAAGAAATATATCTGTACCTCTA
TCCATATCTATGCCTATAGACAAATGGGTAGATAGGTAGATATATCTGTTTATATATGACCTCCAAGGATC
GATC CTC GG AG G C C ATATATAAACAG ATATATCTAC CTATCTATC C ATTTGTCTATAG AC ATAGATATG GATAG AGATAC AGATATATTTCTTTC C ATT A
GGTCCCAGCCGTGGTATAGAACACATTCGCCCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTAGTAGGGGATGGCATATGAAG
TCTAATTTTGCTGTCCACGAAGCTCTCAAAGTGTCCAACTTTCTCTCTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACT
GATCAGTTTGTTCGCTTCTGAATTCGTGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAGCTTTCGCAGGAGTGAGAAAGTTGGACACTA
CGAGAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAGCTCTGAAAGAGGAAGCCTCTCAGGGC
AAATGTGTTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACATATGGATAGATAGGTAGATA
TATCTGTCCATATTTGACCTCCAAGGATC
GATCAGCTTGTTTGCTTCTGAATTCGAGATGAGATGGATTAGTGAAAATCGTGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTA
TGAGAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAATACTGCGAAATACCATGGAACTCTGAAAGAGAAAGCCTCTCAGAGCG
AATGTGTTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATAT
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTA
TGAGAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGATGCCTCTCAGAGG
AAATGTGTTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCTATATCTATGTCTATAGACAAATGGATAGATAGGTAGATA
TATCTGTTTATATATGACCTCCAAGGATC
GATCAGTTTGTCTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAAACATGGGAGGTTTTACATAACTCTTACAGGAGCGAGAAAGTTGGACACTA
TGAGAGCTTCATGGACAGCAAAATTGGACTTCATATGCCATCCCCTACCAACACTGCGAAACACCATGGAACTCTGAGAGAGGAAGCCTCTCAGAGC
AAATGTGTTC TATAC C A C AG CTG G G AC CTAATGGAAAG AAATATATCTGTATCTCTATC C ATATCTATGTCTAT A GAC AAATG G ATG G ATAGGTAG ATA
TATCTGTTTATATATGACCTCCAAGGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTGGCAGGAGTGAGAAAGTTGGACACTA
TGAGAGCTTCATGGACAGCAAAATTAGGCTTCATATGCCATCCCCTACCAACACTGCGAAATACCACGGAACTCTGAAAGAGGAAGCCTCTCAGAGC
AAATGTGTCCTATACCACAGCTGGGACCTAATGGGAAGAGATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATA
TAACTGTTTATATATGAC CTC CAAG GATC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTA
GGTCCCAGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTCCGCAGTGTTGGTAGGGGATGACATATGAAG
TCTAA 1 [ 1 1 GCTGTCCATGAAGCTCTCACAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCT
CGAATTCTGAAGCTAACAAACTGATC
GATCAGGCCAGGTCTTTCCTACATGAAGAGCAAGGAGGCAGGCAGCACTCTTCAGGACTGTTCCAAGAGACAGAACTTTCCTTGAAGGCATCATCCT
AGATGCAGAAGGTTCATTTAAAACATTGCAAAAGAGCTTAAGTCTTCCAGCAATAAATCCTGTGAGTTCTTGCAGAATCACACACATCCTCAGCATGTA
AAAGAAAGGACAGTCAGGTCCACGTATTAGTTGATTCCTTACACCATCTCTCCAGCATAAAAGGGGATC
GATCATCCTGAGTATTATAGAATCTGTAAGCAGTATGATACTAATAAAGATGAAAAATTTGTTATTAGTTTGTCCCTTCCCACTTGTTAATGTCAGGAAT
TTTTGTTTTATATCTGTCTGTTATATACTTACTTCTTTTAC AAC A AGTG G AC C AAC GC AGTATTT ATA AC AAATAGAC AGTAT GTTTT ATAAC AAATA G G C
TATTGTACTAACTGGAAGATC
AAAACATAGAATGTCCTGTCTTACCCGCTGCTTAAGCATGTGGATCAGTTTGTTTGCTTCTGAATTCGAGATAAGTTGGATTAGTGAAAATCATGGGA
GGTTTAACATAACTTCTGCAGGAGTGAGGAAGTTGGACACTATGAGAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCCACCGACACT
GCGAAATACCATGGAACTCAGAATGAGGAAGCCTCTCAGAGCAAGTGTGTTCTATACCACAGCTGGGGCCTAATGGAAAGAAATATATCTGTATCTC
TATCCATATCTATGTCTATAGACAAATGGGTAGATAGGTAGATATATCTGTTTATATATGACCTCCMGGATCCTGTGAATGTACACAGAGACTCTGGA
ATACTGTAAAGC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAACCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTA
TGAGAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGC
GAATGTGTTCTATACCACAGCTGGGACCTAATGGAGAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGACAGGTAGATA
TATCTGTTTATATATGACTCCAAGGATCCACATGCTTAAGCTGCGGGTGAGACAGGACATTCTAAGTTT
AAAACATAGAATGTCCTGTCTTACCCGCTGCTTAAGCATGTGGATCAGTTTGTTTGCTTCTGAATTCGAGATAAGTTGGATTAGTGAAAATCATGGGA
GGTTTAACATAACTTCTGCAGGAGTGAGGAAGTTGGACACTATGAGAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCCACCGACACT
GCGAAATACCATGGAACTCAGAATGAGGAAGCCTCTCAGAGCAAGTGTGTTCTATACCACAGCTGGGGCCTAATGGAAAGAAATATATCTGTATCTC
TATCCATATCTATGTCTATAGACAAATGGGTAGATAGGTAGATATATCTGTTTATATATGACCTCCAAGGATCCTGTGAATGTACACAGAGACTCTGGA
ATACTGTAAAGCCAGATGATCAACCATTCACCGTCTTGTACAGAG

APPENDIX P: C-2 Unidentified Transcripts lday versus 6months (continued)
Comparison
Size <#bp)

Age

C 2 1DayA

GOS

421

C 2 1 Day A

G09b

428

C 2 1 Day A

G12

94

C 2 1 Day A

H06

182

C 2 1DayB

A11

322

C 2 1 Day B

A12

421

C 2 1 Day B

B02

421

C 2 1 Day B

B04

322

C 2 1 Day B

B08b

421

C 2 1 Day B

C01

250

C 2 1DayB

C07

322

C 2 1 Day B

C08

389

C 2 1Day B

C12

640

Sequences
GATCAGGTTGCAAGCATGGATGCCCTCTTGTGGTTGAGATTGCCAAGATATTGGTTTGATTTTATAGGAACCCAAAAGATTTTAAGACTTTTTAAAAAC
AAACAAATGCAGGCTTAATTTGGTTCCTTTAAAAATTTTGGCCTTGATTTTAAAGACACATGAATTAGACTGCTTGTTTTCTTTGAGAAATGAGGCCCAT
AGTATAACTCCACCATTTCTTAGCTTTACATGATTTCTAAGTACAGAACTCAACCACAGTTATATTTGCTGTTGATTACCTATCATACGAAATTTTCTAAA
TATCAGAT1 AT ACAAAGG1ATTGAGATGCAAGAAGAATTTTTAGAGGTGT 1AAA! CAGA1 AT A G ! 1 1 IT AAAAAACAGAAT GTGGGAAGCCTCAT 1 ACT
CAGATATTTAATTCTAATGATC
AAAACTTAGAATGTCCCGTCTCACCCGCAGCTTAAGCATGTGGATCCAGATGTAACCGGGGTGGGGGTGGAGGGGGGTTGGGTGGTTTGAGCTGG
ACTTCCATGCAACAGAGAAGTGATACCAGGAAAGCTCGGGGTCGGTGCTAGTTCAGGTCCACCGAGGGAGTCTGAGGAGAAAGCCAGACAGGTGA
AAGGTATGGGGAGAGCCCGAAAACGATCGAGAGGGACGGCGGGGGGGGGGGAAAAACATCTATATAAAGAAAGGGAGGAGAGTGAGAGTTGGAA
AACGTAGCAGAAAATAATCAATATTATTGGTAATCGCCACAATCCATCCAAGAAAGTAACCATTTTGTATCCGGAATTATAATACCCTCACAAACTCTAC
CCTCTCCAATAGCAAGGAAGAAATATAACAGATTTTACCAACAC
GATCAGACAGAAAAGTTTATCATCTGAGAAGTTAAGTTTGGAACAAAGGGTAAGCTGACATCTCCCATACATCATGGCACACGCAGAAGAGATC
GATCTATAAATGTAGCAGGCTGCTTAATAGAAAATACACTAAACAGACGCGATTTTCTGCATCCCCCTCGGTACGCTCCATGTAGAGAGCACAGATAC
ATATAGTGCGGCACTGTCAGAGAAGTAGAAACGAGTTATGTTGCCATTACCAGCTTCATGCCTCGTTCCTGTCTTTTCTGGATC
GATCAGTTTGTTTGCTTCTGAATTCGGGATGAGTTGGATTAGTGAAAATCATGGGAGGCTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTA
TGAGAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGC
GAATGTGTTCTATACCACAGCTGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCAAGTCTATGTCTATAGACAAATGGATAGATAGGTAGATAT
ATCTGTTTATATATGACCTCCAAGGATC
GATCATTAGAATCAAATATCTGAGTAATGAGGCTTCCCACATTCTGTTTCTTAAAAACTATATCTGATTTAACACCTCCAAAAATTCTTCTTGCATCTCA
ATACCTTTGTTTAATCTGATATTTAGAAAATCTCGTATGAAAGGTAATCAACAGCAAATATAACTGTGATTGAGTTCTGTACTTAGATATCATGTAAAAC
1AAGAAAT UG 1 GGAG 1 1A 1ACAAIGGGCCICAI i I C I C I A A G A G A A C AAACAGAC 1AA1 1 CA 1 G1 G 1 C 1 1 1AAAA 1 CAAGGCCAA1AII 1 11AAGGGAA
ACAAATTAAGCCT GCAT l l G l l i e n n i AAAAAG1 C I TAAAATCTTTTGGU1 1 CC1 AT AAAAI CAAACCAA1 AT C I 1 GGCATTCTCGACCACAGGAGGG
CATCCATGCTTGCAACCTGATC
GATCATTAGAATTAAATATCTGAGTAATGAGGCTTCCCACACTCTGTTTTTTAAAAACTATATCTGATTTAACGCCTCTAAAAATTCTTCTCGCATCTCA
ATACCTTTGTTTAATCTGATATTTAGAAAATTTCGTATGATAGGTAATCAACAGCAAATATAACTGAGGTTGAGTTCTGTACTTAGAAATCATGTAAAAC
TAAGAAATGGlGGAG , nA'lACAAlGAGCC"!CA'n"IC1CAAAGAAAACAAACAGACIAAI I C A I U I U I C I 1 1AAAAI CAAGGCCAAAA11TT1 AAAGGAAA
CAAATTTAGCCT GCAT 11 GGT l G l i m AGAAAGT C I 1 AAAGT C l l l l GGG 1 1 CC 1 A1 AAAAI CAAACCAA1 AT C I 1 GGCA1TCTCAACCACAAGAGGG
CATCCATGCTTGCAACCTGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTA
TGAGAGCTCCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGTAGCCTCTCAGAGT
AAATGTGTTCTATACACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATGGGTAGATAT
ATCTGTTTATATATGACCTCCAGGGATC
GATCATTAGAATTAAATATCTGAGTAATGAGGCTTCCCACATTCTGTTTTTTAAAAACTATATCTGATTTAACACCTCTAAAGATTCTTCTTGCATCTCAA
TACCTTTGTTTAATCTGATATTTAGTAAATTTCGTATGATGGGTAATCAACAGCAAATATAACTGTGGTTGAGTTCTGTACTTAGAAATCATGTAAAACT
AAGAAATGGTGGAGTTATACAATGGGCCTCATTTCTCAAAGAAAACAGACAGACTGATTCATGTGTCTTTAAAATCAAGGCCAAAATTTTT AAAGGAAA
CAAATTAAGCCTACATTTGTTTGTTTTTAAAAAGTCTTAAAATCTTTTGGGTTCCTATAAAATCAAACCAATATCTTGGCATTCTCAACCACAAGAGGGC
ATCCATGCTTGCGACCTGATC
GATCCATTCACCGTGTTTATAACCACTGCTTCTCGGAGTACTTTGTAAAGCTTTTAATGCCAACAGTAATGATGAGAGCTCTAGCACTGACAGGTAGG
AATTTGTTGGCTTTTTAGCTACCACGCTGACCACTTGTAATAGCTGGGGAACTCAAGGGGAAAAAAATGTCTCCTATAGACTAAGCTGTTAGAAAGGT
ATTTATGATATGAAACATAAGTGCAGAGCAACTAGGAAGACTGCAGCTTTGATC
GATCAGTTTGTTTGCTTCTGAACTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTGCAGGAGTGAGAAAGTTGGACACTAT
GAGAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATGCCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCA
AATGTGTTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCACTATCCATGTCTATGTCTATAGACAAATGGACAGATAGGTAGATAT
ATCTGTTTATATATGACCTCCAAGGATC
GATCAGACTTCCTTCCAGTTCTTCCAGTTTTCTGATAGAGACCATCTTTATGTAGGAAACCTTAAAAAAAAGAAGTAGTTCTAGGCAGGCAGTAAGAG
GAGGAGGA1A1 1AAUACA1 1 1 1 1 C 1 AACCCA'I GCTACAA1 1 CC 1 1 CAGAU1 GG 1 1A1A1 CC 1 UCC 1 1 1A1 CA 1 G 1 UC 1 1 1 1 1A1AAAAGCCAG 1 1 ACAA 1
TTCCATCTACACTTTGGAACCAATAGGTTTGTGGTAAATGCGACTGGAAGAATATCTAGGAAAACTCAAGAAGATTCACAGTGAAAAGATGCCATGCC
ATACTGAATTCAGTCGCTCTCTATAAGCATAAGAAGCAGTATCTGGTGTTGTGCTGTAACACGTTGGTGCTCCTGTGACAGCTCATTGGGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAATTGGATTAGTGAAAATCATGGGGGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTA
CGAGAGCTTCATGGACAGCAAAATTAGACTTCATATGCCGTCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGC
AAATGTGTTCTATACCACAGCTGGGACCTAATGGGAAGAAATATATCTGTATCTCTATCCATGTCTATGTCTATAGACAAATGGATAGATAGGTAGATA
TATCTGTTTATATATGACCTCCAAGGATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGGAAATCATGGGAGGTTTAACATAACTTTTG
CAGGAGTGAGAAAGTTGGTCACTATGAGAGCTTCATGGACAGCAAAACTTGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACT
CTGGAAGAGGAAGCCTCTCAGAGCGAATGTGTTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTAT
AGACAAATGGATAGATAGGTAGATATATCTGTTTATATATGACCTCCAAGGA

APPENDIX P: C-2 Unidentified Transcripts lday versus 6months (continued)
Comparison

>

^

*

^

•>>

Ste© (#fop)

Age

C 2 1 Day B

D01

323

C 2 IDay B

D02

323

C 2 1Day B

E02

322

Sequences
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACTGATATATTTCTTTCCATTA
GGTCCCAGCCGTGGTATAGAACACATTTGCTCTGAGAGGCTTCCTCTTACAGAGTTCCATGGCATTTCGCAGTGTTGATAGGGGATGGCATATGAAG
TCTAATTTTGCTGTCCATGAAGCTCTCATAGTGTCCAACTTCCCCACCCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATC
TCGAATTCAGAAGCAAACAGACTGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGACGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGGCACTA
TGAGAGCTTCATGGACAGCAAAATTAGACTTCGTACGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGGAGCCTCTCAGAGC
AAATGTGTTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACGAATGGATAGATAGGTAGATA
TATC TGTTTATATATG AC CTCCAAGGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTAT
GAGAGCTTCATGGGCAGCAAAATTAGACTTCATGTGCCATCCCCTACCAACACTGCGAAATACCGTGGAACTCTGAAGGAGGTAGCCTCTCAGAGCG
AATGTGTTTTATACCACAGCTGGGACCTAATGGAAAGAGATATATCTGTATCTCTATCCATATCTATGTCCATAGACAAATGGATAGATAGGTAGATAT
ATC TGTTTATATATGAC CTC C AAG G ATC
GATCAGACTTCCTTCCAGTTCTTCCAGTTTTCTGATTGAGACCATCTTTATGTACGAAACCTTAAAAAAAGAAGTAGTTTTAGGCAGGCAGTAAGAGGA
TTC ATC TAC AC TTTG G AAC C AATAG GTTTGTG GTAAATG C G AC TGG AAG AATATC TAG G AAAACTC AAG AAG ATTC AC AGTG AAAAG ATGAC ATAC C AT
ACTGAATTCAATCGCTCTCTATAAGCATAAGAAGCAGCATCTGGTGTTGTGCTGTAATACGTTGGTGCTCCTGTGACAGCTCATTGGGATC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCCTTCCACTA
GGTCCCAGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATAGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAG
TCTAATTTTGCTGTCCATGAAGCTCTCATAGTGCCCAACTTTCCCACTCCTGCAAAAGTTATGTTAAACCTCCCTTAATTTTCACTATTACAACACATCT
CGAATTCGAAGGCAAACAAACTGATC
GATCCCAGTGATGATAGAAACGTCTGTGTGCAGCTGCATTTGTAATCCCTGAGTCATAACACAGCTGGTTTGGATTTAAAAATGATAGTTTATGCCAC
TATGCATGTTTGAAGACGAACCTACATAGCCAGCCTTTATTTAGCTGCACGGCAGCTTCCAGTTCAACCAGAGGTCTTGCTAGGCTGAAGCTATACTC
CTACCAAGGTCCAGAAATAGCTGGAGGTATTAAGTTTCTAGACACGACTGTGATC

C 2 1 Day B

ED4

388

C 2 1 Day B

E10

323

C 2 1 Day B

E12

251

C 2 1 Day B

F05

290

C 2 1 Day B

F06b

351

C 2 1 Day B

F07b

323

C 2 1 Day B

H01

323

C 2 1 Day B

H05

321

C 2 1 Day B

H06

123

C 2 1 Day C

A06

216

TAGAATCCGGCGGAGATC
GATCATCAGAATTAAATATCTGAGTAATGAGGCT1 CCCACA I 1C1G1 11 111 AAAAAAC1 AT AT U I GA 1 1 1 AAUACC 1 C t AAAAA 1 I C I I C I IGUAIGTCA
ATACCTTTGTTTAATGTGATATTTAGAAAATTTCGTATGATAGGTAATCAACAGCMATATAACTGTGGTTGAGTTCTGTACTTAGAAATCATGTAAAAC

C 2 1 Day C

A09

422

C 2 1 Day C

B02

308

C 2 1 Day C

B09

323

C 2 1 Day C

C04

322

CATCCATGCCTGCAACCTGATC
GATCCTCACTCCATGTCACCTAGTGGAAATTTTGTTCATTTTCTGGTCGGTTGAACTTTGACGACTGTTTCCTCTTTCTACAATTCTGTAATTGGGCAA
GAGCATCACCATAGTGGGTCTCCAGTGAACACTTTATTGTTGCCCAGGTACCGCATTTTGAGACATAACGAGCAGAGGGTGGTATTTCAGTGTAACC
TAATCCTCAGAAACAAAAGCAGATTTATAAGTAAATATAGTCCTGCAGAGACCATCTCAGAGACTTGAGAGCTAAAGCAATGTGCTCCCATTAAGCAAT
GCATTTTGTGATC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTA
GGTCCCAGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAG
TCTAA 1 1 1 TGCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCGTGA1 111 CACTAATCCAACTCATCT
CGAATTCAGAAGCAAACAAACTGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAACCATGGGAGGTTAGCATAACTTTCGCGGGAGCGAGAAAGTTGGACACTA
TGAGAGCTTCATGGACAGCAAAATCGGACTTCATACGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGC
GTATGTGTTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATA
TATC TGTTTATATATG AC CTC C AAG G ATC

GATCTGGCCACATAAGCTTCACTAGACAATCAATATTCTCAACACCAAAAATATTTACTTAACTGGGCACTCTGAGCTAGTAGAGCTCTGTACTAGTTA
TGGAGGTGAGTTGAGCATGGCACAAGTTCCGATTCCACGTATGCACTATGACCCCAGGCACTAAGACCTAGATATGATTCCTATGAAAACTGCAGGT
GATGTTAACCAACAGGATGTGCCCACAGCTCTGTTAAATGAAGGCTAACTCTCCCCTGAGAAGTATACAACCCATCCTAATAGCATGGATGATC
GATCCAAGTGCTTTCTGCTTTCAGCAGTGCTAAAGACTTAGAGCTCGCACTGAAATCCAAACCACTCATGACTCAAGCTTACAGATGAGAGTAGCTAC
GCTAAATCCATAACTGAAGTACAGAAAAAATATGCTCAGGCTGAAAAAGAATAGTTGGCAGTGAGTGTAATGTGGTAAGCTCAGTAGACAATTGCACA
GACCCCAAACACTCCATCTACTCCATAAACAGGCAGCAAATGTACGCTGTCATTGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTATAGCATAACTTTTGCAGGAGTGAGAAAGTTGGACACTA
TGAGAGCTTCATGGACAGCAAAATTAGACTTCATATACCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGCA
AATGTGTTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTAACCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATAT
ATCTGTTTATATATGACCTCCAAGGATC
GATCATTGGAGGTGCCTCTGAATTCGAGTTGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGCTGGACACT
ATGAGAGCTACATGGACAGCAAAATTAGACTTCTTATGCCACCCCCTACCAACCCTGCCAATTCCCTTGAAACTCCGAGGGGGGAAGCCTCTCAAAT
CGAATGTGTCCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCGTATCTATGTCTATAGACCAATGGTTAGATAGGTAGAT
ATATCTGTTTATATATGACCTCCGAGGATC
GATCCTAGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCCTTCCATTA
GGTCCCAGCTGTGGTATAGAACACATTCGCTCTGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAGTC
TAATTTTGCTGTCCATGTAGCTCTCATAGTGTCCMCTTTCTCACTCCTGCAGAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACCCATCTC
GAATTCAGATGCAAACAAACTGATC
GATCTTGCCATTTTGGTCAGGTAACAATATTTACCACTGCCAATTTCAAACCTGTATTTAAAGCAGCAGGTGAGTCTGAGGGGCGGGTTGTAAGGCAC
ACCAAACAGTTTGTGTTAAGTGATC
GATCACATAACCATCTAGAGAGGAGCTTGAGACTCCAATGTTGTGATATTACTTCAGCAATTTAACAAATTTGTGAAAATCATCATGAGACAATGAACA

APPENDIX P: C-2 Unidentified Transcripts lday versus 6months (continued)
Comparison
S i z e (#bp)

Age

C 2 1 Day C

C10

284

C 2 1 Day C

C11

323

C 2 1 Day C

D04

251

C 2 1 Day C

D06

323

C 2 1 Day C

D09

419

C 2 1 Day C

E02

323

C 2 1 Day C

E06

323

C 2 1 Day C

E08

276

C 2 1Day C

E09b

413

C 2 1Day C

E10

323

C 2 1Day C

F10

250

C 2 1 Day C

G02

321

C 2 1 Day C

G03

323

C 2 1 Day C

G06

281

C 2 1 Day C

G08

320

C 2 1 Day C

H07b

402

Sequences
GATCCCTGCCATTGATATAGCCTGGAAATTTAGAGTCTTCATCATCCTCCCACTACTCTCTATGAATGCTCTTACCTAAATATCCTACTGAATTGATTTT
AAGACATGTTCTAAACAGCTCTTAATTGGCCACTTTTAGAACCAATCACGTCCTGAAAGTCTTGTGGGATTTACTCCAAGCAGAAAGACTGAAGTAAA
GGTTGGTATGAGAATATCCTGTATAGTATGTCATTTATAAGTTGCTGCTTGCTTGTGAGTTGATTTATTTCAAGTGTTTCTTGATC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTA
GGTCCCAGCTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAG
TCTAA I I I TGCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCGTGATTTTCACTAATCCAACTCATCT
CGAATTCAGAAGCAAACAAACTGATC
GATCGCAGTTGTGTCTAGAAACTTTATACCTCCAGCTATTTCTGGACCTTGGTAGGAGCATTGCTTCAGCCTAGCAAGACCTCCGGTTGAACTGGAA
GCTGCTGTGCAGCTAAATAAAGGCTGGCTATGTAGGTTCGTCTTCAAACATGCATAGTGGCATAAACTATCATTTTTAAATCCAAACCAGCTGTGTTA
CGACTCAAGGATTACAAATGCAGCTGCACACAGACGTTTCTACCATCACTGGGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAAACATGGGAGGTTTAACATAACTTTTACGGGAGTGAGAAAGTTGGACACTA
TGAGAGCTTCATGGACGGCAAAATTAGACTTCATATGCCATTCCCTACCAACGCTGCGAAATACCATGGAACTCTGAAAGAGGAGGCCTCTCAGAGC
GAATGTGTTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATACCTATGTCCATAGACAAATGGATAGATAGGTAGATA
TATCTGTTTATATATGACCTCCAGGGATC
GATCATTAGAATTAAATATCTAAGTAATGAGGCTTCCCACACTCTGTTTTTTAAAAACTATATCTGATTCAACACCTCTAAAAATTCTTCTTGCATCTCAA
TACCTTTGTTTAATCTGATATTTAGAAAATTTCGTATGATAGGTAATCAACAGCAAATATAACTGTGGTTGAGTTCCGTACTTAGAAGTCATGTAAAACT
CCATGCTTGCAACCTGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCACGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTAGACACTA
TGAGAGCTTCATGGACAGCAAAATTAGACTTCATATGCCGTCCCCTACCAGCACTGCGAAATACCATGGAACTCCGAACGAGGAAGCCTCTCAGAGC
AAATGTGTTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATAACTATGTCTATGGACAAATGAATAGGTAGGTAGATA
TATCTGTTTATACATGACCTCCAATGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTAGGATTAGTGAAAATCATGGGAGGTTAAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTA
TGAGAGCTACATGGACAACAAAATTAGATTTCGTATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAGGCCCCTCAGAGC
GAATGTGTTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATGGACAAATGGATGGATAGGTAGATA
TATCTGTTTATATATGACCTCCAAGGATC
GATCATTAGAATTAAATATCTGAGTAATGAGGCTTCCCACAGTCTGTTTTTTAAAAACTATATCTGATTTAACACCTCTAAAAATTCTTCTTGCAACTCAA
TACCTTTGTTTAATCTGATATTTAGAAAGTTTCGTATGATAGGTATCAACAGCAAATATAACTGTGGTTGAGTTCTGTACTTAGAAATCGTGTAAAACTA
AGAGATGGTGGAGTTATACAATGGGCCTCATTTCTCAAAGAAAACAAACAGGCTAATTCATGTGTCTTTAAGATC
GATCAAGAATGGGGAAAAACTTCCTTTACCAGGAGAGAAGAAAAGAAGCATTGAGTATCTTCCATCTGGAAAGAAGAATGAAGGGACATCTAATCAAG
ATTTGCAAAATCAGGAATGTGTGAATAAGGTTTATCCAGAGGTTGCTTTCATCAATACTTCCAATACTTCAATTACAGTAGAACAGTAAGTAATCAATTT
ACCAGCCTGCACGTAT
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGACTAGTGAGAATCATGGGAGGTTTAACATAACTTCTGCAGGAGTGAGAAAGTTGGACACTA
CGAGAGCTGCATAGACAGCAAAATTAGACTTCATAAGCCGTCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGAGGAAGCCTCTCAGAGC
AAATGTGTTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTGTCCATATCCATGTCTATAGACAAATGGATAGATAGGTAGATA
TATCTGTTTATATATGACCTCCAAGGATC
GATCCCAGTGATGATAGAAACGTCTGTGTACAGCTGCGTTTGTAATCCTTGAGTCAAACACAGCTGGTTTGGATTTAAAAATGATAGTTTATGCCATTA
TGCATGTTTGAAGACGAACCTACATAGCCAGCCTTTATTTAGCTGCACAGCAGCTTCCAGTTCAACCAGAGGTCTTGCTAGGCTGAAGCAATACTCCT
ACCAAGGTCCAGAAATAGCTGGAGGTATTAAGTTTCTAGACACAACTGTGATC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTACAGACATGGATGTGGATAGAGATACAGATATATTTCTTTCCATTA
GGTCCCAGCTGTGTATAGAACACATTTGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAGT
CTAATTTTGCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCTGGTTTTCACTAATCCAACTCATCTC
GAATTCAGAAGCAAACAAACTGATC
GATCCTTGGAGGCCATATACAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTA
GGTCCCAGCTGTGGTGTAGAACACATTTGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAG
TCTAATTTTGCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCT
CGAATTCAGAGGCAACCAAACTGATC
GATCAGGTTGCAAGCATGGATGCCCTCCTGTGGTTGAGAATGCCAAGATATTGGTTTGATTTTATAGGGACCCAAAGGATTTTAAGACTTTTTAAAAA
CAACCAAATGCAGGCTTAATTGTTTCCTTTAAAAATTTTGGCCTTGA I I I I AAAGACACATGAATTAGTCTGTTTGTTTTCTTTGAGAAATGAGGCCATC
GTATAACTCCACCATTTCTTAGTTTTACATGGTTTCTAAGTACAGAACTCAACCACAGTTATATTTGCTGTTGATTACCGATC
GATCTTCCGGTTAGTACAATAATCTGTATGTTGTTATGATATGTAGTCTTAAATAAAACCAACCATGGAGCTTAAGATTCTACACTACTATTTTCAGGAA
ACATTTATAAAAACCGTTTTGGTCTATTTGTTGTAAAATATACTGTCTATTTGTTATAAATACTGTGTTGGTCTACTTGCTGTAAAAGAAGTAAGTATAAC
TGTAATACTCAGGATGATC
GATCAAGAGATTGCTATGTAACCTGTGTCTCATTTGGGTAGGAGATACTTAATTCCAAGCTTGAGGGGAGCTTCAGTTCCTGTAGGTTGTGTGATGAC
CTTTAAGCCTCTGTTGTGATGAGGAACCCCTGTGGAAAAAGAAGAATCTTATCGGTACATGTCTTGGTAACAACTTGTGTCTAGCTGCGCATGAGAAT
GTGAGTAAAGGATGCCCAGTTACACCAGCTCGGGTGTTTATGACTGTTCGAAAGGCTGAGACACGTAACACAAAACACGCTCTGGGTCTAGAAGCAA
TGACGCAGTTTTCAACAGAACCAGGTAGAATCGAAACAAACAGTATAAAATGAATTATAACAAGACACTGCTGGCAGGTGGGCAAATGGTTATAGGG
GTGTTTCTGATC

APPENDIX P: C-2 Unidentified Transcripts lday versus 6months (continued)
Comparison

Ouorji
Ssse <#bp)

Age

C 2 1DavC

H08

267

C 2 1 Day C

H09

336

C 2 1Day C

H11

309

C 2 1 Day D

A04

323

Sscjtisjncss
GATCATCATTTTCCTCTGAAGTCAGATGTTTTACCTGCAATTCCTGTGTTGTAAATACACCGGCAGTACAGCGCCAACACTTACCAATAAACACATCGC
A I I I GCC I GC I AAGAGACAGAI GAG 1 AGGACAAUGATI T 1 T A A G I A I T A C I 1 1 GAGAAI (J<JA 1 I G I A I I C I 1 I C I 1 IAACI 1 AGACACAAAGAA 1 C 1 G 1 1
GAATACCTTATAAAATTCTTGGTCATTTTCTAAATCAATGTAAGGCATATGAATCTGGAAAACTGATC
GATCAGATGTAACCAGCCTGCACGTATTTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGA
GAGTTGGACACTATGAGAGCCTCACGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCGACACTGCGATATACCATGGAACTCTGAAAGGGGA
AGCCTCTCAGAGCAAATGTGTTCTATACCACAGCTGGAACCTAATGGAAAGAAATATATCGGTATCTCTATCCATATCTATGTCTATAGACAAATGGAT
AGATAGGTAGATACATCTGTTTATATATGACCTCCAAGGATC
GATCCTCATTCCATGTCACCTAGTGGAAA 1 1 1 1 GTTCATTTTCTGGTTGGTTGAACTTTGACAACTGCTTCCTCTTTTCTACAATTCTGTAATTGGGCAA
GAGCGTCATCATAGTGGGTCTCCAGTGAACACTTTATTGTTGCCCAGGTACTGCATTTTGAGACATAACGAGCGGAGAGTGGTATTTCAGTGTAACC
TAATCCTCAGAAACAAAAGCAGATTTATAAGTAAATATAGTCCTGCAGAGACCATCTCAGAGACTTGAGAGCTAAAGCAATGTGCTCCCTTTAAGCAA
CGCATTTTGTGATC
GATCCTTGGAGGTCATATATAAACAGATACATCTACCTATCAATCCATTTGTCTATAGACATAGATATGGATAGAAATACAGATATATTTCTTTCCATTA
GGTCCCAGCTGTGGTATAGAACACATTTGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTTGTAGGGGACGGCATATGAAG
TCTAATTTTGCAGTCCATGAAGCTCTCATAATGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGAI 1 1 1 CACTAATCCAACTCATCT
CGAATTCAGAAGCAAACAAACTGATC
GATCCACAGCACCAGCGCTGCCCATCGAAACCGTATGAGCTCTCCTGGAGCAGCACCAAGTGTAGGGGTGAAAGCCCTTGCTGTAGACTGAGGATA
CATCCAAATGGGCAGAGAGACTGGTCTCAGATTAAGTCATCGATGCTATCCCAGTTTCCACCACAGCAAAAAAACTCCTTTGAACATAGCTTTATGTT
TTAGGTCAAGAAAATAAATGTATCATTCCAGTAGTGTTGGTAGGTCTTTGGAAGTGCTAATTAATGAGCATTCAG 1 1 1 1 CCCTGTGGTGAAGATAGATT

C 2 1Day D

A09

385

C 2 1Day D

A12

322

C 2 1 Day D

B03

322

C 2 1 Day D

B06b

323

C 2 1 Day D

B08

421

C 2 1 Day D

B10

607

C 2 1 Day D

B11

468

C 2 1 Day D

B12b

322

C 2 1 Day D

C04

150

C 2 1 Day D

D01

419

GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGGGGATTAACTTAACTTCTGCGGGAGTGAGAAAGTTGGACACTA
TGGGAGCTTCATGGACAGCAAGATTAGACTTCATATGGCATCCCCTACCAACACTGCGAAATACACGGAACTCTGAAAGGGGAAGCCTCTCAGAGCA
AATGTGTTCTACACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTGTCCATATCTATGTCTACAGATAAATGGATAGATAGGTAGATAT
ATCTGGTTATATATGACCTCCAGGGATC
GATCCTTGGAGGTCGTATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATACGGATAGAGATATAGATATATTTCTTTCCATTA
GGTCCCAGCTGTGGTATAGAACACATTTGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCGGTGTTGATAGGGGATGGCATATGAAG
TCTAATTTTGCTGTCCATGAAGCTCTCATAGTGTCAACTTTCTCACTCCCGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACACGTCTC
G AATTC G G AAG C AAAC AAACTG ATC
GATCCCTGGAGGCCATATATAAACAGATATATCTACCTATCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTA
GGTCCCAGCTGTGGCATAGAACACATTTGCTCTGAGAGGCTTCCTCTTTCAGAGTTCCATGGTATTTCGCAGTGTTGGTGGGGGATGGCGTACGAA
GTCTAATTTTGCTGTCCATGAAGCTCTCATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATC
TCGAAATCAGAAGCAAACAAACTGATC
ATCAGGTTGCAAGCATGGATGCCCTCTTGTGGTTGAGAATGCCAAGATATTGGTTTGATTTTATAGGAACCCAAAAGATTTTATGACTTTTTAAAAAAC
AAACAAATGCAGGCTTAATTTGTTTCCTTTAAAAATTTTGGCCTTGATTTTAAAGACACATGGATAAGTCTGTTTG 1 1 1 1 CTTTGAGAAATGAGACCCAT
TGTATAACTCCACCATTTCTTAGTTTTACATGATTTCTAGGTACAGAACTCAGCCACAGTTATATTTGTTGTTGATTACCTATCATACGAAATTTTCTAAA
CAGATATTTAATTCTAATGATC
GATCTGTTGCTATGCTGTTACCTTAGTTTAAGACTATACTAATAACAGTAATATCCCAGAACATAACAATGGTAAAATAGAGCTGGTTTTCAAAATATTT
ATCATTAATGTACTGGAAAAACTGTGAGAGTGTTTTGTAATCATCCCAAAAGCATCCATTATATATCAGATAATAATTGATTCTGAAATGGTATTCTACT
TCCAGTTATGTGATCATTAGAATTAAATATCTGAGTAATGAGGCTTCCCACATTCTGTTTTTAAAAACTATATCTGATTTAACACCTCTAAAAATTCTTCT
TGCATCTCAATACCTTTGTTTAATCTGATATTTAGAAAATTTCGTATGATAGGTAATCAACAGCAAATATAACTGTGGTTGAGTTCTGTACTTAGAAGTC
ATGTAAAACTAAGAAATGGTGGAGTTATACAATGGGCCTCATTTCTCAAAGAAAACAAACAGACTAATTCATGTGTCTTTAAAATCAAGGCCAAAATTTT
TAAAGGAAACAAATTAAGCCTGCATTTGTTTGTTTTAAAAAGTCTTAAAATCTTTTGGGTTCCTATAAAATCAAACCAATATCTTGGCATTCTCAACCAC
AAGAGA
GATCATTAAAAGTAAATATGTTACTTTAGAGGCTGCCCTCTCCCCGTTGCCCTCAACTATATCGGATTTAACATCTCTGAAAATTCCTCCTGCCTCTCC
AAATAAATCAAGCCCGCTGTTGTTTGTTTTTCAAAAGTCTTACTGGGAAAACCGTTCCTATAAAATCAAACCAATATCTTGGCATTCTCCCCCACAAGA
GGGCATCCATGCTTGCAACCTGATCCCCCGGGCTGCCCCTTCCCAATATCAAGCTTATCTGAATGGTCAACCTC
GATCCTTGGAGGTCATATATAAACAGATATATCTACCTATCTATCCACTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTA
GGTCCCAGCTGTGGTATAGAACACATTTGCTCTGAGAGGCTTCCTCTTTCCGAGTTCCATGGTATTTCGCAGTGTTGGTAGGGGATGGCATATGAAG
TCTACTTTTGCTGTCCATGAAGCTCACATAGTGTCCAACTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCGCTAATCCAACTCAACT
CGAATTCAGAAGCAAACAACTGATC
GATCTCAGAGAAGAGGAACACACGGCTTGCCAAGGAGAAGTAAGCAAGGTCAAGCCTGGGTTTTACGAAGTCATTTATTACCCCAAAGAGAGAACAT
GGTATCACTAAAACCTGCTCAGCATCAATCTGAAGTCGTGACTGTCGGAGATC
UA 1 <JA 1 1 AGAA1 1 AAA 1 C 1 GAG 1 AA 1 GAGGC 1 1 COCACA11 C 1 G 1 1 1 1 1 1 AAAAAC 1 A 1 A 1 C 1 GA 1 1 1 AACACC 1 C 1 AAAAA 1 1 C 1 1 C 1 1 GCA1 C 1 CAA1 A
CCTTTGTTTAATCTGATATTTAGAAAATTTCGTATGATAGGTAATCAACAGCAAATGTAATTGTGGTTGAGTTCTGTACTTAGAAATCATGTAAAACTAA
GAAATGGTGGAGTTATACAATGGGCCTCATTTCTCAAAGAAAACAAACAGACTAATTCATGTGTCTTTAAAATCAAGGCCAAAATCTTTAAAGGAAACA
AATTAAGCCTGCATTTGTfTGTTTTTAAAAAGTCTTAAAATCTTTTGGGTTCCTATAAAACCAAACCAATATCTTGGCATTCTCAACCACAAGAGGGCAT
CCACGCTTGCAACCTGATC

APPENDIX P: C-2 Unidentified Transcripts lday versus 6months (continued)
Comparison
Age

Size (#bp)

C 2 1 Day D

D02

321

C 2 1 Day D

D03b

421

C 2 1 Day D

D08

322

C 2 1 Day D

D12b

359

C 2 1 Day D

F04b

323

C 2 1DayD

F07

322

C 2 1 Day D

F09

170

C 2 1 Day D

F10

421

C 2 1DayD

G01

422

C 2 1DayD

G07

323

C 2 1DayD

H07

421

Sequences
GATCCTTGGAGGTCATATATAAACAGATGTATCTACCTACCTATCCATTTGTCTATAGACATAGATATGGATAGAGATACAGATATATTTCTTTCCATTA
GGTCCCGACTGTGGTATAGAACACATTCGCTCTGAGAGGCTTCCTCCTTCAGAGTTCCATGGTATTTCGCGGTGTTGGTAGGGGATGCCATATGAAA
TCTAATTTTGCTGTCATGAAGCTCTCATGGTGTCCAGCTTTCTCACTCCTGCAAAAGTTATGTTAAACCTCCCATGATTTTCACTAATCCAACTCATCA
CGAATTCAGAGCAACCAAACTGATC
G A I C A I IAGAAI I AAA I A I C I G A A I A A I GAGGC I I CCCACAI I CCG I I I I I IAAAAAC IAIATCTGACTTAATACCTCTAAAAATTCTTCTTGCATC I CAA
TACCTTTGTTTAATCTGATAGTTAGAAAATTTCGTATGATAGGTAATCAACAGCAAATATAACTGTGGTTGAGTTCTGTACTTAGAAATCATGTAGAACT
AAGAAATGGTGGAGTTATACAATGGGCCTCATTTCTCAGAGAAAACAAACAGACTAATTCATGTGTCTCTAAAATCAAGGCCAAAATTTTTAAAGGAAA
CAAATTAAGCCTGCATTTGTTTGTTCTTAAAAAGTCTTAAAATCTTTTGGGTTCCTATAAAATCGAACCAATATCTTGGCATTCTCAACCACAAGAGGGC
ATCCATGCTTGCAACCTGATC
GATCTGAAGGGAAACCAACTAACCATGTAGCATCTTTTTGAATTTATCCCCCACTGTCACCTTCGAAACAACTAGATGGCTATAGATAGATTAGAGACT
ACAACAAGTGATATTTCACAACTCGTAAGGCAAGTGAATCCGTAAGGCCAAGGAGAGGAGCTGTTAGACATTGTGAAAGACTAAATAAAATTGAAGCC
ATTATCTGGTGTGTTTTCATTGCGTATGCCTCAATATCTTAAAAAATACAAACAAACAAAACCCCAGCAACATCAAAATGCACAAAGCTTTTAAAATATG
TTAGAATAAGACATTGGTTGTGATC
GATCCTCACATCTTTCTGGGACTAAACATTAGGATTCTCCTGGTGTATTAAAACAGTTCCTCTGCAGAGAACGGGTGTTTGGAATGGTTTCACATCTG
ATGATATAAATATCTTTGCTGCTATCGGGTGCTCTTTATAATCCAAATGGCGCTTCCAGGAAGGGTAACCTTGCCAATTCAACCATTCACGCTGGATTA
GGGAC1 C1 GAGAAGC1GAAAAGA11 11 '1 CI GA1 GA'l 1 1 A l AAC1CCA1 CAGA11CCAAAACGAAGACAGG1 C I ACAC 1 1 1 C 1 UA1AAAACAGCCGCCA
GAATAGACACAAGTGTGTGTGCAGGGAAATGCACTTTCTCATTCATTCACATCTAGATATGATC
GATCAGTTTGTTTGCTTCTGAATTCGAGATGAGTTGGATTAGTGGAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTTGGACACTA
TGAGAGCTTCATGGACAGCAAAATTAGACTTCGTATGCTATCCCCTACCAACACAGCGGAATATCATGGGACTCTGAAAGAGGAAGCCTCTCAGAGC
GAATGTGTTCTATACCACAGCTGGGACCTTATGGAAAGAGATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATA
CATCTGTTTATATATGACCTCCAAGGATC
GATCAGTTTGTTTGCTACTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAAGAGTGAGTAAGTTGGACACTA
TGAGAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTACGAAATACCATGGAACTCTGAAAGAGGAAGCCTCGCAGAGC
GAATGTGTTCTATACCACAGCTGGGACCTATGGAAAGAGATATATCTGTATCTCTATCTACATCTATGCCTATAGACAAATGGATAGATAGGTAGATAT
ATCTGTTTATATATGACCTCCAAGGATC
GATCCATGGTATTTCGCAGTGGTGGTAGGGGATGGTATATGAGGTCTAATTTTGCTGTCCATGAAGCTCCCATAATGTCCAACTTTCTCGCTCCTGCA
AAAGTTATGTTAAACCTCCCATGATTCTCACTAATCCAACTCATCTCGAATTCTGAAGCAAACAAACTGATC
G A I C A I I A I A A I I A A A I A I C I G A G I A A I G A G G C I ICCCACAI 1 C 1 GG 1 1 1 1 1 AAAAAC I A I A I C IGAI 1 1AACACC 1 C 1AAAAA1 I C I I C I I G C A I C I C A A
TACCTTTGTTTAATCTGATATTTATAAAATTTCCTATGATACGTAATCAACAACGAATATAACTGTGGTTGAGTTCTGTACTTACAAATCATGTAAAACTA
AAAAA 1 GG'I GGAG11A1 ACAA'I AGG1 CCCA 111 CCCAAAGAAAACAAACAGAC1AA1 CCA1G 1 G 1 C 1 1 1AAAA1 CAA 1 GCCAA1A 111 11AAAGGAAACA
AAI IAAGCCIGCAI 1 I G I 1 I G I 1 1 1 I A A A I A G I C I 1 I A A A I C I 1 1 1 GGG 1 ICC 1 A l AAAA 1CAAACCAA1 A l C 1 IGGCAI 1 C 1 CAACCACAAGAGGGCA1
CCATGCTTGCAACCTGATC
GATCATTAGAATTAAATATCTGAGTAATGAGGCTTCCCACATCCTGTTTTTTTAAAGACTATATCTGATTTAACACCTCTAAAAATTCTTCTTGCATCTCA
ATACCTTTGTTTTATCTGATATTTAGAAAATTTCGTATGATAGGTAATCAACAGCAAATATAACTGTGGTTGAGTTCTGTACTTAGAAATCATGTAAAAC
TAGGAAATGGTGGAGTTATACAATGGGCCTCATTTCTCAAAGAAAACAAACAGACTAATTCATGTGTCTTTAATATCAAGGCCAAAATTCTTAAAGGAA
ACAAATTAAGCCTGCATTTGATTGTTTTTAAAAAGTCTTAAAATCTTGTGGGTTCCTATAAAATCAAACCAATATCTTGGCATTCTCAACCACAAGAGGG
CATCCATGCTTGCAACCTGATC
GATCAGTTTGTTTGC1TCTGAATTCGAGATGAGTTGGATTAGTGAAAATCATGGGAGGTTTAACATAACTTTTGCAGGAGTGAGAAAGTCGGACACTA
TGAGAGCTTCATGGACAGCAAAATTAGACTTCATATGCCATCCCCTACCAACACTGCGAAATACCATGGAACTCTGAAAGGGGAAGCCTCTCAGAGC
AAATGTGTTCTATACCACAGCTGGGACCTAATGGAAAGAAATATATCTGTATCTCTATCCATATCTATGTCTATAGACAAATGGATAGATAGGTAGATA
TATCTGTTTATATACGACCTCCAAGGATC
G A I C A I IAGAAI I A A A I A I C I G A G I A A I G A G G C I ICCCACAI I C I G I 1 1 1 1 CAAAAAC 1 A l A I C IGAI 1 1AACACCCC 1AAGAAI I C I I C I I G C A I C I C A
ATACCTTTGTTTAATCTGATATTCAGAAAATTTCGTATGATAGGTAATCAACAGCAAATATAACTGTGGCTGAGTTCTGTACTTAGAAATCATGTTAAAC
TAAGAAATGGTGGAGTTATACAATGGGCCTCATTTCTCAAAGAAAACAAACAGACTAATTCATGTGTCTTTATAATCAAGGCCAAAATTTTTAAAGAAAA
CAAATTAAGCCTGCATTTGTTTGTTTTTAAAAAGTCTTAAAATCTTTTGGGTTCCTATAAAATCAAACCAATATCTTGTCATTCTCAACCACAAGAGGGC
ATCCATGCTTGCAACCTGATC

APPENDIX Q: Table 4: Genes Differentially Upregulated Exclusively at 6 Months and In-vitro in WC Versus SR
Gene Name

Ortholog
1day
copy it

ACTA2
ACTB
ATP6
CANX
CCT6A
CCT8

con
COL1A2
COTL1
DCN
EEF1A1
EIF4A2
FABP4
FBLN5
FKBP9
FN1
LUM
MRPL27
MYH11
MYLK
ND4
NDUFA10
PGM5
PHB2
PRDX1
RHOA
RPL3
RPL32
RPS3
SEC61G
SFRS1
SLC25A6
TPM1
VIM

acyl-CoA synthetase long-chain family member 1
actin, alpha 2, smooth muscle, aorta
beta-actin
ATP synthase FO subunit 6
calnexin
chaperonin containing TCP1, subunit 6A
chaperonin containing TCP1, subunit 8
mitochondrial DNA, cytochrome oxidase subunit II
F07 putative ribosomal protein S3
similar to coactosin-like 1 (dictyostelium) (LOC768420)
dermatan sulfate proteoglycan decorin
eukaryotic translation elongation factor 1 alpha 1
eukaryotic translation initiation factor 4A, isoform 2
mrna for tau-crystalin/alpha enolase
fatty acid binding protein 4, adipocyte
fibulin 5
FC506 binding protein 9, 63 kDa
fibronectin 1
lumican
mitochondrial ribosomal protein L27
myosin heavy chain II, smooth muscle
myosin light chain kinase telokin
Mitochondrial DNA - NADH dehydrogenase subunit 4 gene
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10 , 42kDa, nuclear gene
encoding mitochondrial protein
PG-M mRNA for proteoglycan
prohibitin 2
clone 0058P0007G11 putative peroxiredoxin 1 variant 3
ras homolog gene family, member A
similar to ribosomal protein L3 (LOC771432)
clone ChEST398a16
clone 0058P0031
similar to SEC61 gamma (LOC776639)
splicing factor, arginine/serine-rich 1
clone 0063P0030D07 putative solute carrier family 25 member 6 variant 1
alpha- tropomyosin gene, exons 9c, 9d, and complete cds, alternatively spliced
vimentin

Sweeks
copy it

10

Iday
copy it
1

2

Bmonths
copy it
1
7
- - ' 1 ~-\

6weeks
copy it

6months
copy it
o • '3 ,•, L
- 32,-«.

3

1
9
1
3
2
2

1
158

1
2
4
4
16

3 „f

1
1
1
5
1

1
87
1
159

13
1

1
1
9
3

;.
.
'

\6

15
7
4
10

7 [,C

104

5
2

27
7
2

32
21
1

2

2

SMC In-vitro
WC
SR
copy it
copy it
0
6
- 9 ' '
1
2
3
0
1
1
0
0
1
:
11
28
, - 6
^
1
,,„„0
-»
5
2
1
.
< -1
'"
0
19
- 30
0
"A"
3
r> !i?,2
30
0
„
1
0
29
2
47
18 *
0
0
12
7
4 ."'"
19

, '6'>!/

14
2
17
5
9
18

3
32
9
1
6

2

*

12
1
3
2

21
1
2

<_.

8
0
6
9
2
0
0
5
0
1

1
1
3
20
1
73
0
0
3
1
3
9
0

upregulated at 6month's & In-vitro in WC
downregulated at 6rrionths & In-vitro in WC

APPENDIX R: Table 5: Genes Differentially Upregulated Exclusively at 1 Day and at 1 Day in WC Versus SR
Gene Name

Ortholog

1
<M (wcr" " * ^ \ C-2 f W J I * ^

1day 6weeks
copy # copy #
16SrRNA
ACTA2
ACTB
ATPase6
ChEST751d6

COI

con
DSTN
EIF1
EIF4A2
FBLN5

LUM
MYLK
MRPL27
MYH11

MG
NADH1
NADH4
PRDX1
RPL7
RPL3
RPS3A
SERPIN1
SLC25A6
TPM1

VIM

mitochondrial 16S nbosomal RNA
Actin, alpha 2, smoth muscle, aorta
Beta-actin
ATP synthase FO subunit 6
clone ChEST751d6
Cytochrome c oxidase subunit II
Cytochrome c oxidase subunit II
Destnn
Eukaryotic translation initiation factor 1 variant 1
Eukaryotic translation initiation factor 4A isoform 2
Fibulm 5
Lumican
Myosin light chain kinase ortelokin
Mitochondrial nbosomal protein L27
Myosin, heavy chain II, smooth muscle
Myoglobin
NADH dehydrogenase subunit 1
NADH dehydrogenase subunit 4
Peroxiredoxin 1 variant 3
Ribosomal protein L7
Ribosomal protein L3
Ribosomal protein small subunit 3A
similar to SDF3 (LOC771608)
clone 0063P0030D07 putative solute carrier family 25
member 6 variant 1
Tropomyosin, alpha
Vimentin

7
10

1day 6months
copy#
copy#
2
6
1
7

2

1

C-3 (WC)
6weeks 6months
copy#
copy#

2
32
3

1
4

1
1
3
2

3
1
1
1

1
87
159
15

1

1
3

4
1
3

1
15
10
5

1
9

1

7
7

35
2
104
21

27

32

2

2
1

1
1

3

2

5
2

32
4

1

5

2

21
1
2

1-3 day In-vivo
WC
SR"
copy #
copy #
2
6
6
4
1
0
3
4
1
0
3
0
2
3
1
0

1
2
1
12
0
0
2
1
5
9
2
0
"1
\} 0 "*•>
1
3
1
0

1
2
0
2
1
1
0
0
11
6
3
2
0
1
0
1
0
1

upregulated at 1 day in WC
downregulatedatlday mWC

APPENDIX S Table 6: Genes Differentially Upregulated Exclusively at 6 Weeks and at 6 Weeks in WC Versus SR
Gene Name Ortholog

ACTA2
ACTB
ATP6

COI
C0TL1
EIF4A2
EIF5
EN01
FABP4

FN1
GNAS

LUM
MYH11

ND
ND4
PHB2
PRDX1
RHOA
RPL23

actm, alpha 2, smooth muscle, aorta
beta actm
ATP synthase FO subunit 6
chaperomn containing TCP1, subunit 8
cytochrome c oxidase subunit I
similar to coactosin-like 1 (dictyostelium) (LOC768420)
eukaryotic translation initiation factor 4A, isoform 2
eukaryotic translation initiation factor 5
enolasel, alpha
fatty acid binding protein 4, adipocyte
fibronectm 1
GNAS complex locus, transcript variant 2
lumican
myosin heavy chain 11, smooth muscle
NADH dehydrogenase subunit 1 gene
NADH dehydrogenase subunit 1 gene, mitochondrial DNA
prohibitin 2

clone 0058P0007G11 putative peroxiredoxin 1 variant 3
ras homolog gene family, member A
clone 0058P0057E07 ribosomal protein L32-like
similar to ribosomal protein L3 (LOC771432)
RPS23
ribosomal protein S23,11 days enbryo whole body cDNA, RIKEN full-length enriched library
i l t p l f l l l i similar to yeast ribosomal protein S28
RPS3A
ribosomal protein S3A

KlIE?

P l i l l l f S clone 0064P0021C06 spermadine/spermine N1 -acety Itransferase variant 1-like
SKP1
S-phase kinase-associated protein 1
SLC25A6
clone 0063P0030D07 putative solute carrier family 25 member 6 variant 1
alpha-tropomyosin gene, exons 9c, 9d, and complete cds, alternatively spliced
;
'^r^ M ^ w ^ ^
vimentin

1I1IS3
^sf#kC*3 (WC)
1day 6weeks stiiliitlfil
6weeks 6months
1day 6months
copy it
copy it copylt copy it
copy it
copy it
/
4SJ »
10
1
7
32
2
1
3

jwcjjin

1
4

1
1

2

3

1
16

1
1

1

1

35

5
1

6

1

1

1
9

10

7
27

>

»r

3
17

3
32

1
3
4
34

3
2

1

0
1
0
6
0
3
1
0

ox

4
159

6weeks In-vivo
WC
SR
copytt
copyU

9
2
18
2
25
25
74
6
21
1
2

104
32
2
1

2
1
0
0
0
* 0'
1
13
8
0
13
2
3
9
3
1
1
2
1

6
0
4
1
4
0
74
0
2
2
0
0
30
13
1
7
0
1
1
1
0
0
0
0
1
0
0
0
0

upregulated at 6weeks in WC
downregulated at 6weeks in WC

APPENDIX T: Table 7: Genes Differentially Upregulated Exclusively at 6 Months and at 6 Months in WC Versus SR
Gene Name

?
?
?

16SrRNA
ACTA2
ACTB
CDKN1B
COTL1
COI
COM
COIN
DDX5
EEF1A1
EIF4A2
EN01
GSN
HSP90AA1
LUM
MYH11
MYLK
ND1
ND4
NDUFA10
PHB2
PRDX1
RPL3
RPL4
RPL9

w*aibE?-?a
SAT1
SERPINF2
SLC25A6
TPM1

Ortholog

BACCH261-126J23
BACCH261-16J12
BAC CH261-117C7 (WAG-65N20)
mitochonrial genome
Actm, alpha 2 smooth muscle, aorta
Beta-actin
Cyclin-dependent kinase inhibitor p27 Kip1
Coactosin-like 1
Cytochrome c oxidase subunit I
Cytochrome c oxidase subunit II
Cytochrome c (mitochondrial genome) III
DEAD box polypeptide 5, RNA hehcase
Eukaryotic elongation factor 1-alpha 1
Eukaryotic translation initiation factor 1
Eukaryotic translation initiation factor 4A isoform 2
Enolase 1 alpha
Gelsolin
Heat Shock Protein 90 alpha
Lumican
Myosin, heavy chain II smooth muscle
Myosin light chain kinase
NADH dehydrogenase subunit 1
NADH dehydrogenase subunit 4
Ubiquinone
Prohibitin 2
Peroxiredoxin 1, variant 3
Ribosomal protein L3
Ribosomal protein L4
Ribosomal protein L9
Ribosomal protein S3A
Spermidine/spermine N1-acetyl transferase
Serpin peptidase inhibitor clade F alpha-2
antiplasmin (clone ChEST14214)
Solute carrier protein family 25 member 6
Tropomyosin

C-1 WC)
1 day
6 weeks
copy*
copy*
49

7
10

1 day
copy#

2
1

2
3
4

1
3
1
4
1

3
1
3

1
1

159

43
67
1
9

13
1

10
5

3
2

2

32
9
1
34

3

WCiiBB^

C-3(WC)
6 months In-vivo
6 months 6 weeks 6 months WC copy
SR
copy if
copy if
copy if
it
copy if
34
2
0
3
0
1
1
37
23
0
2
3
6
0
32
0
7
3
0
1
3
4
0
2
1
2
16
1
2
»- 1
0
4
3
1
19
3
1
2
0
0
1
1
0
1
0
3
1
0
1
35
3
0
1
5
6
0
20
6
5
213
175
9
0
7
104
6
0
27
32
1
0
7
21
2
5
2
3
5
2
1
0
1
5
0
17
6
0
5
2
0
18
4
0
2
2
9
1
> o
25
6
0
74
8
0
15
21
1

0
2
1

4
4
2

upregulated at 6months in WC
downregulated at Bmonths in WC

